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Abstract 
ABSTRACT 
New fluorescence methods for the determination of proteolytic enzymes and their 
Inhibitors have been investigated. Fluorescence polarisation and energy transfer 
methods have both been examined and of these two approaches energy transfer 
methods have proven supenor. Out of the energy transfer methods, the use of 
an over-labelled substrate, which is virtually non-fluorescent but becomes highly 
fluorescent upon proteolytic liberation of dye-labelled peptides, has been 
demonstrated to be most successful. A substrate utilising <I.-casein labelled with 
a long-wavelength BODIPY® dye has been synthesised and shown to be a 
suitable intramolecularly quenched conjugate for the determination of proteolytic 
enzymes and their inhibitors in flow-based screening programmes. The assays 
are rapid, taking at most 2 minutes for the enzyme assays and 5 minutes for the 
inhibition assays. Aprotinin, a serine protease inhibitor also used as a drug in 
surgery to prevent blood loss, has been detected at concentrations as low as 
0.161 nM, and limits of detection of 2.50 IlM, 0.14 IlM, and 7.20 nM were 
obtained for 3-mtrophenylboronic aCid, leupeptin, and pepstatin A respectively. 
The adaptation of these assays to a multi-determination format has also been 
considered. 
These f1uorogenic assays combine the sensitivity of long-wavelength 
fluorescence With the ease of automation that can be applied to flow injection 
analysis and could be incorporated into a simple portable fluorescence 
instrument. They have many clinical applications, since proteases are involved In 
virtually all biological functions and dysfunctions and therefore are promising as 
drug targets. The flow-based procedure descnbed here can be used in the high-
throughput screening of candidate drug molecules. 
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Research alms and scope of work 
RESEARCH AIMS 
The objective of this investigation was to develop new fluorescence methods for 
the determination of proteolytic enzymes and their inhibitors. Upon finding a 
sensitive method, this assay was to be transferred to a flow injection analysis 
system to create a procedure that would be suitable for the high throughput 
screening of drug candidate molecules. In order for the assay to be used in a 
high throughput screening function, the assay had the essential requirement of 
being rapid. With this in mind the progression of this work was to aim towards 
the adaptation of the already established assay to a set-up that would allow the 
multi-determination of proteolytic enzymes and their inhibitors. 
SCOPE OF WORK 
The work presented in this thesis reports the investigations that were carried out 
to achieve the above aims. Chapter 1 provides an overview of the subject areas 
that are pertinent to the investigation, while chapter 2 describes the materials, 
instrumentation, and general procedures that have been adopted for use during 
the practical work. 
Chapter 3 deals with the first investigation of a fluorescence method, 
fluorescence polarisation, for the determination of proteolytic enzymes. This 
chapter discusses the work carried out and the conclusions derived from that 
work. 
Chapters 4 and 5 investigate the use of energy transfer fluorescence methods 
The use of fluorescence resonance energy transfer involving substrates that are 
labelled with two different fluorophores is explored as a fluorescence method in 
iii 
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chapter 4. Chapter 5 describes the synthesis of over-labelled single fluorophore 
substrates resulting in energy transfer between neighbouring fluorophore 
molecules. The application of this substrate to a flow injection analysis system 
and subsequent proteolytic inhibitor determinations is demonstrated. 
Chapter 6 discusses set-ups appropriate for multi-determination and investigates 
these set-ups for use in these types of assays. 
Finally. chapter 7 provides a discussion on the practical work that has been 
carried out and the conclusions that can be derived. Ideas on further extensions 
of the work carried out and future directions are also discussed. 
iv 
list of figures 
LIST OF FIGURES 
Figure 1.1 Jablonski diagram showing absorption and emission processes 
of fluorescence and phosphorescence ........ ..... ...... ......... .... 3 
Figure 1.2 Structure of FITC, isomer I ... ... .... ...... ... ......... ......... ............ 7 
Figure 1.3 Structure of tetramethylrhodamine ... ......... ... ... ......... ... ...... ... 8 
Figure 1.4 Structure of BODIPY® 630 1650 -X, succinimidyl ester ... ...... .... 9 
Figure 1.5 Structure of CyTM 5 bisfunctional dye ................. ... ...... ..... 10 
Figure 1.6 Structure of Cr 5 5 bisfunctional dye . ...................... ......... 11 
Figure 1.7 The wave model of light (\/ = velOCity, E = electric field, 
H = magnetic field, vectors) ... ... ......... .. ... ... ... .. ... ... ... ........ 12 
Figure 1.8 Electnc vectors of light randomly distributed (a) and 
parallel (b and c) ... ......... ....... . ......... ...... ... ......... ...... ... .... 13 
Figure 1.9 Schematic representation of spectral overlap required 
for FRET ... ...... ... ...... ... ...... ... .................. ...... .......... ... .... 19 
Figure 1.10 Schematic diagram of a typical simple FIA system ... ... ........ ... 23 
Figure 1.11 Biochemical classes of drug targets of current therapies ......... 27 
v 
list of figures 
Figure 1.12 Dependence of initial velocity on substrate concentration 
for a single-substrate enzyme-catalysed reaction ...... ... .... ... ... 32 
Figure 1.13 Lineweaver-Burk plot ...................................................... 34 
Figure 1.14 Classification of immobilisation methods .............................. 41 
Figure 1.15 Proteolytic action of angiotensin converting enzyme (ACE) .. .. 45 
Figure 1.16 Trend in number of published articles in the areas of 
proteases, protease inhibitors and high throughput 
screening over the last decade ......... .............. ......... .......... 47 
Figure 1.17a Principle of the use of fluorescence polarisation for the 
detection of a large lightly labelled fluorescent protein ..... ... ... 50 
Figure 1.17b Principle of the use of fluorescence polarisation for the 
detection of protease digested fluorescence peptides ... ... ....... 51 
Figure 1.18 Schematic representation of (a) a peptide sequence 
labelled at each end by a donor fluorophore (red) and 
an acceptor fluorophore (green) and (b) cleavage of 
this peptide by a protease causing separation 
of donor and acceptor fluorophores ... ...... ............ ......... . .... 55 
Figure 1.19 SchematiC representing the principle of an 
intramolecularly quenched protein substrate (a) 
and cleavage of this substrate by a suitable 
protease to release fluorescent peptides (b) ......... .......... ...... 58 
vi 
list of figures 
Figure 3.1 Effect of incubation time on the final dye'proteln ratio 
for different reaction mixture ratio conjugates ...... .. ............ 82 
Figure 3.2 Fluorescence intensity of a reference block against 
time after sWitching on the LS 50B spectrophotometer ......... ... 84 
Figure 3.3 Influence of temperature on the digestion of 
fluorescein'albumin by alkaline protease ......... ..... ... ...... ..... 86 
Figure 3.4 Influence of pH and buffer system on the activity 
of alkaline protease .......................................................... 87 
Figure 3.5 Influence of carbonate buffer pH 11.0 concentration 
on the activity of alkaline protease .... ......... ... ...... ... ... ... ..... 88 
Figure 3.6 Influence of incubation time on the conversion of 
substrate to product ......................................................... 89 
Figure 3.7 Influence of alkaline protease concentration on the 
conversion of substrate to product ............. ........................ 90 
Figure 3.8 Time-dependent comparison of the activity of three 
protease enzymes - alkaline protease, proteinase K, and 
a-chymotrypsin - on the substrate fluorescein albumin 
using fluorescence polarisation ............... ...... ...... ............... 91 
Figure 4.1 Alternative scenarios following excitation of the conjugate 
at the donor excitation wavelength ............................ ......... 97 
Figure 4.2 Spectral overlap of FITC (donor) and TMRITC (acceptor) ..... 100 
vii 
List of figures 
Figure 4.3 Absorbance spectra of f1uoresceln and 
tetramethylrhodamine free dyes ..................................... 101 
Figure 4 4 Emission spectra of various 
f1uorescein.tetramethylrhodamine:a-casein conjugates ......... 102 
Figure 4.5 Emission spectra of 
f1uoresceln:tetramethylrhodamine:a-casein conjugates 
exhibiting an emission peak at the TMRITC wavelength ......... 103 
Figure 4.6 Fluorescence emission spectra demonstrating FRET 
between f1uorescein and tetramethylrhodamlne .................... 105 
Figure 4.7 Spectral overlap of Cy 5 (donor) and Cy 5.5 (acceptor) ......... 108 
Figure 5.1 Absorbance spectra of BODIPY solution (a) 
and BODIPY conjugates (b) ... .... ....... ..... ..... . ......... 116 
Figure 5.2 Absorbance spectra showing effect of protease 
digestion on BODIPY·a-casein ......................................... 118 
Figure 5.3 Absorbance spectra showing effect of denaturation 
on BODIPY:a-caseln ... ... ...... ... ...... ...... ......... ... .... ... ........ 119 
Figure 5.4 Excitation spectrum of BODIPY·a-casein ...................... .. 121 
Figure 5 5 Effect of altering excitation wavelength on the 
emission spectrum of BODIPY:a-casein ............................. 124 
Figure 5 6 Effect of cyclodextrins and CHAPS on the 
absorbance spectrum of BODIPY:a-casein ......................... 126 
VIII 
LIst of figures 
Figure 5 7 Effect of cyclodextrins and CHAPS on the 
fluorescence emission spectrum of BODIPY:u-casein ......... 127 
Figure 5.8 Effect of storage conditions on the fluorescence 
characteristics of BODIPY:u-caseln ......... ...... ... ....... ... ..... 128 
Figure 5 9 Stability of BODIPY:u-caseln in aqueous solution 
represented by the percentage decrease In 
fluorescence intensity over time ......... ... ...... ...... ... ...... ... ... 129 
Figure 5.10 Llneweaver-Burk plots for the proteolytic digestion 
of BODIPY:u-casein by various proteases ......................... 131 
Figure 5.11 Fluorescence intensity of a reference block and 
output of the Xe lamp light source over time 
for the F-4500 spectrophotometer ..................................... 134 
Figure 5.12 Fluorescence emission spectra showing enhancement 
seen upon incubation of BODIPY:u-casein with a 
protease enzyme (proteinase K) ........... ....... ................... 137 
Figure 5 13 Influence of BODIPY·u-caseln concentration on the 
production of BODIPY when incubated with a variety of 
proteases in a static system under optimised 
conditions ... ...... ......... ... ... ... ... ... .... .............................. 138 
Figure 514 Fluorescence intensity against enzyme concentration 
to calculate the limit of detection of alkaline protease ............ 140 
Figure 5.15 Fluorescence intensity against enzyme concentration 
to calculate the limit of detection of proteinase K ... ... ... ... ... ... 140 
ix 
List of figures 
Figure 5.16 Fluorescence intensity against enzyme concentration 
to calculate the limit of detection of a-chymotrypsin .............. 141 
Figure 5.17 Fluorescence intensity against enzyme concentration 
to calculate the limit of detection of trypsin .......................... 141 
Figure 5.18 Fluorescence intenSity against enzyme concentration 
to calculate the limit of detection of pepsin ... ... ... ..... .. .. . .. 142 
Figure 5.19 Manifold for flow injection enzyme and enzyme 
inhibition assays ........................................................ ... 144 
Figure 5.20 Sequence of events for the determination of 
proteases and their inhibitors in a flow system ...... .. ... ... ...... 145 
Figure 5.21 Actual layout and equipment used for flow analysIs 
protease and protease inhibition assays ............................. 146 
Figure 5.22 Effect of temperature on the activity of pepsin ...................... 149 
Figure 5 23 Effect of pH and buffer system on the actIVIty of pepsin ........ 150 
Figure 5.24 Effect of buffer concentration on the activity of pepsin ........ ... 151 
Figure 5.25 Effect of incubation time on the activity of pepsin ...... ... .. ...... 152 
Figure 5.26 Influence of pepsin concentration on the formation of 
product when incubated with BODIPY.a-caseln ................... 153 
x 
Figure 5.27 Influence of substrate concentration on the production 
of BODIPY fluorescence when incubated with alkaline 
List of figures 
protease in a flowing system ............................................ 154 
Figure 5.28 Influence of substrate concentration on the production 
of BODIPY fluorescence when incubated with a range 
of proteolytic enzymes in a flowing system .......................•.. 155 
Figure 5.29 Fluorescence intenSity against enzyme concentration 
to calculate the limit of detection of alkaline protease ............ 156 
Figure 5 30 Fluorescence intensity against enzyme concentration 
to calculate the limit of detection of proteinase K ...............•.. 157 
Figure 5 31 Fluorescence Intensity against enzyme concentration 
to calculate the limit of detection of a-chymotrypsin .............. 157 
Figure 5 32 Fluorescence intensity against enzyme concentration 
to calculate the limit of detection of pepsin ... ... ... ... .... ... ... .•.. 158 
Figure 5.33 Influence of pre-incubation time on the inhibition 
of pepsin by pepstatln A .................................................. 165 
Figure 5.34 Influence of incubation time on the inhibition of pepsin 
by pepstatin A .............................. ........ ....................... 166 
Figure 5.35 Influence of substrate concentration on the inhibition 
of pepsin by pepstatln A ............................. .................... 167 
xi 
List of figures 
Figure 5.36 Influence of pepsm concentration on the inhibition 
of pepsin by pepstatin A ......................................... ....... 168 
Figure 5 37 Influence of methanol concentration on the 
fluorescence of BODIPY:a-casein ..................................•.. 170 
Figure 5.38 Influence of percentage concentration of methanol 
on the emission wavelength of BODIPY:a-casein 171 
Figure 5.39 Influence of percentage methanol on the 
fluorescence of BODIPY:a-casem and pepsin ..................... 172 
Figure 5.40 Influence of incubation time on the fluorescence 
of BODIPY:a-casein incubated With pepsin in the 
presence and absence of methanol • ................................. 173 
Figure 5.41 Influence of percentage methanol and DMSO on 
the fluorescence of BODIPY a-casem .............. .......... .... 174 
Figure 5.42 Influence of DMSO percentage concentration on the 
optimum emission wavelength of BODIPY:a-casein ...... ........ 175 
Figure 5 43 Inhibition of proteinase K by 3-nitrophenylboronic acid .......... 176 
Figure 5.44 Inhibition of a-chymotrypsin by aprotmm ...... ...... ............... 177 
Figure 5.45 Inhibition of alkaline protease by leupeptin .......................... 177 
Figure 5.46 Inhibition of peps m by pepstatm A...... ....... .......... ............. 178 
xii 
I 
-
list of figures 
Figure 5.47 Percentage inhibition against inhibitor concentration in 
linear portion to calculate limit of detection .... .............. 179 
Figure 5.48 Percentage inhibition against inhibitor concentration in 
linear portion to calculate limit of detection .......................... 180 
Figure 5 49 Percentage inhibition against inhibitor concentration in 
linear portion to calculate limit of detection .......................... 180 
Figure 5.50 Percentage inhibition against inhibitor concentration in 
linear portion to calculate limit of detection .......................... 181 
Figure 6.1 Schematic of flow injection analysis system for 
multi-determination protease inhibition assays ....... ........................ 189 
Figure 6.2 Sequence of events for multi-determination protease 
inhibition assays using immobilised enzyme reactors ............ 190 
Figure 6 3 Reaction scheme for the immobilisation of enzyme 
onto controlled pore glass .............................................. 191 
Figure 6.4 SEM pictures showing (a) 182 A aminopropyl glass 
and (b) an individual glass chip ......................................... 192 
Figure 6.5 Appearance of the enzyme reactors: top - packed glass 
column, bottom - empty glass column ............................... 193 
Figure 6.6 Fluorescence intensity of BODIPY:u-casein over 
time when incubated in the presence and absence of 
proteinase K - ePG ............................. .......... .......... ... 195 
xiii 
Figure 6.7 Enhancement of fluorescence seen when 
BODIPY:a-casein was incubated with 
List of figures 
proteinase K - CPG compared with CPG ........................... 196 
Figure 6.8 Fluorescent peaks of BODIPY:a-casein injected 
into a buffer stream with and without a raw CPG column ....... 197 
Figure 6.9 Absorbance of 0.1 % a-casein solution before (1) and 
after (2) mixing With glutaraldehyde-activated CPG and 
subsequent readings of freshly added buffer 
Figure 6.10 Injection of naphthofluorescein with and 
199 
without 2.5 cm column ... .. ... ..... ... ...... ... .... . ... ...... ... ....... 202 
Figure 6.11 Injection of Cy5 With and without 2.5 cm column .................. 202 
Figure 6.12 Injection of a-casein with and without 2.5 cm column ... ......... 203 
Figure 6.13 Injection of BODIPY with and without 2.5 cm column ...... ...... 203 
Figure 6 14 Injection of BODIPY:a-casein with and 
without 2.5 cm column .................................................... 204 
Figure 6.15 Reaction scheme for the immobilisation of enzyme 
onto UltraLink Biosupport Medium ..................................... 206 
Figure 6.16 Cahbrallon graph of proteinase K concentration 
using the Bicinchoninic Acid assay............ ......... ...... ......... 208 
xiv 
list of figures 
Figure 6.17 Injection of BODIPY through both an empty column and 
a column packed with proteinase K - Ultra Link ... ...... ... ........ 209 
Figure 6.18 Injection of BODIPY a-casein through both an empty column 
and a column packed with proteinase K - UltraLink 209 
Figure 6.19 Injection of a-casein through both an empty column 
and a column packed with proteinase K - UltraLink ............. 210 
Figure 6.20 Schematic of flow system used for soluble 
mUlti-determination assays ... ...... ... ... ...... .................. ....... 213 
Figure 6.22 Sequence of events for multi-determination 
protease inhibition assays ......... ... ...... ... ... ........... .... . ... 214 
Figure 6.22 Separation of two enzyme peaks uSing 25 cm and 
399 cm length tubing ................................................... 216 
Figure 6.23 Multi-determination uSing two proteolytic enzymes - pepsin 
and proteinase K - and the selective inhibition of these 
enzymes by pepstatin A ... ... ... ......... ......... ... ... ... ...... ..... ... 217 
Figure 7.1 Possible set-ups for mUlti-determination assays: (a) one 
inhibitor, three enzymes with three different pH optima, 
(b) one inhibitor, three enzymes with two different pH optima .. 229 
Figure 7.2 Schematic diagram of the chip designed for enzyme 
assays in [307] ... ... . ............... ................... ..... ......... ... 231 
Figure 7.3 Schematic diagram showing the set-up for a confocal 
fluorescence detection on a chip, taken from [331] ............... 235 
list of figures 
Figure B Appearance of the F-4500 In our laboratory ......................... 289 
Figure C Internal block diagram of the F-4500 ...... .... .. ................... 290 
Figure E Appearance of the LS 50B .............................................. 292 
Figure F Optical layout of the LS 50B fluorescence 
spectrophotometer ........................... ............. .. .......... 293 
xvi 
List of tables 
LIST OF TABLES 
Table 1.1 
Table 21 
Table 3.1 
Table 3.2 
Table 5.1 
Table 52 
Table 5.3 
Table 5.4 
Table 55 
Worldwide sales figures for selected angiotensin 
converting enzyme inhibitors as drugs ... .... ... .... ....... ... ... 46 
Reagents used and their respective supplier ....... . .............. 67 
Initial reaction mixture and calculated final dye:proteln 
ratios for f1uorescein:albumin conjugates ... ... ...... ...... .. .... ..... 81 
Assay parameters and optimum conditions for three 
protease enzymes using the substrate f1uorescein:albumin ...... 85 
Initial reaction mixture and calculated final dye protein 
ratios for BODIPY:a-casein conjugates .. ... ...... ... ... ....... ..... 115 
Initial reaction mixture and calculated final dye:protein 
ratios for various BODIPY:a-casein conjugates ................. 122 
KM and Vmax values obtained experimentally for various 
proteolytic enzymes on the substrate BODIPY.u-casein ........ 132 
Assay parameters studied and optimum conditions 
for various proteolytic enzymes using the f1uorogenlc 
substrate BODIPY·u-casein in a static system ..................... 136 
Limits of detection determined experimentally for various 
proteolytic enzymes using the substrate BODIPY:u-casein 
in a static system ............................................. ............. 143 
xvii 
Table 5 6 
Table 5 7 
Table 5.8 
Table 5.9 
List of tables 
Assay parameters studied and optimum conditions 
for various proteolytic enzymes using the fluorogenic 
substrate BODIPY:u-casein in a flow system ...................... 148 
limits of detection determined experimentally for various 
proteolytic enzymes uSing the substrate BODIPY'u-casein 
in a flowing system ....................................................... 158 
Comparison of assay incubation times for various 
proteolytic enzymes in static and flow system formats ........... 159 
Comparison of enzyme limits of detection between two 
different methods using similar protease substrates 161 
Table 5.10 Assay parameters studied and optimum conditions 
for various enzyme - inhibitor pairs using the fluorogenic 
substrate BODIPY:u-casein in a flow system ...................... 164 
Table 5.11 limits of detection determined experimentally for various 
protease inhibitors using the substrate BODIPY'u-casein 
Table 6.1 
Table A 
Table D 
In a flowing system .... ... ......... ... ......... ......... ...... ... ..... 181 
Amount of different materials flowing through a packed 
proteinase-UltraLink column compared with an 
empty column ............................................................... 210 
Supplier names and addresses ...... ... ......... ...... .... ...... ...... 285 
Instrument parameters of the F-4500 and LS 50B ... ... .... . .... 291 
XVIII 
List of abbreviations 
LIST OF ABBREVIATIONS 
3-NPBA ...... ......... .......... ........... ..................... 3-nitrophenylboronic acid 
ACE ............ .......... ............ ..... . .......... Angiotensin converting enzyme 
SCA ...... ... ...... ... ...... ......... ......... ......... ... ...... ............ Sicinchonimc acid 
CPG ..... .............................................................. Controlled-pore glass 
D.P .......................................................................... Dye:protem 
DMF ............................................................... N, N-dlmethylformamide 
DMSO ..................................................................... Dimethylsulphoxide 
FIA ...... ......... . ........ .................. ...... .... ...... ....... Flow injection analysis 
FI'!'C ...... ............ ...... ...... ............ ...... .......... Fluorescein isothlocyanate 
FP ... ... ... ... ...... ... ......... ... ............ ... ...... ... ...... ... Fluorescence polarisation 
FRET ........................................... Fluorescence resonance energy transfer 
HIV .............................. ............. ............. Human Immunodeficiency virus 
HTS ......................................... ................... High throughput screening 
LED ......................................................................... Light emitting diode 
LOD ............................................................................ limit of detection 
PMT .. ...... ... .. .... .......... ...... ............ ...... ........ Photo-multiplier tube 
QY .................. ............ .. ........ ...... ...... ................... .... Quantum yield 
TMRITC ........................................... Tetramethylrhodamine isothiocyanate 
UV ....................................................................................... Ultraviolet 
& ..................... .... ...... ...... ...... ............ ........ Molar extinction coefficient 
xix 
Table of contents 
TABLE OF CONTENTS 
Acknowledgements .............................................................................. i 
Abstract ...... . .. ... ... ... ... ... ... ... . .. .. . ... ... ... ... ... ... ... ... .. . ... .. . .. . ... .. . ... ... . .. ... .. ii 
Research aims and scope of work ...................................... ................... hi 
List of figures ............................. ............................ ... ... ... ... ... ...... ... v 
List of tables ........ '" ... ... ...... ... ...... ............... . .................................. xvii 
List of abbreviations .......... ... ...... ...... ... .. . ... ... . ... ... ...... ..... .... . xix 
Table of contents ... .... ... ............ ............... ............ ...... ... ...... ...... .. .... xx 
Chapter 1 Introduction .•..•..•....•.•.........•.•.•.•.••..••....•....•..........•..••...... 1 
1.1 Fluorescence ... .........•........•.••...••....•...•....•.....................••........ 2 
1.1.1 Theory of fluorescence ............................................. .. . 2 
1.1.2 Advantages of fluorescence ............ ... ...... ......... ...... . ......... 4 
1.1.3 Long wavelength fluorescence ....................................... ...... 4 
1.1.4 Fluorescent labels ...... . ......... ... ......... .... . ....... .......... ...... 6 
1.1.4 1 Fluorescein isothiocyanate (FITC) ... ... ... ........ ..... 7 
1.1.4.2 Tetramethylrhoda,mine isothlocyanate (TMRITC)... 8 
1.1.4.3 
1.1.4.4 
BODIPY® f1uorophores ...... ......... ...... ......... ... ... 9 
Cyanine dyes (Cr 5 and er 5 5 
bisfunctional dyes) .... 10 
1.2 Fluorescence polarisation ... ............ ................................. ....... 12 
1.2.1 Theory of fluorescence polarisation ... ................................ 12 
1.2.1.1 Dipole model of absorption and 
emission ................................... ............. ... ... 14 
xx 
- - -- - - ------------------
1.2.1.2 
12.13 
Table of contents 
Depolarisation ........................................... 14 
Relationship between fluorescence 
polansation and molecular weight ............ ......... 16 
1.2.2 Advantages of fluorescence polarisation ........... .................. 17 
1.2.3 Disadvantages of fluorescence polarisation .......................... 17 
1.3 Fluorescence resonance energy transfer .................................. 18 
1.3.1 Theory of FRET ............................................................. 18 
1 3 2 Conditions for FRET ........................................................ 19 
1 3 3 FRET donor I acceptor pairs .................... ......... . ............ 20 
1.3.4 Advantages of FRET ............ ............ ....... ... .... ........... .. 21 
1.3.5 Disadvantages of FRET ...... ...... ............ ...... ..................... 21 
1.4 Flow injection analysis (FIA) .................................................... 22 
1 4.1 History of flow Injection analysis ........................... ............. 22 
1.4.2 Theory of flow injection analysis ......................................... 23 
1.5 High throughput screening (HTS) ............................................. 25 
1.5.1 Concept of high throughput screening ................................. 25 
1.5.2 History of screening ......................................................... 26 
1.53 The drug discovery process ............................................... 27 
1.5.4 Miniaturised high throughput screening ............ .............. ..... 29 
1.6 Enzymes...... ...•..... ..... ............................................................ 30 
1.6.1 Introduction to enzymes .............. .................. .... ...... ........ 30 
1.6.2 Factors affecting enzyme activity ........................................ 31 
1.6.3 Enzyme kinetics .......... ............. ..................................... 32 
1.6.4 Proteolytic enzymes ......... .......... ...... . ............... ...... .... 35 
1.6.4.1 Alkaline protease ........ .......... .................. ...... 37 
1 6 4.2 Proteinase K ................................................ 37 
1.6 4.3 Chymotrypsin ........ .. ........... ....................... 38 
xxi 
1.6.4.4 
1.64.5 
Table of contents 
Trypsin ....................................................... 38 
Pepsin .....................................•................. 38 
1.7 Enzyme immobilisation •...... ••... ..• .•... ....•......•............ ...... ......... 39 
1.7.1 Why Immobilise enzymes? ... ... ... ..... ...... .... ... ...... ... ... ... ..... 39 
1.7.2 Immobilisation methods .................................................. 40 
1.7.2.1 Covalent binding method ................................ 41 
1.7.3 Modification of enzyme properties after immobilisation ... 42 
1.74 Immobilised enzymes in FIA ............................................. 43 
1.8 Protease assays ..................... ......................... ......... .......... .... 44 
1.8.1 Importance of protease assays ........................... ............ 44 
1.8.2 General protease assay methods ....................................... 48 
1.8.3 Fluorescent protease assay methods ... .............................. 49 
1 8.3.1 Fluorescence polarisation protease assays ......... 49 
1.8.3.2 Fluorogenic protease assays ........................... 54 
1.8.32.1 
1.8.32.2 
Fluorogenic FRET protease assays .................. 55 
Quenched over-labelled fluorogenic protease 
assays .................................................. 57 
1.9 Enzyme inhibition ................................................................... 61 
1 9 1 Types of inhibition ............ ............ ...... ...... ..... ...... ......... 61 
1.9.1.1 Reversible inhibition ....................................... 61 
1.9.1.2 Irreversible inhibition ............ ...... .................... 63 
1.9.1.3 Product inhibition ...... ............ ........................ 63 
1.9.2 Protease inhibition ...... .... .. ...... ...... ......... ...... .................. 64 
1.9.2.1 
1.92.2 
1.9.2.3 
1.92.4 
Aprotlnin .................. ...... .......... .................. 64 
Leupeptin ................ ......... ... ............ ... ... ... ... 65 
3-Nitrophenylboronic acid ............................... 65 
Pepstatin A...... ...... ......... .......... ...... ............. 65 
xxii 
Table of contents 
Chapter 2 Materials, instrumentation and general procedures •••.•.•..• 66 
2.1 Materials and instrumentation .................................................. 67 
2 1.1 Reagents ........................... .......... ...... ... ... ...... ... ... ..... 67 
2.1.2 Cells ........................................... .......... ..................... 69 
2.1.3 Chromatographic columns ...... ... ...... ... ........ ...... ... .... ..... ..... 69 
2.1 4 Flow system equipment ................... ......... ... ... .. .......... 69 
2.1.5 Pipettes ........................................................................ 70 
2.1.6 Spectrometers ...... ..... ... ... ... ... ... ... ............... ... ... ..... ... ..... 70 
2.1.7 Supplier names and addresses ....... .............. . ...... ........... 70 
2.1.8 Temperature control.... ... ...... ... ...... ............... ................. 70 
2.2 General procedures ................................................................ 71 
2.2.1 Buffer preparation ........................... ............ .... ............... 71 
2.2.2 pH measurement ......... ......... ............... ... ......... ..... .......... 71 
2.2.3 Water purification . ..... ..... ... .... ... ................................. 71 
2.2.4 Mass determination ... ......... ... ...... .................................... 71 
2.2.5 Pipetting ... ............ ... ...... .... .. .................. ............... ........ 72 
2.2.6 Fluorescence measurement ..... . ................ ...... ... ............ 72 
2.26.1 
2262 
F-4500 Spectrophotometer ... ............ ...... ... ...... 72 
LS 50B Spectrophotometer ......................... ... 72 
2.2.7 Fluorescence polarisation measurement ......... .................... 73 
2.2.8 Absorbance measurement ................................................ 73 
2.2.9 Flow system measurements ............................................. 74 
2.2.10 Preparation of dye' protein conjugates ......... ......... .. .......... 74 
2.2.11 Final dye:protem ratio calculations ...................................... 75 
2.2.12 Immobilisation of enzyme onto CPG ............. .. ................. 76 
2.2.13 Immobilisation of enzyme onto Pierce UltraLink biosupport 
xxiii 
Table of contents 
medium ..................................................................... 77 
2.2.14 BCA assay for determination of protein concentration ............. 77 
Chapter 3 Experimental: fluorescence polarisation protease 
assays ..................... ...... ............ ........................... ....... 78 
3.1 Introduction ............................... ....................................... ..... 79 
3.2 Preparation of fluorescein conjugates ....................................... 80 
3.2.1 Procedures ........................................ ...... .. ........... ..... 80 
3.2.2 Results ........ .... .............................. ........................... 80 
3.3 Fluorescence polarisation protease assays ...... .......... ............... 83 
3.3.1 Procedures ....................................... ..................... .... 83 
3.3 2 Results ............ .................. ............ ...... ......................... 85 
3.3.2.1 Effect of temperature ....... ............... ....... ..... 86 
3.3 2.2 
3.3 2.3 
3324 
3.3.2.5 
3.3.2.6 
Effect of pH and buffer system ........................ 87 
Effect of buffer concentration ........................... 88 
Effect of incubation time ..................... ......... 89 
Effect of enzyme concentration ..... ... ... .......... 90 
Comparison of the activity of three proteolytic 
enzymes using fluorescence polarisation ........... 91 
3.4 Discussion.............. ......................................... ..................... 92 
xxiv 
Table of contents 
Chapter 4 Experimental: double labelled FRET based protease 
assays ...............................•........•............................. ..• 95 
4.1 Introduction ........•......•........ ........•..............•......•..........•.•..•.•.• 96 
4.2 Investigation into the use of fluorescein and 
tetramethylrhodamine for FRET protease assays ......... .............. 99 
4.2.1 Procedures ....................................... ...... ..................... 99 
4 2.2 Results ............. ....... ...... ...... ... ...... ......... ... ................. 100 
4 2.2.1 Analysis of the overlapping of f1uorescein 
(donor) and tetramethylrhodamine (acceptor) 
eXCitation and emission spectra ...................... 100 
4.2.2.2 Determination of optimum donor:acceptor.protein 
ratios for use in FRET protease assays .......... 102 
4.2.2.3 Analysis ofthe 5 75:1 
FITC:TMRITC:a-casem conjugate .................. 104 
4.3 Investigation into the use of Cy 5 and Cy 5.5 for FRET 
protease assays .....•....... .•..•. .••.......•............ .•.... ......... ......• ... 107 
4.3.1 Procedures........................... ... ... ... ...... ...... ........ ........... 107 
4.3.2 Results ........................ ............. .. .... ......................... 108 
4 3.2.1 Analysis of the overlapping of Cy 5 (donor) and 
Cy 5.5 (acceptor) excitation and emission 
spectra ...................................................... 108 
4.3.2.2 Analysis of the Cy 5.Cy 5.5:a-casein 
conjugates ... ...... ......... ... .. ...... .... . .. .... 109 
4.4 Discussion............... ......................................... .......•....•... .•• 110 
xxv 
Table of contents 
Chapter 5 Experimental: single labelled substrate protease and 
protease inhibition assays 112 
""""5:1 Introduction....................................... ••••••••• •....• .................... 113 
5.2 Preparation of BODIPY conjugates ......................................... 114 
5.3 
52.1 Procedures ...... ... ... ...... ... ... ... ......... ......... .... ... ............ 114 
5.2.2 Results ........................................................................ 115 
5.2 2.1 Effect of protease digestion on the absorption 
5 2.2.2 
5.2.2.3 
5.22.4 
5.2.2.5 
5.2.2.6 
5 2.2.7 
5.2.2.8 
5.2 2.9 
Protease kinetics 
5.3.1 Procedures 
characteristics of BODIPY:a-casein ...... .......... 118 
Effect of denaturation on the absorption 
characteristics of BODIPY:a-casein ...... ... ....... 119 
Effect of the number of BODIPY dyes attached 
to a-casein on the absorbance spectra of the 
conjugates ....... ... ...... ... ....... ...... ... ... ... ... ... 120 
Comparison of the fluorescence excitation 
spectrum with the absorbance spectrum of 
BODIPY:a-casein ....................................... 120 
Re-evaluation of D:P calculations ................... 121 
Calculation of percentage quenching in the 2.35 
BODIPY a-casein conjugate .......................... 123 
Effect of altering excitation wavelength on the 
emission spectrum of BODIPY:a-casein ........... 124 
Investigation into the effect of additives on the 
absorbance and emission spectra of 
BODIPY:a-casein ........................................ 125 
Stability of BODIPY:a-casein ......................... 127 
xxvi 
130 
130 
Table of contents 
5.3.2 Results ................... ................ .......... ......... ................ 131 
5.4 Protease assays in a static system ......................................... 133 
5.4.1 Procedures. ..... ............. ...... ... ...... ...... ...... ...... ....... 133 
54.2 Results ....................................................................... 135 
5.4.2.1 Optimisation of protease assay conditions ... ..... 135 
5.4.2.2 Calibration curves for BODIPV:u-casein ............ 138 
5.4.2.3 Determination of limits of detection ... ...... ... ...... 139 
5.5 Protease assays in a flowing system ...•.................•.....•••......... 144 
5 5.1 Procedures...... ... ... ... ......... ... ............... ......... ........ ... ..... 144 
552 Results . ... ...... ...... .... ..... ... ...... ... ........ .......... . ............ 147 
5.5.2.1 Effect of temperature ............. . ...... ... ... ...... ... 149 
5.5.2.2 Effect of pH and buffer system ..................... 150 
5.5.2.3 Effect of buffer concentration ... ... ... ............ ..... 151 
5.5.2.4 
5.525 
5.526 
5.5.2.7 
5.5.2.8 
Effect of incubation time . .............................. 152 
Effect of pepsin concentration on the reaction 
rate ... ... ... ... ... ... .... .... ......... ......... ...... ....... 153 
Calibration graphs for BODIPV:u-casein in 
the flowing system ................. .................... 154 
Determination of limits of detection ... ... ... ..... .... 156 
Comparison with previously published work 160 
5.6 Protease inhibition assays ... ............... ......... ................ .......... 162 
5.6.1 Procedures ........................................................... 162 
5.6.2 Results ...... ...... ... ... ... ... ......... ...... ... ...... ...... ... ... .... ........ 162 
5.6 2.1 Effect of pre-incubation time ............ ............. 165 
5.62.2 Effect of incubation time .......... . ...... .......... 166 
5.6.2.3 
5.6.2.4 
56.25 
Effect of substrate concentration ..................... 167 
Effect of enzyme concentration ...................... 168 
Problems with inhibitors ............................. 169 
xxvii 
5.6.2.6 
5.6.2.7 
Table of contents 
Generation of inhibition curves ... ................... 176 
Determination of limits of detection ............ ...... 179 
5:7 Discussion...... ..•...••..••••••••••••••••••••••• ••.••• .............................. 183 
Chapter 6 Experimental: multi-determination protease inhibition 
assays ............... ....... ................................................. 186 
6.1 Introduction ......................................................................... 187 
6.2 Multi-determination protease inhibition assays using 
controlled-pore glass as a support .......................................... 188 
6.2.1 Procedures ................................................................... 188 
6.2 2 Results ........................................................................ 194 
6 2.2.1 Absorbance experiments to investigate sticking 
of a-casein to glutaraldehyde activated CPG ..... 199 
6.2.2 2 Blocking of free aldehyde groups using 
ethanolamine ............................................. 200 
6.2.2 3 Evaluation of CPG with a larger pore size 
of 972 A .................................................... 201 
6 2.2.4 Evaluation of shorter enzyme reactors ............. 201 
6.3 Multi-determination protease inhibition assays using Pierce 
UltraLink Medium as a support ............................................... 205 
6.3.1 Procedures .................................................................. 205 
6.3.2 Results .............................. ......................................... 207 
6.3.2.1 Determination of amount of proteinase K 
immobilised onto Ultra Link Biosupport Medium .. 207 
6.3.2.2 Evaluation of UltraLink as a support for 
multi-determination protease inhibition assays 
xxviii 
Table of contents 
in a flowing system ............ .......... ... ... ... ....... 208 
6.4 Multi-determination protease inhibition assays using 
soluble enzyme ............ ......... ............... ... ............................. 212 
6.4.1 Procedures ... ......... ......... .................. ......... ... ..... .......... 212 
6.4.2 Results ...................................................................... 215 
6 4.2.1 Determination of length of flow tubing required 
for separation of peaks ................................. 215 
64.22 Multi-determination protease inhibition assays ... 217 
6.5 Discussion....... .•................................ .................................. 219 
Chapter 7 Conclusions and future work ....................................... 221 
7.1 Conclusions ........................................................................ 222 
7.2 Future work .......... ........ .......... ........ ........ .................. ....... ..... 226 
7.2.1 Fluorescence polarisation .............................. ...... ... ......... 226 
7.2.2 Double-labelled substrate ... ......... ................... ................. 227 
7.2.3 Single-labelled substrate ............................................... 227 
7.24 Multi-determination ...... ............ ..... ........ ...... ........ 227 
7.2.5 Miniaturised protease and protease inhibition assays ............ 230 
References ............... ..................................................................... 237 
Appendices .................................................................................... 284 
xxix 
Chapter 1 Introducllon 
CHAPTER 1 
Introduction 
1 
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1.1 FLUORESCENCE 
Fluorescence spectroscopy is an extremely powerful analytical tool that has seen 
a remarkable growth in Its use over the past 15 years in a Wide range of areas 
""Jrrom clinical chemistry to environmental mOnitoring. There are numerous 
sources of information on the theory of fluorescence and its applications [1, 2, 3, 
4] with the consequence that the theory will not be discussed in great detail here. 
An excellent paper covers the basic principles of fluorescence spectroscopy [5] 
and a recent book by Lakowicz provides a wealth of knowledge on the basic 
aspects on fluorescence spectroscopy, as well as covering the many 
experimental and instrumental advances that have been made during the last 16 
years [6]. Reviews covering new developments in the theory and practice of 
molecular luminescence for chemical analysis are published every two years [7, 
8] and yearly reviews on advances in atomic emission, absorption, and 
fluorescence spectrometry, and related techniques are also published [9, 10]. 
1.1.1 Theory of fluorescence 
The sequence of events that occur in fluorescence are shown in figure 1.1 and 
are as follows: 
1. A quantum of light IS absorbed by a dipole (a) 
2. Rapid radlationless relaxation (internal conversion) takes the dipole to the 
thermally relaxed 81 level (b) 
3. The dipole retains thiS energy for a certain period of time, generally 
designated as the lifetime (t) 
2 
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4. The excess energy IS dissipated through radiationless de-excitation (c, d, and 
e) caused predominantly through Vibrational and rotational modes and 
collisions with solvent molecules, or by photon emiSSion (f, g). When this 
photon emission is from a singlet electronic state, it is referred to as 
fluorescence (f). Conversely, when the emission is from a triplet state, 
phosphorescence is the result (g). 
Figure 1.1 - Jablonski diagram showing absorption and emission 
processes of fluorescence and phosphorescence. So = ground 
singlet state, S, and S2 = first and second singlet levels 
respectively, T, and T2 = first and second triplet levels respectively 
Singlet state Triplet state 
I I I 
I 
I 
I 
I 
I 
I 
(~) internal conversion 
~ 
i (d) intersystem 
cl crossing 
0 1 
cl c .- I 
0 !!!I 01 Q) 
.., Q)I Q) '(ii I 0 c- >, 0 ~ c ~ Q) 
-0- 0 0 -~ 0 C tJl 
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~ c ~ 0 
~ Q) ::; ~ 
I::: r;:: ~ 
I c .;:: 
01 ~ :: c-
l ~ ~ 
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1.1.2 Advantages of fluorescence 
When compared with conventional absorbance-based techniques, fluorescence 
is several orders of magnitude more sensitive and more selective. Increase in 
sensitivity arises because the emitted radiation is measured directly and can be 
increased simply by increasing the incident power. Moreover, as fluorescence is 
measured at right angles to the incident beam, It is considered a zero 
background technique. Absorbance however, is a measure of the difference 
between incident and transmitted intensities Le., signals are measured as a small 
change in a large background. 
Selectivity in fluorescence-based techniques is also much higher than in 
absorbance-based approaches. All molecules absorb photons. However, only a 
few fluoresce and fewer still phosphoresce at ambient temperatures. Thus the 
rarity of luminescent materials makes fluorescence an attractive technique for the 
resolution of trace fluorescent components in complex mixtures. In addition, the 
ability to employ both excitation and emission wavelengths as selectivity 
parameters gives fluorescence increased selectiVity. 
The ease of handling f1uorophores compared with the expense and difficulties of 
handling and disposing radioactive material makes fluorescence an attractive 
alternative to radioactivity. 
1.1.3 Long wavelength fluorescence 
Fluorescence spectrometry has been accepted for many years as a major 
technique for trace analysIs, but In real samples the sensitivity of fluorescence is 
not as high as that seen in pure solutions that contain the same f1uorophore. 
4 
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molecules being effectively non-fluorescent. Thus, fluorophores with moderate 
molar absorptlvitles and quantum yields can give excellent limits of detection 
because of the low backgrounds due to so few fluorophores that absorb and emit 
at these wavelengths. 
The development of semiconductor-based detectors, photodiodes, and 
inexpensive long wavelength laser diodes and LEDs has allowed the reduction of 
detector noise and an enhancement of the fluorescence signal. There IS 
therefore the opportunity for Simple, robust but sensitive instruments based on 
solid-state light sources and photodiode detectors and cheap and effective fiber 
optics. Both the simplicity and sensitivity of long wavelength fluorescence thus 
make it an obvious choice as a detection method. 
Further discussions of the advantages of long wavelength fluorescence and its 
applications can be found [15, 16]. 
1.1.4 Fluorescent labels 
A variety of fluorescent labels have been used in this study, and the structure, 
advantages, and disadvantages of each fluorophore are discussed below. The 
energy capture efficiency of a fluorescent dye is expressed as the extinction 
coefficient, E, and usually ranges from 10 000 - 250 000 cm-1 M-1_ The emission 
efficiency is expressed as the quantum yield, QY, and usually ranges from 0 05 -
1.0. Quantum yield is strongly influenced by the local environment and so is not 
usually reported as a 'constant' like the extinction coefficient. The best 
fluorophores will have both a high extinction coefficient and high quantum yield. 
6 
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1.1.4.1 Fluorescein isothiocyanate (FITC) 
A more detailed description of FITC can be found elsewhere [17]. 
Figure 1.2 - Structure of FITC, isomer I 
NCS 
HO OH 
Aex = 494nm, Aem = 520 nm, MW = 389.4 
Advantages: 
• high extinction coefficient (73 000 cm·1 M·1) 
• excellent fluorescence quantum yield (- 0.9) 
• good water solubility 
Disadvantages: 
• relatively high rate of photobleaching 
• pH-sensitive fluorescence that is significantly reduced below pH 7.0 
(pK. - 6.4) 
7 
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1.1.4.2 Tetramethylrhodamine isothiocyanate (TMRITC) 
Further reading on this fluorophore can be found [18]. 
Figure 1.3 - Structure of tetra methyl rhodamine, mixed isomers 
HCN ~ 
3 I 
CH3 
o 
+ 
'<:: NCH I 3 
CH3 
Aex = 544 nm, Aem = 575 nm, MW = 443.5 
Advantages: 
• good photostability 
• insensitive to solvent polarity 
Disadvantages: 
• prone to aggregation 
8 
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This is because of background-scattered light and fluorescence signals from 
endogenous sample components. This problem is particularly prevalent in 
biological samples where high levels of proteins and other natural polymers 
cause intense light scattering, and which commonly contain fluorophores whose 
spectra overlap those of the target fluorophore. Substances found in blood 
plasma, for example proteins and amino acids, exhibit fluorescence emission at 
350 nm, and protein-bound bilirubin shows emission at 520 nm. 
A major source of errors in all fluorescence measurements is interferences due to 
scattered light. Scatter is a property of the solvent or particulate matter in the 
sample. Some photons are uniformly scattered without change in frequency due 
to collisions with the solvent molecules. The emitted light has the same 
wavelength as the exciting light since the absorbed and emitted photons are of 
the same energy. This scattering is termed Rayleigh scattering and occurs at all 
wavelengths. Its intensity, however, varies in proportion to A. -4, so its effect can 
be minimised by working at longer wavelengths [11). Raman scattering is a 
source of interference that occurs in aqueous solutions, which are typically used 
for biological samples. Raman scatter always occurs at a constant wavenumber 
difference from the incident light. With longer excitation wavelengths, the Raman 
band decreases in intensity, becomes further displaced from the Rayleigh scatter 
band, and has a wider bandwidth [12). At longer wavelengths therefore, both 
Rayleigh and Raman scatter are much reduced. 
Background fluorescence originating from endogenous fluorescent species and 
from Raman and Rayleigh scattering can greatly limit the potential sensitivity of 
the analysis. However, long wavelength fluorescence detection in the region 600 
-1000 nm has proven to reduce interference [13). 
Photochemical theory predicts a sharp diminution in the quantum yields of 
fluorophores as their emission wavelengths increase (14). In practice the long 
wavelength region boasts a few fairly intense fluorophores, with almost all other 
5 
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1.1.4.3 BODIPY@ fluorophores 
The BODIPY dyes are dibenzopyrrometheneboron difluoride compounds and 
were synthesised for the first time by Treibs and Kreuzer [19], in 1968. Later an 
ionic derivative was synthesised by Worries et al. [20], and several reactive forms 
have been prepared recently by Kang and Haugland [21] . All the BODIPY dyes 
have a difluoro-bora-diaza-indacene structure indicated by the red-circled moiety 
shown in figure 1.4. Different substituents are then added onto this basic 
structure to produce different BODIPY dyes with different excitation and emission 
wavelengths. The particular BODIPY dye that has been used in this study is 
shown in figure 1.4. Numerous sources of information can be found on these 
fluorophores [22, 23, 24]. 
Figure 1.4 - Structure of BODIPY® 630 1 650 -X, succinimidyl ester 
lcez = 625 nm, lcem = 640 nm, MW = 660.5 
Advantages: 
• high extinction coefficients (100 300 cm·1 M-1 for BODIPY® 630/650-
X, SE)) 
9 
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• high fluorescence quantum yields (often approaching 1.0, even in 
water) 
• spectra that are insensitive to solvent polarity and pH due to lack of 
ionisable groups (hence no ionic charge) 
• narrow emission bandwidths 
• greater photostability than fluorescein - they remain intensely 
fluorescent even when constantly illuminated 
Disadvantages: 
• expensive (-£153 per 5 mg BODIPY® 630/650-X, SE) 
• small Stokes shift (15 nm) 
1.1.4.4 Cyanine dyes (CyTM 5 and CyTM 5.5 bisfunctional dyes) 
Papers are available for more comprehensive reading on the cyanine dyes Cy 5 
and Cy 5.5 [25, 26, 27]. 
Figure 1.5 - Structure of Cyn< 5 bisfunctional dye 
:::,. 
N+ 
o ~~ 
o 
"-ex = 649 nm, "-em = 670 nm, MW = 975.15 
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Figure 1.6 - Structure of CyTM 5.5 blsfunctional dye 
o ~~ 
o 
Aex = 675 nm, Aem = 694 nm, MW = 131158 
Advantages: 
• high extinction coefficients (250,000 cm-l M-l ) 
• quantum yields of >0 28 
• highly water soluble 
Disadvantages: 
• small Stokes shift (21 nm for Cy 5 and 19 nm for Cy 5_5) 
• expensive (-£25_00 per mg) 
11 
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1.2 FLUORESCENCE POLARISATION 
The practical application of fluorescence polarisation to the determination of 
proteolytic enzymes has been carried out in order to evaluate the potential of this 
detection method for use in protease high throughput screening assays. There 
are numerous references on the theory of fluorescence polarisation and its 
applications [28 , 29, 30, 31, 32] . The theory of fluorescence polarisation is 
crucia l to the understanding of the idea behind these assays and will therefore be 
described . 
1.2.1 Theory of fluorescence polarisation 
The concept of molecular movement and rotation is the basis of fluorescence 
polarisation . To fully understand the theory of fluorescence polarisation, consider 
the wave model of light as shown in figure 1.7. 
Figure 1.7 - The wave model of light (V = velocity, E = 
electric field, H = magnetic field, vectors) 
H 
12 
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This single ray may be characterised by the orientation of its electric vector within 
a co-ordinate system. Thus, if one looked directly into an oncoming ray, the 
electric vector would be at some angle 9. Likewise, a beam composed of a 
number of rays could be characterised by the angular distribution of its electric 
vectors. Two extreme situations are possible: the vectors can be evenly 
(randomly) distributed (figure 1.8a), or they can be parallel (1 8b and 1 8c). 
Figure 1.8 - Electric vectors of light randomly distributed (a) 
and parallel (b and c) 
.. ~ 
.. ~ 
.. ~ 
.. ~ 
a b c 
These two situations can be differentiated experimentally by viewing light through 
a polariser, which allows maximum transmission of light when it is aligned parallel 
to the electric vector and zero transmission when It is perpendicular. Therefore, 
as the polariser is turned through 1800 In 1.8a, the intensity remains constant. 
However, in 1.8b the intensity would be a maximum with the polariser vertical 
and zero with it horizontal, the converse being true for 1.8c. 
It is this experimental observation that allows one to define the polarisation of 
light as: p = ~V -H~ (equation 1), where p = polarisation, V = vertical component 
V+H 
of emitted light, H = hOrizontal component of emitted light, when excited by 
vertical plane polarised light. 
13 
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As can be seen by equation 1, P ("polarisation unit") is a dlmensionless entity 
and is not dependent on the intensity of the emitted light or on the concentration 
of the f1uorophore. This is a fundamental power of fluorescence polarisation. For 
convenience the term amP" (pronounced "mllllpee") is used, where 1 mP equals 
one thousandth of a P. Applying equation 1 to the situation in figure 1.8a the two 
components Cl! and H) are always equal and p = O. In 1.8b, H = 0 and p = 1, 
while m 1.8c V = 0 and p = -1. When p = 0, the light is called unpolarised or 
natural lIght. With p = ±1, it is completely polarised, whereas with 1~ p ~-1, but 
not equal to 0, it IS partIally polarised. 
1.2.1.1 Dipole model of absorption and emission 
Light is absorbed by and emitted from molecules via electric dipoles, which have 
certain orientations relative to the structure of the molecule. Maximum 
absorption of light occurs when the absorption dipole is parallel to the electric 
vector of the light. Specifically, the probability of absorption IS proportional to 
cos2 {) where {) is the angle between the dipole and the electric vector. 
Therefore, absorption is a maximum when {) = 0° and is zero when {) = 90°. 
Emission from a dipole can occur with the electric vector at any angle to the 
dipole, but the probability is proportional to sm2 E where E is the angle between 
the dipole and the electric vector. 
1.2.1.2 Depolarisation 
The sequences of events that occur in fluorescence have already been 
discussed in section 1.1.1. In each of these processes, changes can occur such 
14 
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that the polarisation of the fluorescent light is different from that of the exciting 
light. 
The absorption process itself IS the first source of depolarisation. As discussed in 
section 1.2.1.1 when undergoing excitation with vertically polarised light the 
vertical dipoles will be preferentially excited. In reality emission from these 
dipoles could give only partial polarisation, as non-vertical dipoles do absorb 
some of the vertically polarised excited light. 
If the emission dipole IS at an angle to the absorption dipole, a second source of 
depolarisation is evident which is dependent upon the angle between the two 
dipoles, the larger the angle the greater the depolarisation. 
A third important depolarising factor is the Brownian rotation of the molecule. 
Rotation of the molecule will result in rotation of the emitting dipole to a new 
orientation. Therefore, if the excited state lifetime is comparable to the time 
required for Brownian rotation to occur over an appreciable angle, significant 
depolarisation results. 
Depolarisation can also result from non-radiative energy transfer. Transfer takes 
place preferentially between parallel dipoles, but nonparallel dipoles can also 
undergo transfer with resulting depolarisation. 
A final mechanism of depolarisation is trivial reabsorption the light emitted from 
one molecule is absorbed by another molecule, which then reemlts It at a 
different orientation. 
The term Po is defined as the intrinsic polarisation of a molecule in the absence of 
any depolarisation due to Brownian rotation or intermolecular processes. 
15 
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1.2.1.3 
Introduction 
Relationship between fluorescence polarisation and molecular 
weight 
Rate of rotation of a molecule is described by the Stokes equation: 
p = 3 ::rv (equation 2), where p = rotational relaxation time, " = viscosity of the 
medium, V = molecular volume, R = gas constant, and T = temperature in 
degrees Kelvin. 
The molecular volume is defined by: V = vM(equation 3), where V = molecular 
volume, v = partial specific volume, and M = molecular weight In Daltons. 
From equations 2 and 3 it can be seen that the higher the molecular weight of a 
molecule the higher the molecular volume and therefore the higher the rotational 
relaxation time will be. 
The Pernn equation (equation 4), which was first described in 1926 [33], 
describes the relationship between the observed fluorescence polarisation, the 
limiting polarisation, the fluorescence lifetime of the fluorophore, and its rotational 
relaxation time: (~ - ~) = (:0 -~)( 1 + ~) (equation 4), where P = polarisation, 
Po = limiting polarisation, t = fluorescence lifetime, and p = rotational relaxation 
time. From equation 4 it can be seen that the smaller the fluorescence lifetime, 
the higher the fluorescence polarisation will be. The smaller the rotational 
relaxation time, the smaller the fluorescence polarisation will be. 
Combining the Stokes equation (equation 2) and the Perrin equation (equation 
4), the relationship between the molecular weight of a molecule and its 
fluorescence polarisation is achieved - the fluorescence polarisation of a 
fluorophore is proportional to its rotational relaxation time, which in turn depends 
16 
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upon its molecular volume and hence its molecular weight (1/P is proportional to 
1/M). The smaller the molecule, the faster it rotates, and so the lower the 
fluorescence polarisation will be This relationship stands provided that the 
temperature and solution viSCOSity remain constant. 
1.2.2 Advantages of fluorescence polarisation 
• fluorescence polarisation is a homogenous technology requiring no 
immobilisation, washing or separation 
• measurements are very rapid 
• reagents are stable 
• large batches may be prepared which results in high reproducibility 
• fluorescence polarisation has proven to be highly automatable 
• in theory fluorescence polarisation is independent of intensity, so is 
relatively immune to the inner filter effect and so works in coloured 
solutions and cloudy suspensions 
• fluorescence polarisation is relatively insensitive to instrument changes 
such as drift, gain settings, lamp changes, etc 
• fluorescence intensity is obtained in addition to polarisation, if required 
1.2.3 Disadvantages of fluorescence polarisation 
• fluorescence polarisation is instrument dependent, the quality of the 
results is directly linked to the quality of the instrument 
• the difference between the size of the starting material and the end 
material should be significant enough to give a reasonable polarisation 
change 
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1.3 FLUORESCENCE RESONANCE ENERGY TRANSFER (FRET) 
1.3.1 Theory of FRET 
Much of the work presented in this thesis relies upon the phenomenon of FRET. 
As numerous sources of information are available on the theory of FRET [34, 35, 
36, 37], it will not be discussed in great detail here. However, as this technique is 
crucial to understanding the theory behind much of the practical work, a bnef 
description Will be given. 
FRET IS a distance-dependent interaction between the electronic excited states 
of two dye molecules in which energy from an electronically excited molecule (the 
donor f1uorophore) is shifted to a neighbouring molecule (the acceptor 
f1uorophore), returning the donor molecule to its ground state without the 
emission of a photon. Once excited, the acceptor can undergo de-excitation by 
the same emissive and non-emissive processes that occur upon excitation of a 
f1uorophore 
Although the phenomenon of resonance energy transfer was observed by Perrin 
at the beginning of the 1900's, it was Forster who proposed a theory describing 
long-range molecular interactions by resonance energy transfer in the late 1940's 
[38]. Forster derived a transfer rate equation that related the interchromophore 
distance and the spectroscopic properties of the chromophores. The rate 
constant for energy transfer is proportional to the inverse sixth power of the 
intermolecular separation, making it useful over distances comparable with the 
dimensions of biological macromolecules [39]. Thus, FRET is an important 
technique for investigating a variety of biological phenomena where markers that 
track physical proximity are necessary or useful. As the efficiency of FRET is 
proportional to r-6 where r = distance of intermolecular separation, not only does 
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energy transfer only occur over short ranges, but It definitely does not occur over 
long ranges Energy transfer is thus an excellent method for use in protease and 
protease inhibition assays where proteolytic action completely abolishes the 
energy transfer between f1uorophores that occurs In the intact protein. Digestion 
of the protein substrate separates the f1uorophores, Increasing the distance of 
intermolecular separation and so completely preventing the phenomenon of 
energy transfer from being able to occur. 
1.3.2 Conditions for FRET 
A number of conditions are crucial for the mechanism of FRET to occur. The 
primary requirement for FRET is that the energy lost by de-excitation of the donor 
molecule be matched by the energy required for excitation of the acceptor. In 
other words, the absorption spectrum of the acceptor molecule must overlap the 
emission spectrum of the donor molecule, as shown in figure 1.9. 
Figure 1.9 - Schematic representation 
of spectral overlap required for FRET 
Donor OVERLAP 
Wavelength (nm) 
Acceptor 
absorption 
The spectral overlap seen in figure 1.9 can involve two chemically different 
molecules as donor and acceptor (as is the case In the protease substrate 
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described in chapter 4), or two identical groups due to the common tendency for 
the excitation and emission spectra of fluorophores to overlap (as is the case in 
the protease substrate described In chapter 5). 
Donor and acceptor molecules must also be in close proximity - typically 10 -
100 A. FRET IS a distance-dependent energy transfer, and the distance at which 
energy transfer is 50 % efficient (i e. 50 % of excited donors are deactivated by 
FRET) is defined by the Forster radius (Ra). The magnitude of Ra is dependent 
upon the spectral properties of the donor and acceptor dyes (the magnitude of 
FRET is dependent upon the quantum yield of the donor), and for good donor-
acceptor pairs, Ra values of 30 to 60 A are common. 
One other fundamental requirement for FRET is that donor and acceptor 
transition dipole orientations must be approximately parallel. 
1.3.3 FRET donor I acceptor pairs 
In recent years, numerous donor I acceptor pairs have been proposed; these 
include 5-{2-aminoethyl)aminonaphthalene-1-sulphonyl (EDANS) I 4-{4-
dimethylaminophenylazo)benzoyl (DABCYL) [40), fluorescein I rhodamine [41), 
pairs based upon the BODIPY® dyes [42), coumarin I fluorescein [43), 0-
aminobenzoyl (Abz) I 3-nltrotyrosine [44), as well as near-infrared squaraine dyes 
Sq635 I Sq660 [45). Different donor I acceptor dye pair combinations have 
previously been discussed with regard to dye pairs with superior spectroscoplc 
properties [46). 
Non-fluorescent acceptors exist which accept energy from a donor Without any 
resulting fluorescence emission. These acceptors as a group are known as 'dark 
quenchers", for example DABCYL. These dyes have the particular advantage of 
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eliminating the potential problem of background fluorescence resulting from direct 
acceptor excitation. 
1.3.4 Advantages of FRET 
• simultaneous observation of quenching and enhancement effects allows 
specific effects to be distinguished from non-specific environmental effects 
on fluorescence intensity 
• distances or changes In distances can be measured in a complex of 
molecules 
• structural information can be gained 
1.3.5 Disadvantages of FRET 
• direct excitation of acceptor causes a high background 
• the availability of adequate donor I acceptor pairs is somewhat limited, 
especially at near infrared wavelengths 
• when measuring a change in distance between two probes, the result is 
scalar and gives no indication of which probe (donor and I or acceptor) 
moves 
• the presence of free unbound labels in solution could mask a change in 
energy transfer 
21 
Chapter 1 Introduction 
1.4 FLOW INJECTION ANAL VSIS (FIA) 
1.4.1 History of flow injection analysis 
The term flow injection analysis was coined in the early spring of 1974 at the 
Technical University of Denmark by Ruzicka and Hansen [47]. FIA was used to 
describe a type of continuous flow analysis that utilises a flowing stream, 
unsegmented by air bubbles, into which highly reproducible volumes of sample 
are injected. Application of this principle to automatic analysis yields a fast, 
precise, accurate, and extremely versatile system that is simple to operate. 
The concept of FIA received earliest attention from the electrochemists. In 1970 
Nagy, Feher, and Pungor published their first in a series of papers describing 
injection of a sample into a flowing stream of electrolyte [48]. Their system _ 
involved passage of the sample carrier stream through a magnetically stirred 
mixing chamber followed by flow past a slllcone-rubber-based graphite electrode. 
This technique was subsequently modified simultaneously by Stewart, Beecher, 
and Hare in the United States [49] and by Ruzicka and Hansen i~ Denmark [47]. 
Their primary innovation was in the use of flow-induced sample dispersion as the 
sample carrier stream was pumped through narrow bore tubing. This allowed 
controlled mixing of the sample as opposed to the gross mixing generated in the 
mechanically stirred chamber, thus avoiding excessive sample dilution. The 
Danish group developed the method using primarily instrumentation normally 
associated with segmented flow analysers (SFA). In contrast, the American 
group based their initial work on high-performance liquid chromatography (HPLC) 
components. 
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1.4.2 Theory of flow injection analysis 
Theory, applications, and developments of FIA are covered by many papers [50 -
57] and books [58 , 59] . The technique of FIA depends on four primary factors: 
unsegmented flow, sample injection , reproducible timing , and controllable sample 
dispersion. A typical FIA system is shown in figure 1.10 and usually consists of 
the following components: (a) a pump (commonly a peristaltic pump), which is 
used to propel the carrier stream through a thin tube at a steady pulse-less rate; 
(b) an injection port, which allows a well-defined volume of sample solution to be 
injected into a carrier stream in a reproducible manner without stopping the flow; 
(c) a reaction coil in which the sample zone disperses and reacts with the 
components of the carrier stream; and (d) a flow-through detector, for example a 
fluorescence spectrophotometer, which transduces some property of the analyte 
into a continuous signal which is recorded . A typical detector output has the form 
of a peak, the height and area of which is related to the concentration of the 
analyte. 
Figure 1.10 - Schematic diagram of a typical simple FIA system 
Pump 
Reaction 
Carrier 
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When the sample is first injected, it forms a well-defined sample plug in the 
stream. As the sample is swept downstream through the narrow bore tubing, the 
plug disperses Into, and thus mixes with, the carner stream under laminar flow 
conditions to form a gradient. The magnitude of this dispersion is dependent 
upon the operating parameters applied to the system, including sample volume, 
tubing bore size, tubing length, flow rate, the molecular diffusion coefficient of the 
species concerned, and, possibly, coil diameter. By changing these parameters, 
the dispersion can be easily manipulated to suit the requirement of a particular 
analytical procedure so that an optimum response is obtained at minimum time 
and reagent expense. 
For the purpose of FIA, the dispersion (0) is defined as the ratio of 
concentrations before and after the dispersion process has taken place in the 
element of flUid that Yields the analytical read out. The dispersion or dilution of a 
sample in an FIA system is given by the following equation: O=~ (equation 
Cmax 
5), where 0 is the dispersion coefficient at the peak maximum produced by the 
ratio between Co, the concentration of a pure dye, and Cmax, the concentration of 
that same injected dye as It passes through the detector. 
A number of alternative modes of FIA have been developed, illustrating the 
versatility of this technique. These include merging zone [60), stopped flow [61), 
sequential injection [62 - 64), bead Injection [65), all injection analYSIS [66), and 
mUlti-component [67 - 72) techniques. 
Flow injection analysis has also been used on a miniature scale where 
microfluidic devices commonly have channels 200 llm wide and 100 llm deep 
with typical channel lengths of 2 - 3 cm long. This is a vast difference to those 
dimensions used in typical FIA where tubing of around 0.8mm intemal diameter 
with lengths of the order of tens of cm are typically used. 
24 
Chapter 1 IntroductIon 
1.5 HIGH THROUGHPUT SCREENING (HTS) 
1.5.1 Concept of high throughput screening 
Drug discovery is a numbers game. The well-known attrition rate of candidates 
screened to drugs on the market is dismal (commonly cited to be 5,000 -10,000 
to 1). With increasing pricing pressure on marketed drugs, escalating research 
costs and competition, and expiring patents on legacy cash cows, the 
pharmaceutical industry needs to improve its efficiency [73]. One simple, but 
hopefully effective, strategy is to screen more compounds more efficiently: test 
more, discover more. 
High throughput screening (HTS) is the process by which large numbers of 
compounds are tested, in an automated fashion, for actIVIty as inhibitors or 
activators of a particular biological target, such as a cell surface receptor or a 
metabolic enzyme. 
It can be seen from figure 1.16 that since 1995 the number of published articles 
on high throughput screening has increased from year to year, illustrating the 
importance that research in this area is gaining. 
Nearly all drug discovery research projects in the pharmaceutical industry employ 
HTS assays as initial steps to discover the chemical leads. The primary role of 
the technology is to detect lead compounds and supply directions for their 
optlmisatlon using other techniques. Many properties critical to the development 
of a successful drug cannot be assessed by HTS, such as specificity, tOXICity and 
pharmacokinetics. The dropout rate during development is stili considerable and 
is associated with high financial losses in the pharmaceutical industry. Only one 
out of approximately ten potential drug candidates entering phase I of 
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development will finally reach the market. Insufficient pharmacological and 
pharmaceutical properties represent the majority of reasons for failure. 
nt2 History of screening 
In the 1970s, lead identification typically involved the manual synthesis of about 2 
g of a compound with screening being carried out in VIVO by injecting about 80 
mice. The major pharmaceutical companies screened approximately two 
compounds per week. 
In the 1980s, in vivo tests were largely replaced by in vitro biological assays 
which were faster and required less compound to be synthesised - screening 
Increased to tens of compounds per week. 
HTS has been developed in the last few years to test several thousands of 
compounds for biological activity per day. Companies are now looking to screen 
hundreds of thousands of compounds per day per machine. 
Although any assays performed on the bench top can, in theory, be applied to 
HTS, conversion to an automated format Imposes certain constraints that affect 
the design of the assay in practice. Procedures that are routine at the bench are 
often extremely difficult to automate. Also, the more steps required for an assay, 
the more difficult to automate the HTS. The ideal assay is one that can be 
performed in a single well with no other manipulation other than addition of the 
sample to be tested. 
A number of assay formats have been developed or modified over the past few 
years to conform to the constraints imposed by HTS. Several of the more 
recently developed or exploited assay protocols for HTS have been the focus of 
several papers [74,75]. 
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1.5.3 The drug discovery process 
Drug discovery is a complex process, which generally starts with the identification 
and characterisation of a target like an enzyme or other protein implicated in a 
disease. 
A comprehensive analysis of the drug targets underlying current drug therapy 
undertaken in 1996 showed that present-day therapy addresses only about 500 
molecular targets and as shown in figure 1.11 , cell membrane receptors, largely 
heterotrimeric GTP-binding protein (G protein)-coupled receptors, constitute the 
largest subgroup with 45 % of all targets, and enzymes account for 28 % of all 
current drug targets. This analysis was discussed in an excellent review that also 
covers the evolution of drug discovery and discusses the historical aspects of 
drug discovery from its infancy to the current day [76]. 
Figure 1.11 - Biochemical classes of drug targets of current therapies 
o Ion channels (5 %) 
IJl Unknown (7 %) 
11 Enzymes (28 %) 
III Receptors (45 %) 
I] Nuclear receptors (2 %) 
DNA (2 %) 
o Hormones and factors (11 %) 
HTS assays are developed to screen for a desired activity against the target. 
The introduction of robotic HTS, with its ability to devour up to 100,000 samples 
per day per machine in mass screening , has given rise to an insatiable demand 
for new compounds and the flood of targets that will ultimately come from the 
Human Genome Project will further compound this demand . Continuing 
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advances in molecular biology, human genetics, genomics [77], and proteomlcs 
[78, 79) have also accelerated identification of the mechanisms underlying a 
growing number of human diseases. This progress has increased the number of 
novel protein targets available for potential therapeutic intervention by drug 
treatment. Historically, a medicinal chemist IS able to synthesise 25 - 100 
compounds per year one-by-one, depending upon complexity. Clearly this 
classical approach is a totally unsatisfactory way to feed the HTS process. 
Combinatorial Chemistry (Combi Chem) is an attempt to increase the productivity 
of medicinal chemists by synthesising large numbers of compounds with the help 
of robots using standardised chemistry (dozens to millions of compounds in one 
run, depending upon technology). 
The bottleneck in drug development has shifted from the generation of lead 
·structures to their transfonnation into orally active drugs with the desired 
physiological properties and performance results in clinical trials. It will therefore 
no longer be enough to synthesise large and diverse libraries; rather, it will 
become more and more important to find ways to integrate demands such as 
bioavailability at an early stage of the drug search. These challenges can only 
be met by creating efficient interfaces between combinatorial syntheses and 
bioassays. Recent developments in this area have been the focus of a recent 
article [80). 
A selection of compounds from combinatorial chemistry is screened using the 
HTS assays to identify active compounds. Hits identified in this first round must 
be retested to confinn their activity. By synthesising a series of compounds that 
are chemically related to the lead compound, lead optimisation then attempts to 
improve the activity, availability, stability, and specificity while reducing toxicity 
and potential side effects. Their improved biological activity is reconfinned and, 
those few that seem to be promising are then moved forward into pre-clinical 
animal stUdies to evaluate biological activity in vivo. 
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1.5.4 Miniaturised high throughput screening 
The transition from slow, low throughput screening to industrialised robotic ultra 
high throughput screening in the last few years has made It possible to screen 
hundreds of thousands of compounds against a biological target in a short time-
frame. The need to minimise the cost of screening has been addressed primarily 
by reducing the volume of sample to be screened. This, in turn, has resulted in 
the miniaturisation of HTS technology as a whole. 
Miniaturisation of HTS results in three significant benefits that address the 
pharmaceutical industry's needs: lower costs, faster turnaround, and reduced 
space requirements. Approximately three-quarters of the costs of screening 
derive from the costs of both chemical and biological reagents. MiniatUrisation 
reduces these costs in proportion to the reduction in volume (typical flow 
dimensions were given in section 1.4.2). Miniaturisation also allows for the 
compression of more samples onto one system, reducing sample-to-sample 
distance. As sample transport is a significant time factor in screening, the total 
analysis time per sample is reduced significantly by miniaturising. Due to the 
picoliter volumes of highly miniaturised systems, and the high-denslty formats 
that can be designed, assay throughput can be increased without an associated 
research and development cost. The concept, scope, and impact of miniaturised 
methods as applied to HTS have been explored [81, 82]. Trends in the field of 
ultra high throughput screening and the technological developments that are 
necessary to enable the routine application of miniaturised systems within an 
industrial environment have been summarised [83]. 
In a recent paper, the parallel development, adaptation, and integration of 
different microelectronic sensors into miniaturised biochips was demonstrated 
[84]. This was carried out for a multiparametric, functional on-line analysis of 
living cells in physiological environments, which would be applied to HTS 
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1.6 ENZYMES 
1.6.1 Introduction to enzymes 
Enzymes are the reaction catalysts of biological systems. They have high 
molecular weights ranging from around 5,000 to over 1 million. They increase 
the rate of chemical reactions taking place within living cells without themselves 
suffering any overall change. The reactants of enzyme-catalysed reactions are 
termed substrates and each enzyme is quite specific in character, acting on a 
particular substrate or substrates to produce a particular product or products via 
an enzyme-substrate intermediate. 
With the exception of a small group of catalytic RNA molecules, all enzymes are 
proteins. Their catalytic activity depends upon the integrity of their native protein 
conformation. If an enzyme is denatured or dissociated into subumts, catalytic 
activity is usually lost. If an enzyme is broken down into ItS component amino 
acids, its catalytic activity is always destroyed. Thus the primary, secondary, 
tertiary, and quaternary structures of enzymes are essential to their catalytic 
activity. The part of the tertiary structure that is responsible for the catalytic 
activity is called the 'active site' of the enzyme, and often makes up only 10 - 20 
% of the total volume of the enzyme. The active site contains the residues that 
directly participate in the making and breaking of bonds. These residues are 
called the catalytic groups. 
Water is normally excluded from the active site unless it is a reactant. The 
non polar character of much of the active site enhances the binding of substrate. 
However, the active site may also contain polar residues, creating a 
microenvironment in which certain of these residues acquire special properties 
essential for catalysis. In addition to hydrophobic interactions, electrostatic 
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bonds, hydrogen bonds, and van der Waals forces mediate reversible 
interactions between enzyme and substrates. These highly specific non-covalent 
enzyme-substrate binding interactions confer upon the enzyme high substrate 
specificity. 
Many sources of literature covering the structure, function and basic concepts of 
enzymes are available for a more detailed discussion [85 - 87]. 
1.6.2 Factors affecting enzyme activity 
Several factors affect the rate at which enzymatlc reactions proceed -
temperature, pH, and the presence of any inhibitors or activators. 
Like most chemical reactions, the rate of an enzyme-catalysed reaction increases 
as the temperature is raised to a maximum level, known as the optimum 
temperature. Activity then abruptly declines with further increase of temperature, 
normally due to denaturation of the enzyme. 
Enzymes are affected by changes in pH. The most favourable pH - the point 
where the enzyme is most active - is known as the optimum pH. Extremes of pH 
generally result in complete loss of activity for most enzymes where activity may 
not be restored even after re-adjustment of the pH. 
Enzyme inhibitors are substances that alter the catalytic action of the enzyme 
and consequently slow down, or in some cases, stop catalysis. Enzyme 
inhibition is discussed in more detail in section 1 9. 
Activators are substances that increase the catalytic activity of an enzyme, are 
used in very small amounts and which, unlike coenzymes, do not participate in 
the enzyme reaction. 
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1.6.3 Enzyme kinetics 
Experimental evidence shows that for many single-substrate enzyme-catalysed 
reactions a hyperbolic relationship exists between initial velocity Vo and initial 
substrate concentration [Sol as shown in figure 1.12. 
Figure 1.12 - Dependence of initial velocity on substrate 
concentration for a single-substrate enzyme-catalysed reaction 
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The graph Vo versus [Sol (figure 1.12) shows three distinct regions: 
1. At low substrate concentration the velocity of the reaction is directly 
related to the substrate concentration; this is the region of first order 
kinetics. 
2. At intermediate substrate concentration there is a big curve, where the 
velocity of the reaction increases more slowly with increase in the 
substrate concentration . 
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3. At high substrate concentration Vmax is attained and the observed velocity 
is independent of further addition of substrate; this is the region of zero 
order kinetics. 
Kinetic models to explain these findings were proposed by Henri (1903) and 
Michaelis and Menten (1913). These were essentially similar, but Michaelis and 
Menton did a great deal of experimental work to give their work a sounder basis. 
The critical feature in their treatment is that a specific enzyme - substrate (E8) 
complex is a necessary intermediate in catalysis. The model proposed, which is 
the simplest one that accounts for the kinetic properties of many enzymes, is: 
k1 k2 
E + 5 ~ • E5 - - .. E + P 
k_1 
where E = enzyme, 8 = substrate, E8 = enzyme - substrate complex, and P = 
product. E combines with 8 to form E8 with a rate constant of k 1. E8 then has 
two fates. It can dissociate to E and 8 with a rate constant of k-1 or proceed to 
form P with a rate constant of k2. 
Vo = Vmax [51 (equation 6) is the Michaelis-Menten equation, the rate equation 
KM + [51 
for a single-substrate, enzyme-catalysed reaction . It is a statement of the 
quantitative relationship between the initial velocity VD, the maximum initial 
velocity V max, and the initial substrate concentration [8], all related through the 
Michaelis-Menten constant KM. 
The meaning of KM is evident from equation 6. When [8] = KM, then V = Vmax 12. 
Thus KM is equal to a substrate concentration at which the reaction rate is half its 
maximal value. 
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The Michaelis-Menten equation gives a hyperbolic curve as shown in figure 1.12. 
This is not entirely satisfactory for the determination of Vmax and KM. Unless, 
after a series of experiments, there are at least three consistent points on the 
plateau of the curve at different [S] values , then an accurate value of Vmax , and 
hence of KM cannot be obtained. 
This prol;Jlem was overcome by Lineweaver and Burk (1934) without making any 
fresh assumptions. They simply inverted the Michaelis-Menten equation thereby 
. If · . . . h I· I 1 KM 1 1 convenlenty transormmg It Into a stralg t- me pot: -=--0-+--
V Vmax [51 V max 
(equation 7) . This is of the form y = mx + c, which is the equation of a straight 
line graph; a plot of y against x has a slope of m and intercept of c on the y-axis. 
As shown in figure 1.13, KM and V max can be read directly from the Lineweaver-
Burk plot. 
Figure 1.13 - Lineweaver-Burk plot 
11 V 
Intercept = -1 1 KM 
1 
Intercept = 1 1 Vmax 
11 [51 
Numerous sources of literature are available that discuss enzyme kinetics in 
greater detail [88 - 90] . 
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1.6.4 Proteolytic enzymes 
Proteases are enzymes that catalyse the hydrolysis of peptide bonds. They are 
widely distributed in cells, and are either soluble, or associated with plasma 
membranes and subcellular organelles, or secreted. This extensive distribution 
of proteases in both organs and subcellular compartments suggests that they 
play a key biological role in both physiological and pathophysiological situations. 
In 1960 the biochemist Hartley (91) proposed that proteases should be classified 
according to their catalytic mechanism: serine proteases, cysteine proteases, 
aspartate proteases, and metallo proteases. 
The serine proteases are characterised by the presence of a catalytic triad 
composed of aspartic aCid (Asp), serine (ser) and histidine (His). Serine acts, In 
this case, as a very reactive reSidue, which forms a covalent bond with the 
substrate. Hydrolysis of the substrate occurs in two successive stages: acylation 
and deacylation of the enzyme. The carbonyl group of the peptide bond to be 
cleaved undergoes nucleophilic attack by the unusually reactive OH group of the 
active site serine, resulting in the formation of a covalent tetrahedral intermediate. 
Decomposition of the tetrahedral adduct results in the release of the amino 
portion of the substrate and the formation of an acyl serine derivative The 
departing amino group receives a proton from the imidazole ring of histidine. 
Subsequent hydrolysis of the acyl enzyme to active enzyme and the carboxylic 
acid product occurs through a reaction sequence analogous to that Involved in 
the formation of the acyl enzyme. This catalytiC process is facilitated by the 
proximity at the enzyme's active site of the histidine and aspartate residues, 
which thus actively participate in the catalysis. 
The cysteine proteases are characterised by the catalytic triad cysteine (Cys) , 
, 
histidine (His), and aspartic acid (Asp). Cysteine IS a very reactive residue, which 
is involved in the formation of the Intermediate complex with substrates. 
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The aspartate proteases are also called acid proteases due to their low pH 
optima. Their catalytic site consists of two aspartic acid residues. The enzyme-
substrate intermediate IS of the general aCid-base type rather than the covalent 
type. The two aspartic acid molecules are linked through a hydrogen bond. 
Aspartate proteases facilitate nucleophilic attack by two Simultaneous proton 
- transfers: the first from a water molecule to the carboxylate ion of one aspartic 
acid residue, and the second from the carboxyl group of the second aspartic acid 
to the oxygen atom of the carbonyl group of the substrate. These transfers lead 
to the formation of a neutral tetrahedral intermediate. The same dual transfer 
mechanism destroys this intermediate, which donates a proton to the carboxylate 
ion of the first aspartic acid, during which the proton of the carboxyl group of the 
second aspartic acid is transferred to the nitrogen atom, thus hydrolysing the C-N 
bond of the substrate. 
The metallo proteases have an active site that contains a metal ion, usually zinc 
(Zn2+), which is an integral part of the protein structure. They do not form 
covalent enzyme-substrate intermediates. In addition to a metal ion, the catalytic 
site always contains a glutamic acid (Glu) residue, sometimes associated with 
tryptophan (Trp) or histidine (His). 
Serine and cysteine proteases therefore form a covalent intermediate complex 
With their substrates because the amino acids at the catalytic site are very strong 
nucleophlles. Aspartate and metallo proteases, on the other hand, usually act by 
an acid-base catalytic mechanism, using a water molecule. 
A variety of sources can be found in the general area of proteolytic enzymes [92 -
95]. 
The proteases play a key role in the digestion of food proteins, zymogen 
activation, activation of the complement system, and in blood coagulation and 
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fibrinolysis. They are also involved in the regulation of blood pressure, tissue 
regeneration, and in reproduction both during ovulation and the fusion of 
gametes. Proteases are also involved in immune response, processing of 
peptides and proteins, and growth and development. When the balance of 
proteases in these biological functions becomes upset, pathological conditions 
occur. As discussed in section 1.8.1, as the proteases are involved in virtually all 
biological functions and dysfunctions they represent an important drug target. 
Five different proteolytic enzymes have been investigated In this work and thus a 
brief description of each is given below. An extremely comprehensive book 
covers databanks, name and history, activity and specifi'city, structural chemistry, 
preparation, biological aspects, and distinguishing features of proteolytic 
enzymes known to date (96). 
1.6.4.1 Alkaline protease 
Alkaline proteases are covered in detail elsewhere [97]. Enzyme commission 
number: unknown, type: serine, MW: 50,000, activity: - 26 Umts I mg solid, 
speclficity: broad, pH: maximal activity at pH 11 0, additional information: type 
XXI protease. 
1.6.4.2 Proteinase K 
Specific proteinase K information is available [98, 99). Enzyme commission 
number: 34.21 64, type: serine, MW: 28,930, activity: 10 - 20 Units I mg protein, 
specificity. peptide bond adjacent to the carboxyl group of aliphatic and aromatic 
amino aCids with blocked alpha-amino groups, pH: active over the range 7.5 to 
12.0, but most often used in pH range 7.5 - 9.0, additional information: remains 
active in the presence of sodium dodecyl sulfate and urea. 
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1.6.4.3 Chymotrypsin 
Enzyme commission number: 3.4.21.1, type: serine, MW: 25,000, activity: 40 -
60 Units I mg protein, specificity: hydrolyses peptide bonds with aromatic or large 
hydrophobic side chains (Tyr, Trp, Phe, Met) on the carboxyl end of the bond, 
pH: maximal activity around pH 8 0, additional information: a- and 1-
chymotrypsins have identical primary structures, but different enzymatlc 
properties, stabilities and tertiary structures - during experimental work a-
chymotrypsin has been used. 
1.6.4.4 Trypsin 
Enzyme commission number: 3.4.21.4, type: serine, MW. 23,800, activity: 1,000 
- 2,000 Units I mg protein, specificity: peptide bonds with arginine or lysine on 
the carboxyl end of the bond with a preference for arginine over lysine that is 2-
to 10-fold, pH: maximal actiVity around pH 8.0, additional information: first 
described and named in 1876 by Klihne as the proteolytic activity in pancreatic 
secretions. 
1.6.4.5 Pepsin 
Enzyme commission number: 3.4.23.1, type: aspartic acid, MW: 35,000, activity: 
3200 - 4500 Units I mg solid, speclficity: preferentially cleaves C-terminal to 
phenylalanine, leucine, and glutamate, does not cleave at valine, alanine, or 
glycine, pH' pH optimum from 2 - 4 (irreversibly inactivated at pH > 6), additional 
information: active in 4 M urea and 3 M guanidine HCr. 
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1.7 ENZYME IMMOBILISATION 
The term 'immobilised enzyme' describes an enzyme that has been chemically or 
physically attached to a water-insoluble matrix, polymerised into a water-
insoluble gel, or entrapped within a water-insoluble gel matrix or water-insoluble 
microcapsule resulting in reduced or complete loss of enzyme mobility These 
immobilised enzymes retain their catalytic activity and can be used repeatedly 
and continuously. The usage of binding enzymes onto solid materials goes back 
to 1916 when Nelson and Griffin [100] first immobilised invertase on charcoal and 
observed that the enzyme retained most of Its actiVity over a long period of time. 
However, this work was largely ignored until the 1950s. Since then 
immobilisation of proteins in general, and enzymes in particular, has been widely 
studied and the number of applications of immobilised enzymes is increasing 
Many sources of information can be found on the preparation, characteristics, 
and application of immobilised enzymes for more detailed reading [101 - 105]. 
1.7.1 Why immobilise enzymes? 
There are several reasons for the preparation and use of immobilised enzymes. 
In addition to a more convenient handling of enzyme preparations, the two main 
benefits are (1) easy separation of the enzyme from the product, and (2) reuse of 
the enzyme. 
Easy separation of the enzyme from the product simplifies enzyme applications 
and supports a reliable and efficient reaction technology. Reuse of enzymes 
provides cost advantages, which are often an essential prerequisite for 
establishing an enzyme-catalysed process in the first place. 
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Immobilised enzymes offer many more advantages over their soluble analogues 
than the two main benefits mentioned above [1061. These Include: 
• increased stability against denaturing conditions such as high temperature 
and extreme pH during storage and use 
• ease of use as no enzyme solution preparation is required 
• greater applicability to multi-determination due to the ease of combining 
immobilised enzymes in a variety of designs in flow systems 
• they do not contaminate the sample and insoluble enzymes can be easily 
recovered from batch experiments, while in the case of continuous flow 
systems the sample is passed through enzyme reactors 
1.7.2 Immobilisation methods 
Immobilised enzymes can be classified on the basis of the methods adopted for 
their Immobilisation, and the classification of immobilisation methods according to 
different chemical and physical properties is shown in figure 1.14. Chemical 
methods of Immobilisation include any that involve the formation of at least one 
covalent bond between residues of an enzyme and a functionalised water-
Insoluble support or between two or more enzyme molecules. Physical methods 
include any that involve localising an enzyme In any manner, which is not 
dependent upon covalent bond formation. 
The immobilisation procedure should be conducted in a way that allows the 
enzyme to maintain its active conformation and necessary catalytic flexibility. 
Furthermore, catalytically essential residues of the enzyme should be 
undisturbed and conselVed. 
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Figure 1.14 - Classification of immobilisation methods 
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The method of enzyme immobilisation that has been adopted for use in the 
practical work descnbed in this theSIS has been the use of the bi-functlonal 
reagent glutaraldehyde to covalently immobilise proteases onto the support 
controlled-pore glass (CPG). This method has been described elsewhere [107] 
and the reaction scheme of the coupling of enzyme to CPG is shown in figure 
63. 
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Glutaraldeyde is one of the most extensively used linking reagents and has been 
discussed in detail elsewhere [108). For this study, aminopropyl-CPG has been 
used. Glutaraldehyde has been used to covalently link proteolytic enzymes to 
'~e CPG as it has a high reactivity with an amino group. The reaction of an 
amino-terminal support with glutaraldehyde leads to the introduction of aldehyde 
groups onto the support that can bind enzymes. This reaction has been termed 
activation. 
Controlled pore glass has gained much acceptance as a support for 
immobilisation and has been widely used over the last couple of decades [109 -
114). 
CPG has many advantages as a support: 
• high surface area giving high coupling of ligands and high yield 
• high mechanical strength 
• thermostable and autoclavable 
• high flow rate giving higher throughput 
• rigid glass structure which is immune to biological degradation and inert to 
solvents or changing conditions 
1.7.3 Modification of enzyme properties after immobilisation 
Immobilisation of an enzyme results in a change in many of the physical and 
kinetic properties of the corresponding soluble counterpart. One of the main 
concerns is the reduction in the biological actiVity due to immobilisation. 
However, immobilisation can also induce novel characteristics to make enzymes 
tolerant to even harsh environments. Some attempts to intentionally modify the 
catalytic behaviour have been reviewed [115). These changes in enzyme 
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properties that occur upon immobilisation may be due to changes in the protein 
conformation after Immobilisation, structural modification of the protein dunng 
immobilisation, or changes in the protein microenvironment resulting from the 
interaction between the support and the protein. Goldstein et al. made one of the 
earliest demonstrations that immobilisation can markedly affect the properties of 
enzymes [116] It was shown that the pH-activity curves of immobilised trypsin, 
when compared with those of soluble trypsin, were displaced 2 - 3 pH units 
towards the alkaline region. This effect was attributed to a pH difference 
between the microenvironment of the polymer matrix and the bulk fluid. 
Numerous enzymes have been reported with an increase in long-term storage 
and thermal stability upon immobilisation [117, 118]. This Increase in stability 
may be due to the stabilisation of the native structure of the enzyme. 
1.7.4 Immobilised enzymes in FIA 
A variety of flow injection systems using immobilised enzymes have been 
described [119 - 129]. 
The application of immobilised enzymes to flow injection analysis systems allows 
the combination of immobilised enzymes in different arrangements to permit 
multi-determination. An excellent review discusses the determination of two or 
more species in the same sample with a single flow injection analysis system [70] 
and the simultaneous determination of several components by flow injection 
analysis using one or more detectors has also been discussed [71]. Analysis of 
more than one analyte is made possible by using immobilised enzyme reactors in 
parallel [130 - 132] or in series [133]. Stnklng examples of the advances that 
, 
have been made in this area are the determination of a single analyte by using a 
single immobilised column and progressing towards the determination of five or 
six analytes [69,134 -135] 
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1.8 PROTEASE ASSAYS 
1.8.1 Importance of protease assays 
Since the discovery of pepsin in the late eighteenth century there has been 
continuing investigation into the chemistries and activities of the proteolytic 
enzymes. Recent years have seen a remarkable acceleration of the pace of this 
research, fuelled by numerous applications in biotechnology, and the realisation 
that the proteases are major therapeutic targets. As a result of worldwide media 
attention, the term 'protease inhibitor" has been closely associated With HIV - so 
much so, that the publicity has eclipsed the fact that proteases are involved m 
virtually all biological functions and dysfunctions Protease inhibitors for HIV 
work by blocking a key enzyme involved in viral replication, the HIV protease. 
First mtroduced in late 1995, protease inhibitors are widely used for the treatment 
of HIV infecllon, in combination with other antiretroviral drugs. Approximately 
215,000 of the estimated 350,000 patients receiving treatment for HIV infection in 
the United States take at least one protease inhibitor. The worldwide market for 
protease inhibitors was nearly $2 billion in 1999. However, the proteases are 
involved in many other conditions such as lung disease [136 - 138], osteoporosis 
[139], microbial infections [140, 141], viral infections [142 - 144], malaria [145], 
and the common cold [146]. As such, protease inhibitors have broad potential as 
a class of drugs [147]. 
There are around 400 known human proteases and of these about 14% are 
currently under investigation as drug targets [148]. In addition to the involvement 
of these enzymes in so many disease states their popularity as drug targets also 
stems from the accumulated data on their enzymology, high throughput assays, 
biochemistry, physiology, pathology, 3D structures, small-molecule mhlbitors, and 
endogenous inhibitory proteins. The Human Genome Project, by revealing all 
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potential proteins, Will also have a major effect on both academic and 
pharmaceutical protease research. 
Proteases as drug targets can be broken down into groups - the serine 
proteases, for example thrombin as a target for cardiovascular disease [149 -
152], cysteine proteases, e.g. the cathepsins as targets for inflammatory disease, 
the aspartic proteases, for example renin which has had tremendous effort 
expended on it for the treatment of cardiovascular disease [153], and also HIV 
inhibitors for the treatment of HIV [154], and the metalloproteases, for example 
angiotensin converting enzyme inhibitors for the treatment of cardiovascular 
diseases and more recently the matrix metallo protease inhibitors which are 
being looked at for inflammation and cancer [155 -157]. 
One of the most successful groups of protease inhibitors from the pharmaceutical 
Industry point of view over the last 20 years has been the discovery of the 
angiotensin converting enzyme (ACE) inhibitors. These have seen tremendous 
sales in the treatment of high blood pressure (hypertension) and heart failure. As 
shown in figure 1.15, the proteolytic angiotenSin converting enzyme converts 
angiotensin I into an active form called angiotensin 11. Angiotensin 11 is a 
vasopressor and so stimulates the contraction of the smooth muscle of blood 
vessels causing a rise in blood pressure. If the formation of the vasopressor 
angiotensin 11 could be prevented there would be a drop in blood pressure. A 
protease inhibitor that would stop angiotenSin converting enzyme from working, 
hence preventing the formation of angiotensin 11, would therefore be a potential 
drug for high blood pressure. 
Figure 1.15 - Proteolytic action of angiotensin converting enzyme (ACE) 
, ACE 
Angiotensin I -----. Angiotensin 11 (ACTIVE)CI =~> VASOPRESSOR 
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GENERIC NAME OF TRADE NAME OF SALES FOR FINANCIAL 
DRUG DRUG YEAR ENDING 2000 
Lisinopril Zestril + others $ 1, 800, 000, 000 
Enalapril Renitec + others $ 1, 800, 000, 000 
Captopril Capoten + others $ 400, 000, 000 
Table 1.1 - Worldwide sales figures for selected angiotensin 
converting enzyme inhibitors as drugs 
Table 1.1 shows just three compounds that are angiotensin converting enzyme 
inhibitors. Their "generic" names are given and one example each of a Trade 
Name (drugs are marketed under different Trade Names usually depending on 
the country of sale or whether the compound is licensed to additional companies 
for marketing) . The worldwide sales for these three inhibitors alone were more 
than 4 billion US dollars . This is a very significant amount in drug sales terms 
and illustrates just how profitable protease inhibitors can be to pharmaceutical 
companies. 
During screening for promising drug candidates, hundreds of thousands of 
compounds need to be assayed. Figure 1.16 shows the number of 'hits' i.e. the 
number of published articles, obtained on Web of Science when the terms 
protease, protease inhibitor, and high throughput screening are put as keywords. 
A trend can be seen over the last ten years of an increase in published papers in 
these three fields illustrating the importance of the application of high throughput 
screening assays for protease inhibitors. The development of a simple, sensitive, 
and efficient method for assaying protease activity, which would facilitate the 
testing of a large number of samples using HTS, was therefore investigated in 
this work. 
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Figure 1.16 - Trend in number of published articles in the 
areas of proteases, protease inhibitors and high throughput 
screening over the last decade 
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Detection of protease activity is also important for biochemical applications such 
as quantifying protease activity in cell or tissue extracts, during enzyme 
purification , and for quality control testing . Contaminating protease activity 
directly impacts product or reagent stability and biological efficacy in the 
synthesis, production , and purification of naturally occurring or genetically 
engineered recombinant proteins. Some protease assays may require detection 
of specific protease activity; for example certain pathogens use proteolytic activity 
as a virulence mechanism and differ from their non-pathogenic counterparts in 
this characteristic. Conversely, assay for contamination of biological 
preparations by unknown proteases requires a substrate that can detect a variety 
of proteases. 
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1.8.2 General protease assay methods 
The concept of assaying proteolytic activity is not a new one and this type of 
assay has been around for many years. Gel electrophoresis [158 - 160], 
radioactivity [161], capillary electrophoresis [162], a dot-blotting method [163], 
immuno-quantification [164], and detection through an indicator enzyme [165] 
have all been used in the past to detect proteolytic enzymes. However, such 
methods are either time consuming or utilise relatively large quantities of 
substrates. 
Several protease assays have been described that use HPLC to analyse the 
products of peptidase hydrolysis of peptide or protein substrates [166 - 169]. 
There are, however, several drawbacks to HPLC procedures, aside from the high 
cost of the equipment. Only one sample can be analysed at a time, turn-around 
times for injections may be long and will vary with the type of column and 
solvents used, contamination of the column and loss of resolution can occur, and 
analytical columns need to be replaced at regular intervals. 
Luminogenic substrates have also been applied to the assay of proteolytic 
enzymes [170 - 174], as well as chromogenic substrates [175 - 178]. However, 
due to fewer luminescent species than fluorescent ones and the increase in 
sensitivity of fluorescence over absorbance-based methods, fluorescence 
spectroscopy seems more versatile as a method. 
Different methods for assaying proteases have been reviewed elsewhere [179], 
and so discussions here will concentrate solely on fluorimetric protease assays 
as these are relevant to this particular work. Comprehensive reading on 
fluorimetric assays of proteolytic enzymes can also be found [180 -183]. 
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1.8.3 Fluorescent protease assay methods 
Protease assays using a variety of fluorescently labelled substrates have been in 
use for many years [184 - 187]. These assays have frequently employed 
proteins such as haemoglobin [187) , and fluorescent dye-labelled proteins such 
as fluorescein thiocarbamoyl casein (FTC-casein) [188 - 190). These methods 
include precipitation assays where the undigested substrate is insoluble , such as 
fibrin [186), or is made insoluble by treatment with trichloroacetic acid or 
hydrochloric acid [187, 191). However, such assays require sampling at time 
intervals , careful control of sample volume, and quantitative separation of the 
labelled peptides from the unhydrolysed protein . 
1.8.3.1 Fluorescence polarisation protease assays 
Fluorescence polarisation was first described in 1926 by Perrin [33) . This was 
expanded to cover biological applications by Weber [192 - 194). The first 
instrumentation for the measurement of fluorescence polarisation was also 
developed by Weber [195). Several groups have used this technique for the 
study of antigen-antibody and hormone-receptor interactions [196 - 199), as well 
as its use commercially for the monitoring of therapeutic drug levels [200) . 
Recently this technique has been introduced for high throughput screening in the 
drug discovery process [201 - 205). 
However, despite the fact that there is a solid theoretical foundation with regards 
to fluorescence polarisation , it has proven to be a very under-utilised tool and 
only recently has it become recognised as a valuable tool in the area of high 
throughput screening . The main reason for this is lack of high-performance and 
low-cost instrumentation. 
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The principle of how fluorescence polarisation is used to detect protease activity 
using a fluorescent substrate is shown in figure 1.17 a and b. 
A relatively large fluorescent molecule such as a fluorophore-Iabelled protein has 
a significant fluorescence polarisation value. If a protease is introduced, the 
labelled fragments produced have a lower fluorescence polarisation value which 
drops with time, the decrease in fluorescence polarisation being a measure of 
proteolytic activity. 
Figure 1.17a - Principle of the use of fluorescence polarisation for the 
detection of a large lightly labelled fluorescent protein 
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Figure 1.17b - Principle of the use of fluorescence polarisation for the 
detection of protease digested fluorescence peptides 
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The application of fluorescence polarisation to protease assays has long been 
established [189,190, 203, 207, 208] . 
An early paper by Maeda [189] described a detailed study of proteolytic enzyme 
assay development in which various fluorescein isothiocyanate conjugated 
proteins were used as substrates. These reactions were carried out in a static 
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cuvette and enzyme reactions that required a pH that was different to that of the 
pH of the measurement (pH 7 to 9) were adjusted back prior to detection. The 
results showed a near linear decrease in polarisation with time due to the 
apparent decrease in molecular weight of the substrates with hydrolysis. This 
method was shown to be simple and sensitive with trypsin activity being detected 
as low as 0 .05 ~g / ml. This was comparable at the time to the most sensitive 
methods using synthetic chromogenic substrates where trypsin was used at 0.01 
to 0.1 Ilg / ml [206] or to those utilising radiolabeled substrates, which allowed the 
determination of trypsin at 0.065 ~g / ml [161] . Maeda also demonstrated the 
proteolytic inhibition of papain or trypsin using various protease inhibitors 
(Ieupeptin , soybean trypsin inhibitor or antipain). 
More recently Bolger and Checovich [190] compared the sensitivity of a 
fluorescence polarisation-based protease assay that used fluorescein 
thiocarbamoyl (FTC)-casein as a substrate with a non-fluorescence polarisation 
acid precipitation technique, as described by Twining [188] . Twining had 
previously estimated that the FTC-casein assay, which requires separation of the 
intact casein from the cleaved peptides by differential precipitation with 
trichloroacetic acid (TCA) and subsequent quantification of cleaved peptide by 
fluorimetry, was several orders of magnitude more sensitive than the 
measurement of cleaved peptides at A28o. In general it was found that the 
fluorescence polarisation assays resulted in an increase in sensitivity of 2- to 20-
fold compared with the non-fluorescence polarisation assay of Twining , 
depending on the protease tested. In addition , the fluorescence polarisation 
assay also eliminates the centrifugation and two transfer steps required for the 
TCA assay and therefore is much simpler in design. These fluorescence 
polarisation assays took 1 hour to be carried out. 
Due to the pH sensitivity of FITC, these methods cannot be utilised at low pH 
values without the necessity of adjusting the solution pH prior to detection. In 
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more recent years a new pH-independent fluorescent protein substrate has been 
developed based upon BODIPY-FL:a-casein [202, 207] . 
Since many proteases of interest in drug discovery do have optimum pH values 
below pH 6, where fluorescein is essentially non fluorescent, and because of a 
general desire to move into the red portion of the spectrum to minimise potential 
interferences from fluorescent library members, the potential of BODIPY 
fluorophores was explored as labels in fluorescence polarization protease assays 
[202]. The BODIPY fluorophores used were BODIPY FL (ex = 502 nm, em = 510 
nm) and BODIPY TRX (ex = 588, em = 616). The assays were highly sensitive 
and could detect less than 1 ng / ml pepsin and less than 10 ng / ml trypsin, with 
a 5 minute incubation time. Soybean trypsin inhibitor (STI) could be readily 
detected at less than 50 ng / ml with a 5 minute incubation time. 
BODIPY FL (ex = 504 nm , em = 511 nm) conjugated to a-casein was also shown 
to be successful as a substrate for proteases over the pH range 2 to 11 [207]. 
The molar ratio of BODIPY to protein was 0.14 and it was suggested that a molar 
ratio of 0.1 to 0.2 is optimum for fluorescence polarisation work. Addition of 
trypsin at a final concentration of 0.5 fig / ml gave a decrease in fluorescence 
polarisation of about 150 mP in 3 minutes at 37°C. This large decrease in the 
fluorescence polarisation of BODIPY:a-casein showed that this conjugate was 
excellent for use as a substrate for protease assays. S. griseus alkaline protease 
activity on the BODIPY:a-casein substrate produced a decrease in polarisation of 
137 mP units in the first minute and proteinase K produced a 128 mP units 
decrease in the first minute. 
Molecular Probes Inc. currently market a polarisation kit for proteases using 
BODIPY FL and BODIPY TR-X conjugates of casein [208]. 
A fluorescence polarisation assay was designed to measure proteolytic cleavage 
of a specific peptide substrate for human cytomegalovirus protease in a 96 well 
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format [209] . The peptide substrate was derivatised by biotinylation of the amino-
terminus and labelled with a fluorophore at the carboxy-terminal end. Incubation 
of the substrate with the protease and addition of avidin produced a polarisation 
signal that was proportional to the relative amounts of cleaved and uncleaved 
substrate. Due to the specificity of the substrate for the protease of interest, this 
protease assay is more useful than those previously described assays and can 
be further utilised by designing specific substrates. The effects of absorptive 
interferants were evaluated by including increasing concentrations of dye 
interferants absorbing in the wavelength region of either the fluorophore 
absorption or emission. The assay was found to be insensitive to a wide range of 
absorptive interferants that may be present in complex mixtures such as blood, 
when screening for protease inhibitors. An absorptive dye interferant resulted in 
greater than 90% loss in total fluorescence, while the fluorescence polarisation 
varied less than 10%. The results showed that while absorptive interferants 
dramatically affected total fluorescence, they had little effect on fluorescence 
polarisation. The ability of this assay to study the inhibitory activity of 3, 4 -
dichloroisocoumarin (a cytomegalovirus protease inhibitor) suggested the 
versatility of this technique for the study of protease inhibitors. 
BODIPY:u-casein has also been used to measure the proteases in subgingival 
plaque [210], implicated in the pathogenesis of adult periodontitis. This assay 
was rapid , sensitive and quantitative. 
1.8.3.2 Fluorogenic protease assays 
The use of fluorogenic substrates for proteases is widespread [211 - 214]. These 
substrates are non- or weakly fluorescent but are converted by an appropriate 
enzyme to a highly fluorescent product. Such methods combine the amplification 
effects of the catalytic enzyme action with the high sensitivity of fluorescence 
spectrometry alongside low background fluorescence. 
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1.8.3.2.1 Fluorogenic FRET protease assays 
Specific proteases have commonly been assayed using fluorogenic substrates 
involving Fluorescence Resonance Energy Transfer (FRET) . Substrates in which 
a peptide sequence is constructed to match the specificity of a particular enzyme 
are labelled at one end by a donor fluorophore and at the other by an acceptor 
fluorophore. FRET from donor to acceptor quenches the donor emission , an 
effect reversed upon proteolysis due to separation of donor and acceptor 
moieties . The increase in fluorescence intensity is proportional to enzyme 
activity. This method of detecting proteases is represented schematically in 
figure 1.18. 
Figure 1.18 - Schematic representation of (a) a peptide sequence labelled 
at each end by a donor fluorophore (red) and an acceptor fluorophore 
(green) and (b) cleavage of this peptide by a protease causing separation of 
donor and acceptor fluorophores 
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FRET is one of the most sensitive methods for the detection of proteolytic activity 
as first shown by Latt et al. [215] for carboxypeptidase A. This method has been 
applied to the determination of a variety of specific proteases including 
Alzheimer's disease-associated proteases [216, 217], hepatitis C virus [218, 
219], human and feline immunodeficiency virus proteases [40, 217, 220, 221] , 
Escherichia coli leader peptidase [222], renin [217, 223, 224], tail-specific 
protease (which represents a new class of proteases that have no sequence 
homology to any well-characterised proteases) [225], and angiotensin-converting 
enzyme [226] amongst others [227 - 246]. One paper describes a general 
method for the preparation of these FRET protease substrates using solid-phase 
synthesis. The paper uses the donor and acceptor pair of 5-[(2'-aminoethyl)-
amino]naphthelenesulfonic acid (EDANS) and 4-[[4-
(dimethylamino)phenyl]azo]benzoic acid (DABCYL) and synthesises substrates 
for rennin and HIV proteinase as examples [247]. These assays are sensitive, 
easy to perform, and ideal for the detection of specific proteases with known 
sequences of proteolytic cleavage. However, these assays are not useful as 
general proteolysis detection tools and require synthetic expertise. Several 
papers describe the synthesis of some of these FRET substrates [248 , 249] . 
Another potential problem with this type of substrate is that peptides in aqueous 
solutions can take conformations such that the donor and acceptor moieties are 
in close proximity, causing quenching of the emissions of the fluorophores . In 
general , if the fluorophores have hydrophobic characteristics then they will form 
dye-to-dye close contact in an aqueous environment. 
A FRET protease assay designed for interstitial collegenase and gelatinase [250] 
has been used as a test system in an investigation into the feasibility of assay 
miniaturisation [251] . The investigation described preCise and rapid 
measurement of the progress of an enzymatic reaction and its inhibition, which 
was carried out by mixing at the 200 III level and detecting in 2 III volumes with 
less than 6 minutes of total assay time. For comparison to a standard format , the 
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same assay was performed in a 96-well microtiter plate in 200 III using 30 
minutes of incubation. Median inhibitory concentrations (ICso) for actinonin , an 
analog inhibitor of collegenase , of 73 ± 16 and 100 ± 14 nM were obtained in the 
2- and 200-111 assays, respectively. 
The use of these FRET protease substrates was further expanded by using 
homogeneous time-resolved fluorescence [252] . This assay relied upon the 
cleavage of a peptide substrate, which was labelled at the N terminus with biotin 
and had a phosphotyrosine residue downstream of the cleavage site . In the 
presence of streptavidin conjugated XL665, a cross-linked conjugate of 
allophycocyanin, and a europium-labelled antiphosphotyrosine antibody FRET 
occurs and a signal was generated. Upon cleavage, FRET is abolished and the 
signal decreased. This assay was developed for human immunodeficiency viral 
(HIV) protease and combined the sensitivity of lanthanide-based techniques with 
a time-resolved measurement. 
These substrates have also been used in a solid-phase assay for the complete 
subsite mapping of the active site of endoproteases [253]. Using a variation of 
this approach, a solid-phase combinatoria l assay has been demonstrates which 
allows the rapid discovery of potent fluorogenic FRET substrates for use in the 
assay of novel proteolytic enzymes [254]. This technology has the potential to 
greatly facilitate the drug discovery process by speeding up the development of 
high throughput screening assays. This exploits more effectively the ever-
increasing information gained from genomics and combinatorial chemistry. 
1.8.3.2.2 Quenched over-labelled fluorogenic protease assays 
Assays based on fluorogenic protein substrates, which are over-labelled by a 
suitable fluorophore to such an extent that the dye is efficiently quenched by 
internal energy transfer in the protein conjugate, have also been employed [255 -
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259]. As shown in figure 1.19, upon protease digestion this internal energy 
transfer is abolished and the virtually non-fluorescent substrates release highly 
fluorescent dye-labelled peptides, the fluorescence intensity increases being 
proportional to enzyme activity. This type of protease assay removes the 
necessity for the separation of substrate from degradation products . 
Figure 1.19 - Schematic representing the principle of an intramolecularly 
quenched protein substrate (a) and cleavage of this substrate by a 
suitable protease to release fluorescent peptides (b) 
PROTEASE 
(a) (b) 
Fluorescein-Iabelled bovine serum albumin (BSA) or casein have commonly 
been used in this type of assay [256, 257] . Porphyromonas gingivalis was used 
in a study using FITe-labelled proteins as it has been implicated as one of the 
causative organisms of periodontal disease in humans [256] . 
FITe labelled bovine serum albumin (BSA) has been shown to serve as a 
general protease fluorescent enhancement substrate [257] . However digestion 
with trypsin yielded a lower fluorescence increase than that seen with pronase, 
a.-chymotrypsin and proteinase K. This reduced fluorescence enhancement was 
consistent with the specificity of FITe conjugation for the 8-amino groups of lysine 
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residues, which along with arginine residues are required for tryPSin activity. This 
effect is serious, as it is hard to achieve an adequate degree of fluorescence 
quenching in f1uorescein conjugates unless the degree of labelling is very high. 
These heavily labelled conjugates may no longer be sUitable as substrates for 
the assay of enzymes that depend upon the availability of the lysine residues to 
which the dyes are typically conjugated. The substitution of a large number of 
positive lysine residues with the negative charges of f1uorescein may also cause 
conformational changes such that the interaction of the protein with the active 
site of the enzyme becomes problematic. Moreover f1uorescein is only weakly 
fluorescent below pH 6, so f1uorescein conjugates are not sUitable for stUdies of 
acid proteases. 
For these reasons the BODIPY® f1uorophores have been investigated [2551. 
The BODIPY dyes, discussed in section 1.1.4.3, have no charge and It was 
found that conjugation of equivalent amounts of f1uorescein and BODIPY dyes to 
both casein and BSA gave substrates that were 89 - 93% and 98 - 99% 
quenched, respectively. Conjugation of 4.5 to 6 BODIPY FL or even fewer 
BODIPY TR-X dyes to each casein molecule was optimal As less BODIPY dye 
is needed for quenching this should minimise the effects of dye conjugation on 
the protein substrate conformation and enzyme-active site interactions. A 
dramatic increase in detection sensitivity of various enzymes with the BODIPY-
casein substrates was seen (2- to 3D-fold depending on which enzyme), 
compared to the FTC-casein fluorescence polarisation assay as reported by 
Bolger & Checovich, 1994 [1901. Hydrolysis of the BODIPY FL casein substrate 
by chymotrypsin, protease XIV, and proteinase K, generated over a twofold 
increase in fluorescence intensity when compared with hydrolysis of BODIPY FL 
BSA, indicating that BODIPY FL casein may have advantages for use as a 
general protease substrate relative to BODIPY FL BSA. The BODIPY dye 
labelled substrates are insensitive to pH, making it possible to measure the 
actiVity of various enzymes such as pepsin and cathepsin 0, which are most 
active at low pH. The inhibition of tryPSin proteolytic actiVity by pre-incubation 
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with aprotinin was demonstrated. Trypsin was pre-incubated with aprotinin for 20 
minutes and then incubated with a casein conjugate of the f1uorescein analogue 
BODIPY-FL for 1 hour at room temperature, followed by fluorescent 
measurement. Full inhibition was observed at 4 Ilg mrl aprotinin and 44 % 
inhibition was observed with 2 Ilg mrl aprotinin. 
The BODIPY FL dye has also been used in these over-labelled substrates for the 
, ~determinatlon of the protease calpain in a microtlter plate format [258] and as a 
probe for monitoring of protein degradation in intact cells [259]. 
Molecular Probes market two protease assay kits using intramolecularly 
quenched substrates of BODIPY FL:casein and BODIPY TR-X:casein which emit 
at 513 nm and 617 nm, respectively. These assays are carried out in 1 hour 
[260]. 
A new assay for O-Sialoglycoprotein endopeptidase was demonstrated which 
was based on the increased fluorescence which resulted from proteolytic 
cleavage of a fluorescence-quenched micellar substrate, BODIPY-FL:glycophonn 
A [261]. Micellar association of glycophonn A molecules resulted in 97% 
fluorescence quenching despite a low molar ratio of BODIPY-FL'glycophorin A. 
This assay was different to those that use hyperconjugated dye protein 
substrates in that this substrate has only five Iysines available for conjugation. 
However, it readily aggregates, and the resultant intermolecular Interactions 
between f1uorophores contribute to fluorescence quenching within the micelle. 
Glycoprotease was incubated with substrate for 10 -15 minutes and as little as 1 
ng of glycoprotease could be detected. 
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1.9 ENZYME INHIBITION 
1.9.1 Types of inhibition 
Inhibitors are substances that decrease the rate of an enzyme-catalysed 
reaction. There are two broad classes of enzyme inhibitors: reversible and 
irreversible. These types of inhibition will be descnbed briefly, but more detailed 
accounts can be found for further reading [262, 263). Information covering the 
use of enzyme inhibitors as drugs can be found elsewhere [264, 265). 
1.9.1.1 Reversible inhibition 
In this type of inhibition the inhibitor binds to the enzyme in a reversible fashion 
and can be removed by dialysis (or simply dilution) to restore full enzymatic 
activity. Three distinct mechanisms of reversible inhibition are known, which are 
recognised by the effect of substrate concentration on the inhibition. 
(I) Competitive inhibition 
Competitive inhibitors often closely resemble the substrates whose reactions they 
inhibit, and because of this structural similanty they compete with the substrate 
(8) for the active site of the enzyme (E). Inhibitor (I) binds to the enzyme to form 
an enzyme-inhibitor (El) complex. While the inhibitor occupies the active site It 
prevents binding from the substrate. 
r"::4~======·~ ES • E + P 
Equation 8 El 
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It can be seen from equation 8 that El and ES complexes are formed and no ESI 
complex appears in this type of inhibition. As the inhibitor binds reversibly to the 
enzyme, the competition can be biased to favour the substrate simply by adding 
more substrate and hence making the reaction proceed towards ES and then 
product (P) formation. Inhibitor can only bind with free enzyme and not with the 
ES complex By Increasing the substrate concentration, percentage inhibition 
decreases 
(ii) Uncompetitive mhlbitlOn 
An uncompetitive inhibitor binds to the enzyme at a site distinct from the 
substrate. As shown in equation 9, in uncompetitive inhibition the inhibitor can 
bind only with the ES complex and not with the free enzyme. In this case 
therefore, a high concentration of substrate is unable to reverse the inhibition, 
rather an increased substrate concentration actually Increases the percentage 
inhibition 
E + S ~ ..==~" ES ----... E + P 
11+1 
ESI 
Equation 9 
(ill) Noncompetitive inhibition 
A non-competitive inhibitor is one that binds to a site distinct from that that binds 
the substrate. Inhibitor binding does not block substrate binding (or vice versa). 
This means that inhibitor and substrate can bind at the same time to an enzyme 
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to form ES, El, and ESI complexes (equation 10). The enzyme is inactivated 
when inhibitor is bound, whether or not substrate IS also present. As such, non-
competitive inhibition completely depends upon the inhibitor concentration and is 
unaffected by the substrate concentration. 
E + S::ii .. ======~~ ES -----I .. ~ E + P 
It+ I It + I 
ESI 
Equation 10 
EI+S 
1.9.1.2 Irreversible inhibition 
Irreversible inhibitors are those that combine With or destroy a functional group 
on the enzyme that is essential for its actiVity. Formation of a covalent link 
between an irreversible inhibitor and an enzyme is common. In this type of 
inhibition the enzymatic activity cannot be restored by dilution or dialysis. 
1.9.1.3 Product inhibition 
The final step in an enzyme-catalysed reaction, the release of product, is often 
neglected, but is of course an essential component of the process. The product 
is bound to the active site by the same bonds that bind the substrate. As a 
result, product molecules are capable of binding to free enzyme to form enzyme-
product complexes. In a single-substrate enzyme this is really a specialised form 
of competitive inhibition as substrate and product are mutually exclusive and 
compete for the enzyme active site as both cannot bind together. 
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1.9.2 Protease inhibition 
In this work a variety of inhibitors have been Investigated and thus a brief 
description of each is given. Comprehensive accounts of different protease 
" inhibitors can be found in an excellent book [266]. 
1.9.2.1 Aprotinin 
Aprotinin (also know as basic pancreatic trypsin inhibitor (BPTI), Kunitz protease 
inhibitor, and trasylol) is a competitive reversible serine protease inhibitor with an 
approximate molecular weight of 6,500. Most aprotinin-protease complexes 
dissociate at pH > 10 or < 3. It is water-soluble and due to its compact (pear-
shaped) tertiary structure is relatively stable against denaturation due to high 
temperature, acid, alkalies, organic solvents, or proteolytic degradation. 
Numerous papers cover the biochemistry and kinetics of aprotinin [267 - 272]. 
Aprotinin has been used in numerous clinical settings, including open heart 
surgery and coronary artery bypass surgery [273], acute pancreatitis, adult 
respiratory distress syndrome, trauma, and septic shock. In the 1960s, aprotinin 
was used In adult cardiac surgery in an attempt to reduce excessive blood loss 
thought to be due to increased fibrinolysis. By 1984, the benefits of aprotinin in 
paediatric cardiopulmonary bypass surgery were being studied, and decreases in 
postoperative blood loss and fibrin split products were demonstrated [274]. The 
ability of aprotlnin to blunt the inflammatory response IS, in fact, equally as 
effective as corticosteroid treatment. Aprotinln has also been investigated as an 
anti-coagulant [275]. 
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1.9.2.2 Leupeptin 
Leupeptin is a serine and cysteine competitive reversible inhibitor. It has a 
molecular weight of 475 6 and is a transition-state analogue, acting by mimicking 
the tetrahedral intermediate formed dUring peptide bond hydrolysis. Leupeptin is 
a tripeptide containing an aldehyde moiety in place of the usual carboxylate. It is 
water-soluble and solutions are stable for Just a few hours. More Information on 
leupeptin can be found elsewhere [276, 277]. 
1.9.2.3 3-Nitrophenylboronic acid 
3-nltrophenylboronic acid is a reversible competitive serine protease inhibitor with 
a molecular weight of 166.93 and acts as a transition state analogue. 
Saccharides have been shown to act as a 'co-inhibitor' In the boronic aCid 
inhibition system [278]. Investigation into the mechanism of binding of peptide 
boronic acids to proteases have been carried out [279, 280]. 
1.9.2.4 Pepstatin A 
Pepstatin A is a potent uncompetitive reversible inhibitor of pepsin and other 
aspartate proteases. It has a molecular weight of 685.9, is a pentapeptide-like 
compound, and is soluble in methanol and DMSO but insoluble in water. 
Pepstatin A was discovered in 1970 by Umezawa and co-workers [281] in the 
course of searching for inhibitors of therapeutically important enzymes. The 
crystal structure of human pepsin and its complex with pepstatin A has been 
determined [282]. 
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2.1 MATERIALS AND INSTRUMENTATION 
2.1.1 Reagents 
REAGENT SUPPLIER 
Buffer reagents 
Citric acid, dihydrate Sigma 
Glycine Sigma 
Sodium carbonate, anhydrous Sigma 
Sodium dihydrogen orthophosphate Fisher Scientific UK 
Sodium hydrogen carbonate Fisher Scientific UK 
Sodium phosphate, dibasic anhydrous Sigma 
Enzymes 
a-chymotrypsin Type 11: from bovine 
pancreas Sigma 
Pepsin: from Porcine stomach mucosa Sigma 
Protease Type XXI: from Streptomyces 
gnseus Sigma 
Proteinase K: from Tntlrachium album Sigma 
Trypsin Type II-S: from porcine pancreas Sigma 
Fluorescent labels 
BODIPY® 630 /650-X, SE Molecular Probes 
CyTM 5 bisfunctional dye Amersham Pharmacia Biotech UK 
CyTM 5.5 bisfunctional dye Amersham Pharmacia Biotech UK 
Fluorescein isothiocyanate isomer I Sigma 
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Naphthofluorescein 
Tetramethylrhodamlne Isothiocyanate 
mixed isomers 
~mmobilisation supports 
Controlled pore glass, aminopropyl, 972 
A mean pore diameter, 200/400 mesh 
Controlled pore glass, aminopropyl, 182 
A mean pore diameter, 200 1400 mesh 
UltraLini(I'M blosupport medium 
Inhibitors 
Aprotinin: from bovine lung 
4-hydroxycoumarin 
Leupeptin hemisulfate salt 
3-nitrophenylboronic acid 
Pepstatin A 
Warfarin (3-(a-acetonylbenzyl)-4-
hydroxycoumarin) 
Other reagents 
Blcinchoninic acid 
CHAPS (3-[3-cholamidopropyl)-
dimethylamino )-1-propane sUlfonate 
Copper (11) sulfate pentahydrate 98 % 
a-cyclodextrin 
/3-cyclodextrin 
N, N-dlmethylformamide (DMF) 
Dimethyl sulphoxide (DMSO) 
Ethanolamine 
Glutaraldehyde grade 11 
68 
In-house [283) 
Sigma 
Cambio 
Cambio 
Pierce 
Sigma 
Sigma 
Slgma 
Sigma 
Molecular Probes 
Slgma 
Sigma 
Sigma 
Sigma 
Sigma 
Sigma 
Sigma 
Sigma 
Fisher Scientific UK 
Sigma 
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. 
2-hydroxypropyl-/3-cyclodextrin Sigma 
Methanol. spectrophotometric grade Sigma 
Sodium cyanoborohydrlde Sigma 
Urea Fisher Scientific UK 
Proteins 
a-casein' from bovine milk 
Albumin. bovine 
Albumin. bovine - fluorescein 
isothiocyanate 
Sigma 
Sigma 
Sigma 
Table 2.1 - Reagents used and their respective supplier 
2.1.2 Cells 
Quartz fluorescence cell (3500 ,d volume. 1 cm light path) ......... Hellma 
Quartz UV cell (3500 ,.d volume, 1 cm light path) . ... ................ Hellma 
Flow cell (UV and fluorescence, 25 ,.d volume, 
1.5 mm X 1.5 mm light path) ...... ...... ...... ............ ...... ...... ...... Hellma 
2.1.3 Chromatographic columns 
PD-10 column ............................... Amersham Pharmacia Biotech UK 
2.1.4 Flow system equipment 
Enzyme reactors (3.0 mm microbore chromatography column, 25 mm 
length with 0.17 ml bed volume, and 50 mm length with 0.35 ml bed 
volume), frits (stainless steel 2J.lm, and PTFE 25 J.lm), injection valves 
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(manual with 25 III sample loop), Teflon® flow tubing (1 6 mm OD X 0.8 
mm ID), 'T' 3-way flow connectors, and switching 4-port manual rotary 
valve ... ... ... ... ... ... ... .... ... ... ... ... ... ... ... ..• ... ... ... ... ...... ... ... ... ... Omnifit 
Peristaltic pump (Gilson mini puis 3) ............................ AD Instruments 
Pump tubing ............ ..... ........................... ...... ... . ...... ... ....... Elkay 
2.1.5 Pipettes 
Automatic adjustable pipettes: P20, 100, 200, 1000 and 5000 .. Anachem 
Volumes 0.5111-10 III ............ Eppendorf 
Volumes 0.5 111- 10 III ..... ..... ... ...... Elkay 
2.1.6 Spectrometers 
Model F-4500 Fluorescence Spectrophotometer .... ... ... ......... ... Hltachi 
LS 508 Fluorescence Spectrophotometer ....................... Perkin Elmer 
Unlcam 8700 Series 
UV I Visible spectrometer .... ... ... ......... ...... Unicam Analytical Systems 
2.1.7 Supplier names and addresses 
A list of supplier names and addresses is given in appendix A. 
2.1.8 Temperature control 
Water bath (0 - 99 0C) .......................................................... Grant 
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2,2 GENERAL PROCEDURES 
2.2.1 Buffer preparation 
Buffers were prepared in triply deionised water throughout. Carbonate, citrate, 
glycine, and phosphate buffers have been used during experimental work. 
2.2.2 pH measurement 
pH measurements were carried out using a Whatman PHA 230 bench pH meter, 
with a pH range of 0 00 to 1400 and an accuracy of ± 0 01 pH. The instrument 
was calibrated with high-resolution buffer solutions at pH 4.000, 7.000, and 
10.000, ± 0.005, before use. 
2.2.3 Water purification 
Solutions were prepared using triply deionised water purified by a Maxima ultra 
pure water system (USF Elga Ltd.). 
2.2.4 Mass determination 
Weighing measurements were carried out on two balances depending on the 
weighing range needed: 
• Precisa 300 series electronic balance, weighing range from 41 g to 12400 g 
• Precisa 40SM-200A four decimal place electrOnic balance 
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2.2.5 Pipetting 
Pipetting was carried out using Gilson (supplied by Anachem), Eppendorf, and 
Elkay variable volume automatic pipettes. 
2.2.6 Fluorescence measurement 
Two fluorimeters were used in this study - the Hitachi F-4500 Fluorescence 
Spectrophotometer, and the Perkin-Elmer LS 50B. 
2.2.6.1 F-4500 Spectrophotometer 
The appearance of the F-4500 spectrophotometer is shown in appendix B. The 
block diagram (taken from [284]) of the signal processing and control systems of 
the F-4500 can be seen in appendix C. The spectrophotometer mainframe has 
a xenon lamp light source, the beam of which is incident on the excitation 
monochromator. The beam after wavelength selection with the excitation 
monochromator ("-ex) is irradiated onto the sample cell. Light emitted from the 
sample in the form of fluorescence ("-em) then passes through the emission 
monochromator (which is at right angles to the incident light) to remove any light 
that is not at the emission wavelength. The Intensity of fluorescence is detected 
via a red-sensitive photomultiplier tube. Instrument parameters are shown in 
appendix D. 
2.2.6.2 LS SOB Spectrophotometer 
The appearance of the LS 50B Spectrophotometer is shown in appendix E. The 
optical layout of the LS 50B (taken from [285]) can be seen in appendix F. As 
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with the F-4500, the LS 50B is composed of a pulsed xenon excitation source, a 
scanning excitation monochromator, a scanning emission monochromator, and a 
red-sensitive R928 photomultiplier tube. The LS 50B is fitted with FL WinLab 
version 2.01 software and parameters for the LS 50B are shown in appendix D. 
The LS 50B is also fitted with a Fast Filter Accessory for the measurement of 
fluorescence polarisation (amongst other things), descnbed in 2.2.7. 
2,2,7 Fluorescence polarisation measurement 
Fluorescence polarisation measurements were carried out on a Perkin Elmer LS 
50B spectrophotometer using the Fast Filter Accessory. With this accessory, 
filters appropriate for the application are rotated into the excitation or emission 
beam. The rotation of the wheel is synchronised to the mains frequency so that 
when a filter is momentarily in the correct position in the beam, the source is 
triggered and energy passes through that filter. The wheel then rotates 90· 
before the next flash occurs. When the Fast Filter Application IS not being used, 
the fast filter wheels are parked in the clear beam position With none of the filters 
in either beam. Each measurement takes into account a G-factor measurement 
to correct for instrumental bias. 
2.2.8 Absorbance measurement 
Absorbance measurements were carried out on an Unicam 8700 Series 
UVNisible Spectrometer using distilled water or buffer solution to obtain a 
baseline. 
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2.2.9 Flow system measurements 
Flow system measurements were taken using the basic set-up shown in figure 
5.19, and variations thereof. Buffer solution was pumped using a peristaltic 
pump and injections of substrate, enzyme, and inhibitor into the flowing stream 
were made using manual sample injection valves fitted with 25 111 sample loops. 
A manual 4-port rotary valve was used to direct the main flow stream into an 
incubation loop where assay components were captured. The incubation loop 
was situated in a thennostatted water bath to enable the reactions to occur at a 
defined temperature. The rotary valve was then again switched to direct the 
assay components back into the main stream. This flowed through a 
fluorescence flow cell situated in the Hitachi F-4500 fluorescence detector to 
measure the fluorescence Intensity and then through to waste. 
2.2.10 Preparation of dye:protein conjugates 
Dye:protein conjugates were prepared according to the following method. 
FITC:albumin was prepared for fluorescence polarisation experiments, 
BODIPY:a.-casein for single-labelled experiments, and FITC:TMRITC:a.-casein 
and Cy 5:Cy 5.5:a.-casein for double-labelled experiments. The preparation will 
be illustrated by the conjugation of FITC to albumin (in reaction mixture ratios of 
50:1 and 100:1), but the general method is applicable to all conjugates prepared. 
1. 2.5 mg I ml albumin was prepared by dissolving 2.5 mg albumin in 1 ml 
0.1 M carbonate buffer pH 9.0. 
2. Amount of FITC required for 50:1 and 100:1 reaction mixture ratios of 
FITC:albumin were calculated by multiplying the number of moles of 
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albumin by the molecular weight of FITC followed by multiplying by the 
ratio. 
3. FITC solutions for each reaction mixture ratio were made up by dissolving 
the required amount of FITC in DMF. 
4. For each reaction mixture ratio conjugate, the standard FITC solution in 
DMF was added to a 2.5 mg I ml albumin solution. The total volume was 
made up to 2.5 ml with 0.1 M carbonate buffer pH 9.0. 
5. The solutions were incubated for 2 hours in the dark at room temperature. 
6. Two PD-10 Sephadex columns were equilibrated each with 25 ml 0.1 M 
phosphate buffer pH 7.2. 
7. Each conjugate was passed through a PD-10 column in order to remove 
unconjugated dye from the conjugate. 
8. 3.5 ml 0 1 M phosphate buffer pH 7.2 was added to each PD-10 column in 
order to elute the conjugate. Allquots of conjugate were stored in black 
mlcrocentrifuge tubes in the freezer. 
2.2.11 Final dye:protein ratio calculations 
Final dye'protein (D:P) ratios were calculated using the Beer Lambert Law, which 
states that absorbance is related to the molar extinction coeffiCient E (In cm·l M·l ), 
concentration c (in M), and path length I (in cm) by A = ECI. Absorbance values 
were taken for the conjugate at protein and dye wavelengths, which were 
corrected for dye absorbance at the protein wavelength and vIce versa. Using 
the Beer Lambert Law, the concentration of both dye and protein was calculated 
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using the actual protein and dye absorbance values and their respective molar 
extinction coefficients. The dye concentration divided by the protein 
concentration gave a final dye'protein ratio. 
2:2.12 Immobilisation ofenzyme onto controlled pore glass (CPG) 
Proteolytic enzymes were immobilised onto CPG using a method previously 
described by Masoom and Townshend [120]. 30 ml 25 % aqueous 
glutaraldehyde (grade 11) was added to 0 5 g aminopropyl CPG in a well-
stoppered glass vial in the fume cupboard and left for 1.5 hours at room 
temperature on a roller bed. Nitrogen was passed through the solution to remove 
oxygen every 10 minutes for the first 40 minutes. The activated glass was then 
washed with dlslllled water. 
0.5 g activated CPG was added to a cold (4°C) solution of enzyme in 2.5 ml 
0.1 M phosphate buffer pH 6.0 and placed on a roller bed. Nitrogen was bubbled 
through the solution every 10 minutes for 2.5 hours. The immobilised enzyme 
was washed first with cold 0 1 M phosphate buffer pH 6.0, then with cold distilled 
water to remove free enzyme and then stored moist at 4°C. 
To block unreacted groups 10 ml 30 M ethanolamine pH 9.0 was added to the 
beads. 10 mM sodium cyanoborohydride was also added to the beads to make 
the linking permanent. Initial miXing by shaking was carried out and then the 
beads were left standing overnight. The beads were then washed and stored In 
0.1 M phosphate buffer pH 6.0 at 4°C. 
The reaction scheme for immobilisation of enzyme onto CPG is given in figure 
6.3. 
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2.2.13 Immobilisation of enzyme onto Pierce UltraLink biosupport medium 
Proteolytic enzymes were immobilised onto Pierce UltraLink biosupport medium 
according to the manufacturer's instructions. 0.125 g of UltraLink were weighed 
out. A solution of enzyme in 2 ml cold (4°C) 0.1 M carbonate buffer pH 8 5 was 
added to the dry beads and the solution vortexed, followed by gentle rotation on 
a roller bed for 2 hours at room temperature The solution was then filtered to 
remove unbound enzyme from the beads and this filtrate was kept in order to 
determine the amount of enzyme not coupled to the beads using the BCA assay. 
A quench solution of 2.5 ml 3.0 M ethanolamine pH 9.0 was then added to the 
beads to block un reacted azlactone sites, vortexed and gently rotated on a roller 
bed for 2.5 hours at room temperature. The beads were then separated from the 
quench solution by filtration and resuspended in 2.5 ml 0.1 M phosphate pH 8.0 
followed by vortexing and gentle rotation for 15 minutes. Buffer was removed by 
filtration and the beads were resuspended in 2.5 ml 1.0 M NaCI to remove non-
specifically attached protein. The solution was vortexed and rotated for 15 
minutes after which the NaCI was removed by filtration and the beads 
resuspended in 0.1 M phosphate pH 8 0, the solution vortexed and gently rotated 
for 15 minutes followed by filtration to remove the buffer. This last step was 
repeated and the beads stored in 0 1 M phosphate buffer pH 8.0 at 4°C. Figure 
6.15 depicts the reaction scheme for immobilisation of enzymes onto UltraLink. 
2.2.14 Sicinchoninic Acid (SeA) assay for determination of protein 
concentration 
The BCA assay (286) was used to determine the amount of enzyme Immobilised 
onto UltraLink blosupport medium. This method was adopted as the use of 
Tnton® X-100 surfactant in the bead production may have interfered with an 
assay using absorbance at 280 nm for the measurement of uncoupled enzyme. 
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3.1 INTRODUCTION 
The principle of how fluorescence polarisation is used to detect proteolytic activity 
using a fluorescent substrate was shown in figure 1.17 (a) and (b), and previous 
work that has been carried out in this area was discussed in section 1 8 3.1. 
Lightly labelled substrates for use in fluorescence polarisation studies could offer 
an advantage over highly quenched fluorogenic substrates. It seems likely that 
highly derivatlsed molecules might hinder the proteolytic action of some 
proteases. The substrate may possess fluorescent ligands at a strategic 
positlon(s) that keeps the protein from being cleaved by some proteases due to 
steric hindrance. 
Fluorescence polarisation is a very elegant technique with numerous advantages 
(discussed In section 1.2 2), the most prominent advantage over other 
fluorescence techniques being its relative immunity to the inner filter effect. 
These obvious benefits gained from using fluorescence polarisation therefore 
lead to an interest in whether this technique could be suitably applied to the study 
of proteases 
The aim of these experiments was to determine whether fluorescence 
polarisation is an appropriate method for the sensitive and rapid detection of 
protease enzymes. 
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3.2 PREPARATION OF FLUORESCEIN CONJUGATES 
3.2.1 Procedures 
Fluorescein:albumin conjugates were prepared according to the method 
descnbed in section 2.2.10. A concentration of 2.5 mg I ml albumin was used 
and reaction mixture ratios of 7:1,25:1, 50:1, 75:1, and 100:1 dye:protein were 
prepared. 
All absorbance measurements were taken using an Unicam 8700 UV I viSible 
spectrometer with a path length of 1 cm. A standard 3 ml quartz absorbance 
, 
cuvette was used and baselines were taken with buffer prior to measurements. 
3.2.2 Results 
FITC solution was used to obtain an UV spectrum to calculate absorbance at 280 
nm as a percentage of that at 494 nm. This was found to be 40 %, (appendix G), 
and this absorbance of the dye at the protein wavelength was taken into account 
during final dye:protein (D:P) ratio calculations (calculated as described in section 
2.2.11). 
Initial reaction mixture ratios and calculated final dye:protein molar ratios are 
given for each conjugate in table 3.1. 
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REACTION MIXTURE RATIO CALCULATED DYE:PROTEIN RATIO 
7:1 1.70:1 
25:1 2.14:1 
50.1 1.80:1 
75:1 178:1 
100:1 1.61:1 
Table 3.1 -Initial reaction mixture and calculated final dye:protein 
ratios for f1uorescein:albumin conjugates 
From table 3.1 it can be seen that the calculated final D.P ratios did not appear to 
truly reflect the number of dye molecules per protein molecule. It would be 
expected that as the amount of dye In the reaction mixture was increased, a 
concomitant increase would be seen in the final D.P ratio. However, the 
calculated final D:P ratios increased with the first increase in reaction mixture 
ratio and then decreased with increasing amounts of FITC in the reaction 
mixture, the opposite of what might be expected. For an unknown reason, the 
rules for the final D:P ratio calculations appeared to have broken down. One 
possibility was that the absorbance measurements were inaccurate. As the 
absorbance at 280 nm was much smaller than that at 494 nm, the error 
associated with the protein concentration was much larger. All protein 
absorbance values used for the calculation of protein concentration were below 
04 absorbance units, and the most accurate readings are between 0.5 and 1.0 
absorbance units. In addition, above reaction mixture ratios of 50:1, the peak at 
494 nm was above 1.5 absorbance units, again outside the accurate range. 
Unfortunately due to the difference between the absorbance values of the 280 
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nm and 494 nm peaks, it was impossible to strike a balance and obtain accurate 
absorbance values. These inaccuracies could very well explain the apparent 
error in final D:P ratios. All ratios henceforth will therefore be given in terms of 
reaction mixture ratios. 
The protocol for conjugate preparation (section 2.2 .10) required an incubation 
time of 2 hours for the conjugation of dye to the protein before separation of free 
dye from the conjugate. This incubation time was increased for 4 different 
reaction mixture ratio conjugates to see if this had an effect upon the final 
dye:protein ratio. Incubation times of 2 hours , 5 hours , and 24 hours were 
investigated. 
Figure 3.1 - Effect of incubation time on the final dye:protein 
ratio for different reaction mixture ratio conjugates 
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It can be seen from figure 3. 1 that incubation time did not greatly affect the final 
dye:protein ratio. An incubation time of 2 hours was therefore kept for all 
preparations of conjugates . 
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3.3 FLUORESCENCE POLARISATION PROTEASE ASSAYS 
3.3.1 Procedures 
As mentioned previously, reaction mixture ratios of 7:1, 25:1, 50:1, 75:1, and 
100:1 fluoresceln:albumm were prepared. When subjected to polarisation 
measurements, only the 7:1 reaction mixture ratio conjugate resulted in a 
decrease in fluorescence polarisation upon incubation with protease. This 
conjugate was therefore used for further polarisation experiments. This was in 
line with findmgs by Jolley [202], who found that at high labelling ratios the initial 
fluorescence polarisation and assay span were reduced. At these ratios the 
"fluorescence became highly quenched and the fluorescence polarisation dropped 
to very low values, probably due to a mechanism of depolarisation resulting from 
non-radiative energy transfer. A low initial substrate fluorescence polarisation 
value will make a poor substrate for these types of experiments, which mOnitor 
decreases in polarisation. 
When substrate concentration was varied from 0.5 - 2.3 Ilg I ml, no polarisation 
change was seen upon incubation with proteinase K except for at a concentration 
of 1.19 Ilg I ml. This substrate concentration was therefore used in all 
experiments. 
Fluorescence polarisation measurements were carried out on a Perkin Elmer 
LS 50B spectrophotometer using the Fast Filter Accessory as described in 
section 2.2.7. A G-factor (grating factor) of 0916 was used to counteract the 
instrument polarisation response. An excitation wavelength of 488 nm and 
emission wavelength of 520 nm was used with excitation and emission 
bandwidths of 10 nm. A substrate concentration of 1.19 Ilg I ml was added to 
buffer in a standard 3 ml quartz fluorescence cuvette and incubated with enzyme 
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in a total volume of 3 ml in a thermostatted water bath The cuvette was then 
transferred to the LS 50B and fluorescence polarisation readings taken. 
To determine the precision of the fluorescence polarisation measurements taken 
on the LS 50B, 20 replicate readings were taken of a single fluorescein:albumin 
sample in buffer. Between each reading, the cuvette was removed from the 
holder and inverted three times. Measurements of 15, 0, 10, 0, 10, 5, 15, 0, 5, 
10, 10,5, 10,5, 10, 15,5,20, 15, and 15 mP Units were obtained corresponding 
to an average of 9 mP Units with a standard deviation of 5 8 mP Units. 
The stability of the Perkln Elmer LS 50B spectrophotometer xenon lamp was 
tested using a fluorescence reference block of anthracene and naphthalene and 
an excitation wavelength of 296 nm. As can be seen from figure 3.2, the output 
of the xenon lamp was relatively stable over a period of 5 hours, which was 
c-. 
suitable for carrying out experimental readings. 
Figure 3.2 - Fluorescence intensity of a reference block 
against time after switching on the LS SOB spectrophotometer 
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Three proteolytic enzymes - alkaline protease, proteinase K, and a-chymotrypsin 
- were Investlg'lted in these experiments (descriptions in section 1.6.4). 
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3.3.2 Results 
The effect of the fo llowing parameters on each enzyme were studied and 
optimised : 
• [enzyme] 
• incubation time 
• temperature 
• pH 
• buffer system 
• [buffer] 
Results showing range of values studied and corresponding optimised va lues for 
each parameter are shown in table 3.2 for all three enzymes. 
KEY: CA = Carbonate, PH = Phosphate 
[ENZYME] TIME TEMPERATURE pH BUFFER [BUFFER] 
(~g I ml) (m inutes) (0 C) (mM) 
ALKALINE 
PROTEASE 
RANGE STUDIED 0-14 0-20 20 - 50 7 -11 PHICA 6 - 100 
OPTIMUM 2.67 15 40 11 .0 CA 10 
PROTEINASE K 
RANGE STUDIED 0-14 0-20 20-60 7 -11 PH ICA 5·100 
OPTIMUM 6.67 10 40 9.5 CA 10 
a·CHYMOTRYPSIN 
RANGE STUDIED 0-14 0-20 20- 55 7 -11 PH/CA 5 - 100 
OPTIMUM 13.33 10 40 7.5 PH 10 
Table 3.2 - Assay parameters and optimum conditions for three protease 
enzymes using the substrate fluorescein:albumin 
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As there were multiple enzymes and each behaved similarly with changes in 
assay parameters, the effect of temperature, pH , buffer system, and buffer 
concentration wi ll be discussed only for alka line protease. 
3.3.2.1 Effect of temperature 
The effect of temperatu re on the activity of alkaline protease was examined over 
the range 20 - 50 °C using a thermostatted water bath. The polarisation resu lts 
were corrected for the changes in polarisation of the blank conjugate with 
temperature thereby giving specific resu lts for enzyme activity. From figu re 3.3 it 
can be seen that as temperature is increased from 20 - 40°C there is an 
accompanying increase in enzyme activity. However, after 40 °C there is a 
decrease in enzymatic activity. This is probably due to the disruption of the 
quaternary structure of the enzyme at high temperature and hence a disruption of 
the catalytic site resulting in loss of activity. 
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Figure 3.3 - Influence of temperature on the digestion of 
fluorescein:albumin by alkaline protease 
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Maximal enzyme activity, signified by the greatest decrease in fluorescence 
polarisation , occurred at 40 QC and this optimal temperature was therefore used 
in further experiments . However, as polarisation is temperature-dependent, the 
effects seen are a combination of temperature effects on the enzyme and 
polarisation of the fluorophore. As values were corrected for substrate 
polarisation , these effects are not dependent on the effect of temperature on the 
substrate. 
3.3.2.2 Effect of pH and buffer system 
The influence of pH and buffer system on the activity of alkaline protease was 
also investigated using a pH range of pH 7.0 - 11 .0, and two buffer systems -
carbonate and phosphate. The buffer concentrations were kept constant at 
0.1 M. 
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As shown by figure 3.4, a relatively steady polarisation value was seen from pH 
7.0 - 10.0 irrespective of buffer system. From pH 10.0 - 11 .0 there was a sharp 
decrease in polarisation value with pH 11 .0 showing a maximum decrease. This 
was expected , as the description of alkaline protease in section 1.6.4.1 states 
that this enzyme shows maximal activity at pH 11 .0. 
As optimal enzyme activity occurred at pH 11 .0 (carbonate buffer), this pH and 
buffer system was used in subsequent experiments. 
3.3.2.3 Effect of buffer concentration 
The influence of carbonate buffer pH 11 .0 concentration between the values of 
6 - 100 mM on the activity of alkaline protease was studied. As shown in figure 
3.5, a maximum peak in activity was seen with a buffer concentration of 10 mM, 
with a reduction in activity either side of this value. 
~ 
Figure 3.5 - Influence of carbonate buffer pH 11 .0 concentration 
on the activity of alkaline protease 
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An optimised carbonate buffer pH 11.0 concentration of 10 mM was selected for 
further experiments as this concentration yields a maximum enzyme activity 
whilst maintaining sufficient buffering capacity. 
3.3.2.4 Effect of incubation time 
The influence of incubation time on the enzymatic reaction was evaluated 
between 2 to 20 minutes. It can be seen from figure 3.6 that as incubation time 
was increased the amount of proteolytic activity on the substrate also increased, 
represented by a drop in polarisation indicating the digestion of the protein 
substrate into smaller peptides. As incubation time was increased from 2 
minutes to 15 minutes there was more time for the enzyme to act on the 
substrate and hence more product was formed . At 15 minutes a maximum was 
seen and further increases in incubation time produced no further increases in 
the enzymatic reaction. At this point another factor has become limiting , for 
example there is no substrate left due to the complete conversion to product. 
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Since a maximum in the enzymatic reaction occurred at 15 minutes of incubation, 
this was used in all subsequent experiments. 
3.3.2.5 Effect of enzyme concentration 
Using the optimum conditions found for pH, buffer system, buffer concentration , 
temperature and time, it was possible to follow the effect of changing the 
concentration of alkaline protease on the hydrolysis of the substrate. Figure 3.7 
shows that at a constant concentration of substrate , the reaction rate increased 
with increasing enzyme concentration until a maximal velocity was reached . This 
saturation effect was due to more substrate being converted to product by adding 
more enzyme to carry out the reaction . However, at an enzyme concentration of 
2.67 Ilg / ml the enzyme was in excess and the substrate became limiting. 
Further increase in reaction rate was impossible without increasing the 
concentration of substrate because at an enzyme concentration of 2.67 Ilg / ml 
all the substrate was converted to product efficiently by this amount of enzyme. 
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A maximum reaction rate was seen at an alkaline protease concentration of 
2.67 [1.g / ml. 
3.3.2.6 Comparison of the activity of three proteolytic enzymes using 
fluorescence polarisation 
Using the optimised conditions shown in table 3.2 for each enzyme, the time 
dependent proteolysis of fluorescein :albumin by all three enzymes was 
compared. These results are shown in figure 3.8. From this comparison it can 
be seen that a-chymotrypsin exhibited poor proteolytic activity on 
fluorescein:albumin when compared with proteinase K and alkal ine protease. 
Alkaline protease had the greatest proteolytic activity, and proteinase K also has 
good proteolytic activity although lower than alkaline protease. This method has 
therefore proved to be applicable to the determination of proteolytic enzymes. 
Figure 3.8 - Time-dependent comparison of the activity of three protease 
enzymes - alkaline protease, proteinase K, and a-chymotrypsin - on the 
substrate f1uorescein :albumin using fluorescence polarisation 
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3.4 DISCUSSION 
The use of covalently linked dye:protein conjugates for fluorescence polarisation 
studies assumes that the dye:protein conjugate is a rigid particle because then 
the rotational properties of the dye are identical to those of the macromolecule. 
The linkage between the fluorophore and the protein must be as short and as 
rigid as possible to avoid the ·propeller effect" i e. the fluorophore moving 
independently of the protein. The fluorophore must have the appropriate lifetime 
and as high a quantum yield and extinction coefficient as possible. Fluorescein 
fulfils these criteria. 
It was suggested in section 3.1 that lightly labelled substrates for use in 
fluorescence polarisation studies might offer an advantage over highly quenched 
fluorogenic substrates. The use of fluoresceln:albumin as a fluorescent substrate 
for the determination of protease enzymes using fluorescence polarisation has 
been investigated. It has been demonstrated that fluorescence polarisation has 
indeed successfully been used to analyse different proteases with broad 
specificity. This has enabled the comparison of the catalytic activities of alkaline 
protease, proteinase K, and a-chymotrypsin with time. 
However, polarisation changes are small, and in such cases, the accuracy of the 
assay suffers. Polarisation changes could be detected down to 5 mP, at which 
point noise prevented accurate readings from being taken. 
The use of fluorescein as a label rather limited the choice of enzymes that could 
be looked at due to its pH sensitive fluorescence that is significantly reduced 
below pH 7 (pK. - 6.4). Longer wavelength fluorophores would be preferred due 
to the reasons discussed in section 1.1.3 of increased sensitivity. The BODIPY 
fluorophores would overcome both of these limitations found with fluorescein. 
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These dyes are pH insensitive and can be obtained with a variety of excitation 
and emission wavelengths including the long-wavelength region of the spectrum. 
Experiments with BODIPY 630/650-X, SE as a label f1uorophore were carried out 
without success using the substrate 5:1 BODIPY:a.-casein. It has been observed 
that fewer BODIPY dye molecules are required to produce quenching effects 
than with fluoresce in [255] and indeed 5:1 BODIPY:a.-casein worked extremely 
well as an Intramolecularly quenched protein substrate as discussed in chapter 5. 
It is apparent that only lightly labelled substrates are needed for this type of 
assay in comparison to the highly derivatised substrates in fluorescence 
enhancement experiments. This can be attributed to a high rate of depolarisation 
through non-radiative energy transfer in over-labelled substrates, as discussed in 
section 1.2.1.2. This was in line with findings by Jolley [202] who found that at 
high labelling ratios the initial fluorescence polarisation and span were reduced. 
To further the studies of the application of fluorescence polarisation to the assay 
of proteolytic enzymes an investigation into the use of long-wavelength dyes 
needs to be carried out. This would constitute future work. Preferably a pH 
insensitive long-wavelength dye should be used due to advantages of a pH-
insenSitive dye and of long-wavelength fluorescence. However, such a dye 
would require a suitable fluorescence lifetime for appreciable Brownian rotation to 
occur. There are worries about the extent of polarisation effects with short-
lifetime long-wavelength f1uorophore molecules (section 1.2.1.3). This may be 
one of the few areas where long-wavelength f1uorophores are not very useful. 
However, if a SUitable long-wavelength f1uorophore could be found this could 
prove valuable. 
The usefulness of this technique is also limited by the requirement of a cuvette-
based approach, with the associated low throughput and high reagent usage A 
flow-based system would improve this throughput significantly. To do thiS an 
evaluation of the application of fluorescence polarisation to this type of system 
would be needed in order to determine the related sensitivity. 
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It seems reasonable to presume that polarisation methods would be less 
sensitive than straight fluorescence methods. Inherent problems in polarisation 
methods include (a) polarisation filters reducing exciting and emitted light 
intenslties; (b) polarised light pre-selecting only a fraction of the potentially 
excitable molecules; and (c) polarisation changes being small and temperature 
sensitive. One disadvantage of fluorescence polarisation is that measurements 
are instrument dependent and the quality of the results IS directly related to the 
quality of the instrument. Unfortunately the LS SOB spectrophotometer is not 
particularly sensitive and the availability of cheap sensitive fluorescence 
polarisation instruments is somewhat limited. Whilst fluorescence polarisation 
does possess attractive features in that it is simple. homogeneous. and relatively 
immune to the inner filter effect that is found in other homogeneous fluorescence 
techniques and so works in coloured solutions and cloudy suspensions (an 
obvious advantage in HTS). energy transfer techniques seem more promising. 
The deCision was therefore taken to concentrate on the use of highly quenched 
fluorogenic substrates in protease assays. 
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CHAPTER 4 
Experimental: double 
labelled FRET based 
protease assays 
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4.1 INTRODUCTION 
The aim of this experimental section was to investigate the use of donor -
''''acceptor fluorophore pairs for use in Fluorescence Resonance Energy Transfer 
(FRET) based protease assays. 
The principle behind this work was similar to that described In section 1.8 3.2.1 
and depicted in figure 1.18. However, in this work the principle described in 
section 1.8.3.2.1 has been modified such that instead of using a specific peptide 
sequence, the protein a-casein has been used as the substrate. This protein 
was labelled with many donor and acceptor fluorophore molecules (unlike a 
Single donor and acceptor molecule used with specific peptide sequences) with 
the idea that upon donor excitation, FRET from donor to acceptor would quench 
donor emission whilst enhancing acceptor emission. Upon proteolytic cleavage 
this effect is reversed and the increase in donor fluorescence and decrease in 
acceptor fluorescence is proportional to enzyme activity. The ability to measure 
both donor enhancement and acceptor quenching offers an advantage over other 
fluorescence techniques as the simultaneous observation of quenching and 
enhancement effects allows proteolytic cleavage effects to be distinguished from 
non-specific environmental effects on fluorescence intensity. As intensity ratio 
measurements are in effect being taken, instrument fluctuations will largely 
cancel out, which is a significant advantage over other energy transfer methods. 
However, one disadvantage of this method is that, as shown in figure 4.1, several 
competing events can occur. 
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Figure 4.1 (a, b, and c) - Alternative scenarios following excitation of 
the conjugate at the donor excitation wavelength 
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Figure 4.1 (a) shows excitation of the donor f1uorophore followed by energy 
transfer to the acceptor in the protein conjugate, and subsequent disruption of 
this energy transfer caused by proteolytic cleavage of the substrate accompanied 
by donor enhancement and acceptor quenching. ThiS sequence of events 
represents those that are needed for the protease assays. However, (b), (c), and 
(d) represent competing events that could also occur. Figure 4.1 (b) shows 
excitation of the donor and internal energy transfer between donor f1uorophores, 
With the consequence that the substrate is virtually non-fluorescent. Figure 4.1 
(c) depicts direct excitation of acceptor f1uorophore by the donor wavelength and 
Internal energy transfer between acceptor molecules causing quenching. Finally, 
figure 4.1 (d) shows direct excitation of either or both donor and acceptor 
molecules followed by emission with no energy transfer. 
In reality, any of the situations shown in figure 4.1 may exist, as well as any 
combination of those situations. As a number of fates of the exciting light can 
occur, this makes interpretation of the results more complex and also requires 
much optimisation of the concentrations of donor and acceptor f1uorophores 
needed to favour FRET from donor to acceptor, a requirement of thiS assay. 
The donor-acceptor pairs of f1uorescein isothlocyanate (FITC) I 
tetramethylrhodamine isothiocyanate (TMRITC), and Cyanine™ 5 (Cy 5) I 
Cyanine™ 5 5 (Cy 5.5) and the conditions required to synthesise a suitable 
substrate using these pairs for use in protease assays were investigated. 
This work was carried out in conjunction With James E. Allard as a research 
project submitted in partial fulfilment of the requirements for the award of Master 
of Science. 
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4.2 INVESTIGATION INTO THE USE OF FLUORESCEIN AND 
TETRAMETHYLRHODAMINE FOR FRET PROTEASE ASSAYS 
4.2.1: Procedures 
Fluorescence measurements were carried out using a Perkin Elmer LS 50B 
fluorescence spectrophotometer with an excitation wavelength of 480 nm for 
FRET conjugate experiments. Excitation and emission wavelengths of 480 nm 
and 520 nm and 551 nm and 575 nm were used for f1uorescein and 
tetramethylrhodamine free dyes respectively. Excitation and emission 
bandwidths of 10 nm were used throughout. Measurements were made statically 
in a standard 3 ml quartz fluorescence cuvette 
All absorbance measurements were taken uSing an Unicam 8700 UV I Visible 
Spectrometer. A standard 3 ml quartz absorbance cuvette was used and 
baselines were taken with buffer prior to measurements 
Fluorescein:tetramethylrhodamine:a-casein conjugates were prepared as 
described in section 2.2.10 using 2 5 mg I ml a-casein with reaction mixture 
ratios of 10:40:1,25:25:1, 1:50.1,40:10:1, and 5:75:1. Final molar dye:protein 
ratios were not calculated due to the complex absorbance spectra obtained with 
these conjugates. 
Fluoresceln and tetramethylrhodamine were chosen for initial FRET studies as 
these dyes have promising spectral characteristics and are cheap. 
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4.2.2 Results 
4.2.2.1 Analysis of the overlapping of fluorescein (donor) and 
tet ramethylrhodamine (acceptor) excitation and emission 
spectra 
Solutions of FITC and TMRITC were used to obtain the excitation and emission 
spectra for these dyes. As shown in figure 4.2, the emission spectrum of the 
donor fluorophore (fluorescein) overlapped the excitation spectrum of the 
acceptor (tetramethylrhodamine), a primary condition for FRET. This suggested 
that these dyes were suitable, in theory, for use in FRET protease assays . 
Figure 4.2 - Spectral overlap of FITC (donor) and TMRITC (acceptor) 
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From figure 4.2 it can be seen that the excitation wavelength of fluorescein was 
494 nm. However, using this excitation wavelength the influence of the scatter 
peak on the emission peak was too great and the two were in danger of being 
inadequately resolved . In addition to this it is evident from figure 4.3 that the 
absorbance spectra of fluorescein and tetramethylrhodamine strongly overlap, 
with the consequence that a fluorescein excitation wavelength would also directly 
excite the tetramethylrhodamine fluorophore. Direct acceptor excitation needed 
to be kept to a minimum, as excitation by FRET from the donor is required for the 
protease assays. For these reasons a sub-optimal excitation wavelength of 480 
nm was used in all subsequent experiments. 
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4.2.2.2 Determination of optimum donor:acceptor:protein ratios for use 
in FRET protease assays 
Conjugates were prepared with reaction mixture ratios of 1:50:1, 5:75:1,10:40:1, 
25:25: 1, and 40: 1 0: 1 fluorescein: rhodamine:a-casein to represent conjugates 
containing different ratios of dyes with tetramethylrhodamine in excess, 
fluorescein in excess, and equal quantities of donor and acceptor. As shown in 
figure 4.4, the 10:40:1, 25:25:1, and 40:10:1 conjugates all showed an 
overwhelming fluorescein emission peak. The tetramethylrhodamine emission 
peak at 575 nm was not evident because the fluorescein dye was so fluorescent 
that its peak completely hid any tetramethylrhodamine fluorescence. 
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Figure 4.5 - Emission spectra of 
fluorescein:tetramethylrhodamine:a-casein conjugates 
exhibiting an emission peak at the TMRITC wavelength 
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It was found that tetramethylrhodamine emission was only observed in 
conjugates containing an excess of tetramethylrhodamine, as demonstrated by 
figure 4.5 which shows the fluorescence of the 5:75:1 and 1 :50: 1 conjugates . 
These results suggest that optimum conditions require lightly labelled donor and 
heavily labelled acceptor conjugates for use in FRET protease assays. This was 
likely to be due to the fact that high donor ratios are more susceptible to 
quenching by the energy transfer mechanism. In these heavily donor labelled 
conjugates, fluorescein-to-fluorescein energy transfer competes with fluorescein-
to-tetramethylrhodamine energy transfer. As shown by figure 4.2, the excitation 
and emission spectra of fluorescein overlap to a considerable degree. The 
fluorescein-to-fluorescein energy transfer is thus likely to be quite efficient. To 
favour fluorescein-to-tetramethylrhodamine energy transfer therefore, an excess 
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of acceptor is required . As the amount of acceptor increases, the probability of 
one or more TMRITC groups being attached close to the donor also increases: 
energy transfer is thus more efficient because of the lower mean distance 
between the fluorescein and tetramethylrhodamine groups. 
A more defined tetramethylrhodamine peak was observed in the 5:75:1 
conjugate when compared with the 1 :50: 1 conjugate. This was probably due to 
more transferred light from a higher concentration of fluorescein in the 5:75:1 
conjugate being able to excite the tetramethylrhodamine fluorophore. As this 
conjugate looked to be more promising as a FRET substrate further experiments 
were carried out using the 5:75:1 conjugate. 
4.2.2.3 Analysis of the 5:75:1 FITC:TMRITC:u-casein conjugate 
5:1 FITC:u-casein and 75:1 TMRITC:u-casein conjugates were also prepared 
with the assumption that in theory these conjugates should contain roughly the 
same quantity of dye as the doubly labelled conjugate. This would obviously only 
be a crude estimate because in reality a great excess of the label to protein is 
normally used in labelling experiments , and possibly even an excess of label to 
linking (lysine) residues. It is thus not easy to argue that the degree of labelling 
in the single conjugate is going to be the same as in the double conjugate. If the 
linking reactions and their rates are assumed to be the same, there is going to be 
competition between fluorescein and rhodamine for a limited number of Iysines, 
hence in this particular case rhodamine would be more likely to win and less 
fluorescein would be bound. Nevertheless, this experiment was carried out with 
a view to considering the rough rather than exact extent of direct excitation of 
FITC and TMRITC and any donor-to-donor or acceptor-to-acceptor energy 
tra·nsfer. 
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Tetramethylrhodamine would emit fluorescence only if excited . There were just 
two ways that this could occur: by direct excitation and by FRET from fluorescein 
emission . 
The 75:1 TMRITC:a-casein conjugate was excited at 480 nm and as shown in 
figure 4.6 upon excitation at this wavelength an emission peak appeared . 
Unfortunately direct excitation of TMRITC by the fluorescein wavelength was 
expected due to the considerable overlap in their absorbance spectra (figure 
4.3). However, it was assumed that this peak, and therefore its height, was 
solely due to the direct excitation of TMRITC. The 5:75:1 conjugate was excited 
at 480 nm and it could be concluded that the peak that resulted at the 
tetramethylrhodamine wavelength was an additive combination of direct 
excitation of TMRITC and FRET from FITC. It therefore followed that the 
difference in peak heights, in theory, could be attributed to the phenomenon of 
FRET between donor and acceptor. 
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To confirm these results, a 5:1 FITC:u-casein conjugate was prepared with the 
idea that the fluorescence emission spectrum of this conjugate should have a 
peak height above the 5:75:1 conjugate. The difference between these two 
heights would in theory be equivalent to that previously found with 75:1 conjugate 
as shown in figure 4.6. This was under the assumption that energy gained by 
TMRITC equals energy lost by FITC. 
However, as demonstrated in figure 4.6, this was not observed experimentally. 
The 5:1 FITC:u-casein peak was much lower than the peak at the fluorescein 
wavelength found with the 5:75:1 FITC:TMRITC:u-casein conjugate. The most 
plausible reason for this observation was due to competition for binding sites on 
the protein molecules during conjugation . In the doubly labelled conjugate 
fluorescein and tetramethylrhodamine compete for the same sites to bind to 
whereas in the fluorescein:u-casein conjugate only fluorescein can bind. It would 
seem likely that more fluorescein is able to bind to the protein in the absence of 
competition i.e. in the fluorescein :u-casein conjugate. A higher fluorescein 
concentration in the single labelled conjugate may have produced a quenched 
substrate due to internal energy transfer between fluorescein molecules, 
accounting for the low fluorescence intensity found in this conjugate. 
It was evident from figure 4.6 that the 75:1 TMRITC:u-casein conjugate displayed 
a peak in the fluorescein region , which was unexpected. An emission spectrum 
was taken of the TMRITC free dye obtained from Sigma with extreme care to 
prevent contamination . It was seen that the Sigma sample also contained a peak 
at the fluorescein wavelength and it was therefore concluded that the dye 
supplied by Sigma contained a contaminant. This emission at the fluorescein 
wavelength may have also contributed to the peak height found in the 5:75:1 
conjugate at the fluorescein wavelength which would have further complicated 
the situation described above where 5:1 FITC:u-casein was synthesised to 
determine energy transfer. 
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4.3 INVESTIGATION INTO THE USE OF CY 5 AND CY 5.5 FOR FRET 
PROTEASE ASSAYS 
4.3.1 Procedures 
Fluorescence measurements were carried out using a Perkin Elmer LS 508 
fluorescence spectrophotometer with an excitation wavelength of 649 nm for 
FRET conjugate experiments. Excitation and emission wavelengths of 649 nm 
and 670 nm and 675 nm and 694 nm were used for Cy 5 and Cy 5.5 free dyes 
respectively. Excitation and emission bandwidths of 10 nm were used and 
measurements were made statically in a standard 3 ml quartz fluorescence 
cuvette. 
Cy 5:Cy 5.5:a-casein conjugates were prepared as described in section 2.2. 10 
using 1.0 mg I ml a-casein and reaction mixture ratios of 2:30: 1 and 5:20:1. As 
Cy 5 and Cy 5.5 were more expensive than either FITC or TMRITC, the amount 
of protein was reduced in order that the reaction mixture ratios could be scaled 
down to use lower concentrations of Cy dyes. It was decided that 2:30:1 and 
5:20:1 Cy 5:Cy 5.5:a-casein conjugates should be synthesised , as it had 
previously been shown (section 4.2.2.2) that optimum conditions for use in FRET 
protease assays required lightly labelled donor and heavily labelled acceptor 
conjugates . 
This FRET pair was chosen because these Cy dyes have suitable spectral 
characteristics, are pH-insensitive, and emit in the long-wavelength region (ca. 
600 - 800 nm). Cy 5 and 5.5 have also previously been shown to act as an 
energy transfer pair [287, 288]. 
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4.3.2 Results 
4.3.2.1 Analysis of the overlapping of Cy 5 (donor) and Cy 5.5 (acceptor) 
excitation and emission spectra 
Excitation and emission spectra were taken of the Cy 5 and Cy 5.5 free dyes. 
From figure 4.7 it can be seen that these dyes showed significant spectral 
overlap between the Cy 5 (donor) emission and Cy 5.5 (acceptor) excitation . 
This suggested that these dyes were ideal as a donor-acceptor pair for use in 
FRET protease assays. 
Figure 4.7 - Spectral overlap of Cy 5 (donor) and Cy 5.5 (acceptor) 
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4.3.2.2 Analysis of the Cy S:Cy S.S:u-casein conjugates 
Fluorescence emission spectra were taken of the 2:30:1 and 5:20:1conjugates 
using an excitation wavelength of 649 nm. However. a broad emission peak was 
'Obtained with both conjugates over the spectral region of around 665 nm to 
720 nm with no distinct Cy 5 or Cy 5.5 peaks. As the emission wavelengths of 
Cy 5 and Cy 5.5 were so close (670 nm and 694 nm respectively). It was likely 
that the broad peak was due to the merging of both the Cy 5 and Cy 5.5 peaks. 
It was therefore concluded that the Cy 5 I Cy 5.5 dye pair was not ideal as an 
energy transfer pair. Unfortunately due to lack of time. the use of Cy 5 and 
Cy 5.5 was not pursued for use In protease assays. However. from these initial 
results it would appear that a great deal of work would need to be carried out in 
order to establish the optimum ratio of donor and acceptor fluorophores for 
energy transfer to occur and to be able to monitor both the donor enhancement 
and acceptor quenching effects that would be seen upon proteolytic cleavage of 
the substrate. In addition. the use of multivariate statistical analysis using a 
software package such as Unscrambler to resolve overlapping peaks may be 
needed. 
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4.4 DISCUSSION 
Experiments were conducted to establish whether fluorescein I 
, tetramethylrhodamine and Cy 5 I Cy 5.5 could be used as fluorophore pairs for 
use in protease assays based on the phenomenon of FRET. 
Results suggested that optimum conditions required lightly labelled donor and 
heavily labelled acceptor conjugates for use in FRET protease assays. This was 
in agreement With findings by Um et al., who similarly found that these conditions 
were necessary for an energy transfer immunoassay for human serum albumin 
[41]. It was shown that the phenomenon of energy transfer may have occurred in 
the 5:75:1 FITC:TMRITC:u-casein conjugate. However, these results were 
extremely difficult to interpret due to the competing events shown in figure 4.1 
and therefore not concrete evidence of energy transfer. As the synthesis of 
these substrates was not successful, the application of these substrates to 
protease assays was not carried out. 
The initial results obtained with Cy 5 and Cy 5.5 were not promising and 
suggested that this would be a very complicated dye pair to work with. 
One area that was not investigated, which would improve these assays and 
perhaps simplify the analysis of results, would be the effect of altering the 
fluorescence spectrophotometer bandWidth. Direct excitation of the acceptor 
fluorophore was a significant obstacle, as it occurred in addition to and in 
competition with the donor excitation. This happened because of the overlapping 
of the donor excitation and acceptor excitation spectra. Thus, at larger 
bandwidths the likelihood of direct acceptor excitation is much greater. The use 
of smaller bandWidths may have therefore improved the process of FRET 
between donor and acceptor and would be well worth investigating in any further 
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studies. However, although narrower bandwidths may show up more energy 
tra~sfer, it would presumably be at the expense of sensitivity. Laser excitation 
may therefore be more helpful, which may allow less direct excitation of the 
acceptor at the same time as increasing the sensitiVity. 
It was obvious from experiments with both FITC I TMRITC and Cy 5 I Cy 5 5 that 
optimum conditions required for FRET to occur would need to be Investigated to 
a much greater depth, which time did not permit. The synthesis of these doubly 
labelled conjugates was eVidently not as simple or quick as that for the single 
labelled conjugates used in chapter 5 and so single labelled conjugates were 
pursued in this study for the determination of proteolytic enzymes and their 
inhibitors. However, although making doubly labelled conjugates of this kind IS 
obViously more complex both to investigate and then to achieve in routine 
practice, If It can be done this kind of method may give advantages over other 
energy transfer methods. 
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5.1 INTRODUCTION 
DUring screening for promising drug candidates, hundreds of thousands of 
compounds need to be assayed. The aim of these experiments was therefore to 
develop a simple, sensitive, and efficient method for assaying protease activity 
thatwould facilitate the testing of a large number of samples using HTS. 
The application of a long-wavelength pH-insensitive intramolecularly quenched 
substrate to the determination of proteolytic enzymes and their inhibitors is 
demonstrated uSing the principle that was shown in figure 1.19. A substrate 
utilising u-casein labelled with a long-wavelength BODIPY® dye has been 
synthesised and these assays have been incorporated into a flow injection 
analysis system that allows the rapid determination of protease Inhibitors. 
Fluorescein:albumin has previously been used in this type of assay [256, 257], 
but the substitution of a large number of positive lysine residues with the negative 
charges of f1uorescein may cause conformational changes such that the 
Interaction of the protein with the active site of the enzyme becomes problematic. 
However, BODIPY dyes have no charge and less dye is required for quenching 
[255]. This should minimise the effects of dye conjugation on the protein 
substrate conformation and enzyme-active site interactions. 
In addition, the pH dependence of f1uorescein has prompted the use of the pH-
insensitive BODIPY dyes in place of f1uorescein in this type of assay. 
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5.2 PREPARATION OF BODIPY CONJUGATES 
5.2.1 Procedures 
BODIPY® 630 I 650 - X, SE:a-casein conjugates (from this point referred to as 
BODIPY for ease) were prepared using the method described in section 2.2.10. 
A-concentration of 2.5 mg I ml a-casein was used and reaction mixture labelling 
ratios of 5:1, 15'1, and 45:1 BODIPY:a-casein were prepared To determine the 
final dye protein (D:P) conjugate ratios, the Beer-Lambert Law was used to 
calculate dye and protein concentrations, as shown in section 2.2.11. 
All fluorescence spectra were obtained using an Hitachi F-4500 fluorescence 
spectrophotometer with a standard 3 ml quartz fluorescence cuvette. 
All absorbance measurements were taken using an Unicam 8700 UV I VISible 
Spectrometer. A standard 3 ml quartz absorbance cuvette was used and 
baselines were taken with buffer prior to measurements. 
An absorbance spectrum of a solution of BODIPY was taken and used to 
calculate the BODIPY absorbance at 280 nm as a percentage of that at 630 nm 
This was found to be 9.5 % (calculation in appendix H), which was taken into 
account in final D.P ratio calculations. The molar extinction coefficient of a-
casein was also determined. A 0.1 % solution of a-casein was made up, the 
absorbance measured, and these absorbance values applied to the Beer-
Lambert Law to calculate the molar extinction coefficient. ThiS was found to be 
21 151 cm·1 M-1 as shown in the calculations in appendix I. A molar extinction 
coefficient of 100 300 cm-1 M-1 was used for BODIPY. Absorbance values were 
corrected for dye absorbance at the protein wavelength of 280 nm (9.5 %) and 
for protein absorbance at the dye wavelength of 630 nm (0 %). 
114 
Chapter 5 Experimental: single labelled substrate protease and protease inhibition assays 
5.2.2 Results 
Calculated final O:P ratios along with initial reaction mixture ratios for three 
BOOIPY:a-casein conjugates are given in table 5.1 . 
REACTION MIXTURE RATIO CALCULATED DYE:PROTEIN RATIO 
5:1 0.55:1 
15: 1 0.46:1 
45:1 0.52 :1 
Table 5.1 -Initial reaction mixture and calculated final 
dye:protein ratios for BODIPY:a-casein conjugates 
The results in table 5.1 show that as the amount of BOOI PY in the reaction 
mixture was increased relative to the amount of a.-casein, the actual dye:protein 
ratio did not change. However, this seems illogical and suggests that for some 
reason the rules of O:P ratio calculations have broken down. 
The absorbance spectra that were taken of the free BOOIPY dye (figure 5.1 (a)) 
and of the three BOOIPY:a-casein conjugates (figure 5.1 (b)) for the D:P 
calculations are shown below. As shown in figure 5.1, upon conjugation , the 
absorption peak at 630 nm of the BODIPY solution (a) unexpectedly split into two 
peaks at 597 nm and 642 nm in the conjugates (b). 
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This phenomenon may be explained by H-dimer formation . This is a non-
fluorescent complex of two neighbouring and aligned dye moieties that has an 
absorption maximum that is typically 20 - 40 nm shorter than the usual 
absorption maximum for a given chromophore. Similar behaviour has been 
demonstrated with tetramethylrhodamine and Cy dyes [287 - 289] . If this 
interpretation is correct then the following should be observed : 
• Upon protease digestion of the labelled protein the 597 nm 
band should decrease relative to the 642 nm band 
• Upon denaturation of the labelled protein the 597 nm band 
should decrease relative to the 642 nm band 
• The 597 nm band should increase relative to the 642 nm 
band as the number of dyes attached per protein is increased 
• The 597 nm peak should be absent on the fluorescence 
excitation spectrum of the labelled protein because it is due to 
absorption by the non-fluorescent dimer 
Experiments have therefore been carried out to establish whether the above 
criteria are observed. 
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5.2.2.1 
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Effect of protease digestion on the absorption characteristics 
of BODIPY:a-casein 
As shown in figure 5.2, upon incubation with the protease alkaline protease, the 
absorbance spectrum of BODIPY:a-casein changed such that the 597 nm band 
decreased relative to the 642 nm band. 
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Figure 5.2 - Absorbance spectra showing effect of protease 
digestion on BODIPY : a-casein 
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The fact that protease digestion of BODIPY:a-casein had the above effect 
suggests H-dimer formation . 
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5.2.2.2 Effect of denaturation on the absorption characteristics of 
BODIPY:a-casein 
Figure 5.3 shows the effect of denaturation through heating and urea upon the 
absorbance spectrum of BODIPY:a-casein conjugate. 
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Figure 5.3 - Absorbance spectra showing effect of 
denaturation on BODIPY : a-casein 
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It can be seen that the 597 nm band decreased relative to the 642 nm band upon 
denaturation, again suggesting the formation of H-dimers between the BODIPY 
molecules. 
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Effect of the number of BODIPY dyes attached to a-casein on 
the absorbance spectra of the conjugates 
The absorbance spectra of the three BODIPY conjugates - 5:1, 15:1 , and 45:1, 
'Were shown above in figure 5.1 (b) . From these spectra it can be seen that as 
the number of BODIPY molecules attached to a-casein was increased, the 597 
nm band increased relative to the 642 nm band. This evidence further supports 
the H-dimer theory and also indicates that the D:P calculations shown in table 5.1 
are incorrect. If the H-dimer theory is indeed correct, it follows that as the 597 
nm band increased relative to the 642 nm band with increasing amounts of 
BODIPY in the reaction mixture, the number of BODIPY molecules attached to 
the a-casein molecule also increased. The D:P calculations did not suggest this, 
hence adding more weight to the fact that the calculations are wrong. 
5.2.2.4 Comparison of the fluorescence excitation spectrum with the 
absorbance spectrum of BODIPY:a-casein 
The fluorescence excitation spectrum of BODIPY:a-casein was obtained using 
excitation and emission bandwidths of 10 nm , a scan speed of 240 nm / min , and 
an emission wavelength of 655 nm. The excitation spectrum (figure 5.4) showed 
a lack of the 597 nm peak, which was apparent on the absorbance spectrum 
(figure 5.1 (b)) . This evidence also supports the theory that BODIPY H-dimers 
have been formed in the conjugate, as the dimer is non-fluorescent. However, 
the dimer does absorb light. As a change in structure has occurred, the dimer 
could really be thought of as another chromophore and so a double peak 
appears on the absorbance spectrum. The first peak is due to absorption by the 
dimer, the second by the single fluorophore molecule. 
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Figure 5.4 - Excitation spectrum of BODIPY:u-casein 
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5.2.2.5 Re-evaluation of D:P calculations 
Calculation of D:P ratios makes one big assumption: that the spectral 
characteristics of the free dye and that of the conjugated dye are identical. 
Clearly this is not the case with BODIPY and BODIPY:u-casein, as shown by 
figure 5.1 . The shape of the absorbance spectrum changes upon conjugation . 
This would greatly affect the D:P calculations if not taken into consideration and 
would help to explain why the D: P ratios given in table 5.1 seem so illogical. 
With this in mind, the D:P ca lculations were altered such that a wavelength of 
350 nm was chosen to calculate the dye concentration using the Beer-Lambert 
Law. As highlighted by figures 5.1 (a) and (b) , the shape of the BODIPY 
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spectrum doesn't significantly change around 350 nm upon conjugation and so 
this wavelength was chosen for further calculations. 
D:P calculations were carried out by measuring absorbances at 280 nm for a-
casein and 350 nm for BODIPY, and were corrected for any dye contribution at 
the protein wavelength and vice-versa . a-casein absorbance at 350 nm was 
found to be 11 % of that at 280 nm (appendix J) , and BODIPY absorbance at 280 
nm was found to be 35 % of that at 350 nm (appendix K). Molar extinction 
coefficients of 21, 151 cm-l M-l (appendix I) and 41, 627 cm-l M-l (appendix L) 
were used for a-casein and BODIPY respectively. 
Four BODIPY:a-casein conjugates were prepared as described in section 2.2.10 
using reaction mixture ratios of 2:1 , 5:1, 10:1, and 15:1. Final D:P ratios were 
calculated using the re-evaluated D:P calculation method with a dye wavelength 
of 350 nm. Initial reaction mixture and calculated final D:P ratios are given in 
table 5.2. 
REACTION MIXTURE RATIO OF FINAL DYE:PROTEIN RATIO 
DYE:PROTEIN 
2:1 0.71 :1 
5:1 2.35:1 
10:1 3.93:1 
15:1 5.10:1 
Table 5.2 - Initial reaction mixture and calculated final dye:protein 
ratios for various BODIPY:u-casein conjugates 
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As would be expected , as the amount of dye in the reaction mixture was 
increased relative to the protein concentration , a concomitant increase was seen 
in the final D:P ratio. As this ratio was increased, it might be expected that the 
suitability of the substrate as a quenched protease substrate would also have 
increased. In practice, however, the conjugate with a final D:P ratio of 2.35 gave 
the best fluorescence enhancement after treatment with enzymes, and so this 
conjugate was used in all subsequent work. 
5.2.2.6 Calculation of percentage quenching in the 2.35 
BODIPY:a.-casein conjugate 
In order to determine the amount of quenching that there was in the BODIPY:a.-
casein conjugate chosen for all further work, solutions of free BODIPY dye and 
conjugate were taken and absorbance readings taken at 350 nm. These 
solutions were adjusted such that the absorbance value of both solutions was 
identical i.e. the concentration of dye was the same in each. 
Fluorescence emission spectra were then taken of each solution to compare the 
fluorescence of free and conjugated dye to calculate the amount of fluorescence 
quenching in the substrate. An excitation wavelength of 605 nm was used with 
excitation and emission bandwidths of 5 nm. Fluorescence intensities were 
corrected for any buffer fluorescence. Intensities of 389.14 and 1444.24 were 
obtained for conjugate and free dye, respectively. This indicated that the 2.35 
BODIPY:a.-casein conjugate was 73 % quenched. 
73 % quenching in the conjugate indicated that BODIPY:a.-casein should indeed 
act as an efficient intramolecularly quenched protease substrate. However, if 
more time were available this percentage quenching could be improved which 
would increase assay sensitivity. 
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5.2.2.7 
Experimental: single labelled substrate protease and protease inhibition assays 
Effect of altering excitation wavelength on the emission 
spectrum of BODIPV:a.-casein 
Figure 5.4 showed that the optimum excitation wavelength of BODIPV:a.-casein 
was 625 nm. However, the optimum emission wavelength of BODIPV:a.-casein 
is 644 nm, which gives a Stokes shift of just 19 nm. Using excitation and 
emission bandwidths of 10 nm and a solution of BOBIPV:a.-casein in a standard 
3 ml quartz cuvette, emission spectra were taken using a variety of excitation 
wavelengths. 
Figure 5.5 - Effect of altering excitation wavelength on the 
emission spectrum of BODIPV:a.-casein 
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Figure 5.5 illustrates the increasing interference from the scatter peak on the 
emission peak as the excitation wavelength was increased to the optimum 
excitation wavelength. The use of the optimal excitation wavelength of 625 nm 
was therefore not practical because the Stokes shift was so small. Although a 
loss in fluorescence intensity was seen with lower excitation wavelengths, which 
will therefore decrease the sensitivity of the protease assays, a balance between 
sensitivity and interference was required and a sub-optimal wavelength of 605 
nm was chosen for use in all subsequent experiments. 
5.2.2.8 Investigation into the effect of additives on the absorbance 
and emission spectra of BODIPY:u-casein 
It has previously been shown in our lab that the fluorescence properties of a 
fluorophore can be changed by the appropriate choice of solvent environment 
[290] . This paper described the dependence of the optimum excitation 
wavelength of naphthofluorescein on the presence of additives such as 
cyclodextrins and (3-[3-cholamidopropyl]-dimethylamino)-1-propane sulfonate 
(CHAPS). Such effects were used to red-shift the excitation wavelength to match 
the output of a 635 nm diode laser for use in a simple and sensitive fluorescence 
detector. 
The effect of cyclodextrins and CHAPS on the absorbance and emission 
wavelengths of BOOIPY was therefore investigated to see if this phenomenon 
could be applied to assays involving BODIPY:u-casein. 
It can seen from figure 5.6 that the inclusion of different cyclodextrins and 
CHAPS into the solvent environment of BOOIPY:u-casein had no great effect 
upon the peak absorbance wavelengths. The use of these additives to shift the 
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optimum excitation wavelength of BODIPY:u-casein towards that of the output of 
a 635 nm diode laser is therefore not applicable. 
1.0 
Figure 5.6 - Effect of cyclodextrins and CHAPS on the absorbance 
spectrum of BODIPY:u-casein 
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From figure 5.7 it is apparent that the inclusion of neither CHAPS nor the different 
cyclodextrins tested had much effect upon the emission wavelength of 
BODIPY:u-casein. The greatest effect (if any) was seen with 2.0 % 13-
cyclodextrin , and this was to shift the optimum to a lower wavelength . This would 
have no benefit at all , as it would only serve to lower the Stokes shift and 
introduce more error through scatter. 
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Figure 5.7 - Effect of cyclodextrins and CHAPS on the 
fluorescence emission spectrum of BODIPY:a-casein 
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Stability of BODIPY:u-casein 
In order to determine the best condition for BODIPY:a-casein storage, 
BODIPY:a-casein was kept in brown bottles in a cupboard at room temperature 
and in the fridge, and also in aliquots in microcentrifuge tubes wrapped with black 
tape in the freezer. Over a period of 3 months samples were taken and the 
fluorescence monitored. All samples were first left to equilibrate to room 
temperature and then incubated in a water bath at 18 °C for 5 minutes. Emission 
spectra were then taken using an excitation of 605 nm and excitation and 
emission bandwidths of 10 nm. All readings were taken first thing in the morning. 
The effects of these different storage conditions are shown in figure 5.8. 
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Figure 5.8 - Effect of storage conditions on the fluorescence 
characteristics of BODIPY:a.-casein 
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From figure 5.8 it is evident that the ideal storage condition for BODIPY:a.-casein 
was in the freezer. For the first 20 days the stability of BODIPY:a.-casein with 
respect to its fluorescence properties remained relatively constant with all three 
storage conditions. After 20 days however, both the fridge and room temperature 
samples began to increase in fluorescence intensity. This was most likely due to 
degradation of the quenched conjugate causing an increase in fluorescence due 
to abol ished internal energy transfer. The freezer samples however remained 
relatively constant over a period of 3 months. All BODIPY:a.-casein conjugate 
was thus stored in the freezer in 30 fl l aliquots in microcentrifuge tubes 
surrounded by black tape, and thawed as required. 
As BODIPY:a.-casein was made up in buffer for use in protease and protease 
inhibition experiments, the stabil ity of BODIPY:a.-casein in solution was tested . 
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Conjugate was prepared in glycine and carbonate buffers at different pH values. 
The fluorescence of the conjugate was measured and plotted as a percentage 
decrease in fluorescence over time after the solution had been made whilst 
sitting at room temperature in the lab (figure 5.9). 
Figure 5.9 - Stability of BODIPY:u-casein in aqueous solution represented 
by the percentage decrease in fluorescence intensity over time 
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It was noticeable from figure 5.9 that in lower pH solution the BODIPY:u-casein 
conjugate was unstable. At higher pH values the substrate was more stable and 
it was seen that BODIPY:u-casein was most stable in carbonate buffer at a pH of 
10.0. BODIPY:u-casein diluted in this buffer gave a percentage decrease in 
fluorescence intensity of 10 % over 253 minutes, which was adequate for 
carrying out experiments. The drop in fluorescence over time was most likely 
due to photodecomposition. 
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5.3 PROTEASE KINETICS 
Simple experiments were carried out to illustrate the use of the fluorogenic 
BODIPY:a-casein substrate in enzyme kinetics. This was not part of the 
objective of this work and was purely to demonstrate that enzyme kinetics can be 
done. The results of these experiments are therefore not strictly important, the 
aim was to show the principle. A discussion of enzyme kinetics was given in 
section 1.6.3. 
5.3.1 Procedures 
Fluorescence measurements were carried out statically in a 3 ml standard quartz 
cuvette using an Hitachi F-4500 fluorescence spectrophotometer with an 
excitation wavelength of 605 nm and excitation and emission bandwidths of 10 
nm. A range of increasing substrate concentrations was used and the 
fluorescence intensity measured and converted to fluorescence intensity units 
per minute. Lineweaver-Burk graphs were then plotted for the proteolytic 
cleavage of BODIPY:a-casein by proteinase K, a-chymotrypsin, and pepsin , as 
shown in figure 5.10. Measurements were carried out in triplicate and error bars 
represent plus and minus one standard deviation. 
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5.3.2 Results 
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Figure 5.10 - Lineweaver-Burk plots for the proteolytic digestion 
of BODIPV:u -casein by various proteases 
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From figure 5.10 values of KM and Vmax were determined and these are given in 
table 5.3. 
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PROTEOLYTIC KM Vmax 
ENZYME (nM) (fluorescence units I min) 
PROTEINASE K 17.86 312.5 
a-CHYMOTRYPSIN 17.24 86.21 
PEPSIN 129.72 312.5 
Table 5.3 - KM and Vmax values obtained experimentally for 
various proteolytic enzymes on the substrate BODIPY:a -casein 
Figure 5.10 demonstrates that the proteolytic digestion of BODIPY:a-casein by 
proteinase K, a-chymotrypsin, and pepsin obeyed classical Michaelis-Menten 
kinetics. Values of KM and Vmax have also been determined (table 5.3) . 
Comparing KM values indicates that BODIPY:a-casein is a more efficient 
substrate for proteinase K and a-chymotrypsin than for pepsin . 
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5.4 PROTEASE ASSAYS IN A STATIC SYSEM 
5.4.1 Procedures 
Fluorescence measurements were made for the protease assays using an 
Hitachi F-4500 fluorescence spectrophotometer with excitation and emission 
bandwidths of 10 nm and an excitation wavelength of 605 nm. Static 
measurements were carried out in a standard quartz fluorescence cuvette. 
Five protease enzymes, each with varying pH optima, ranging from pH 2.5 - 9.0, 
were investigated in these experiments - alkaline protease, proteinase K, (t-
chymotrypsin, trypsin , and pepsin. A description of each is given in section 1.6.4. 
In order to test the stability of the F-4500 fluorescence spectrophotometer, the 
fluorescence of a rhodamine B reference block was monitored over time. An 
excitation wavelength of 558 nm with excitation and emission bandwidths of 2.5 
nm was used. An emission scan was performed immediately after the 
spectrophotometer had been switched on and then every 30 minutes thereafter. 
The shutter between the excitation beam and reference block was shut between 
readings so as not to heat or photobleach the block. A measurement was also 
taken of the Xe lamp output along side the fluorescence readings. These results 
are shown below in figure 5.11 . 
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Figure 5.11 - Fluorescence intensity of a reference block and output of 
the Xe lamp light source over time for the F-4500 spectrophotometer 
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Figure 5.11 indicates that although the Xe lamp output remains relatively 
constant over 9 hours, the fluorescence reading of a reference block increases 
rapidly over the first hour after the F-4500 had been switched on. After this initial 
instability the readings were sufficiently stable. For all experiments that were 
carried out therefore, the F-4500 was switched on and allowed to stabilise for 1 
hour before fluorescence readings were taken . 
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5.4.2 Results 
5.4.2.1 Optimisation of protease assay conditions 
Assay conditions for each enzyme were optimised univariately. The effect of the 
following parameters on the enzyme assay were studied : 
• [enzyme] 
• incubation time 
• temperature 
• pH 
• buffer system 
• [buffer] 
The assay parameters studied and optimum conditions found for each enzyme 
are shown below in table 5.4. 
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KEY: CA = Carbonate, Cl = Citrate, GL = Glycine, PH = Phosphate 
[ENZYME] TIME TEMPERATURE pH BUFFER [BUFFER] 
(~gfml) (minutes) ("C) (mM) 
ALKALINE 
PROTEASE 
RANGE STUDIED 0-7 0 - 30 20-55 1- 11 PH f CA 5-75 
OPTIMUM 2.65 10 40 9.0 CA 10 
PROTEINASE K 
RANGE STUDIED 0-17 1 -20 20-45 1-11 PH f CA 6-90 
OPTIMUM 9.9 5 40 7.0 PH 8 
a-
CHYMOTRYPSIN 
RANGE STUDIED 0-17 1- 20 20-45 7-9 PH 5-100 
OPTIMUM 3.3 10 40 7.5 PH 10 
PEPSIN 
RANGE STUDIED 0-17 1-20 20-55 1-3 GLfCI 10 - 100 
OPTIMUM 13.2 10 50 2.5 GL 50 
TRYPSIN 
RANGE STUDIED 0-22 1-20 20-50 5-9 Cl f PH 8-90 
OPTIMUM 4.29 15 45 7.0 PH 10 
Table 5.4 - Assay parameters studied and optimum conditions for 
various proteolytic enzymes using the fluorogenic substrate 
BODIPY: a-casein in a static system 
As optimisation experiments will be described in detail fo r the protease assays 
carried out in a flowing system, individual optimisation experiments for the assay 
conditions for the 5 proteolytic enzymes investigated here wi ll not be described. 
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Under the optimised conditions given in table 5.4, BODIPY:u-casein was 
incubated with the protease proteinase K. As shown in figure 5.12, incubation of 
conjugate with proteinase K gave a fluorescence increase of approximately 9-
fold , indicating that BODIPY:u-casein is promising as a f luorogenic protease 
substrate. 
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Figure 5.12 - Fluorescence emission spectra showing 
enhancement seen upon incubation of BODIPY:u-casein with a 
protease enzyme (proteinase K) 
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5.4.2.2 Calibration curves for BODIPY:u-casein 
The effect of substrate concentration was examined for each of the proteolytic 
enzymes under optimised conditions. Readings were taken in triplicate and error 
bars show plus and minus one standard deviation. 
Figure 5.13 -Influence of BODIPY:u-casein concentration on the 
production of BODIPY when incubated with a variety of proteases in a 
static system under optimised conditions 
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The activities of a variety of proteolytic enzymes on the substrate BODIPY:a-
casein were compared , as shown in figure 5.13. These enzymes represent 
proteases with activities over a wide pH range - 2.5 to 9.0. It was therefore 
possible to compare the activities of acid, neutral , and alkaline proteases of 
different classes (pepsin being an aspartic protease and alkaline protease , 
proteinase K, trypsin, and a-chymotrypsin being serine proteases) on the same 
graph using the same substrate merely by changing the buffer system. It can be 
seen that alkaline protease is by far the most efficient protease, followed by 
proteinase K. Trypsin and a-chymotrypsin have extremely similar efficiencies, as 
would be expected from these closely related enzymes. Pepsin also has a lower 
activity towards BODIPY:a-casein than both alkaline protease and proteinase K. 
5.4.2.3 Determination of limits of detection 
Limits of detection , defined as the analyte concentration giving a signal equal to 
the blank signal plus 3 standard deviations of the blank [291], were determined 
for each of the five proteolytic enzymes in the static system. Fluorescence 
intensity against enzyme concentration was plotted for the linear portion of the 
graphs for each of the enzymes, which are shown in figures 5.14 to 5.18. 
Measurements were taken in triplicate and error bars are given which represent 
plus and minus one standard deviation. 
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Figure 5.14 - Fluorescence intensity against enzyme concentration 
to calculate the limit of detection of alkaline protease 
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Figure 5.15 - Fluorescence intensity against enzyme 
concentration to calculate the limit of detection of proteinase K 
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Figure 5.16 - Fluorescence intensity against enzyme 
concentration to calculate the limit of detection of a-chymotrypsin 
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Figure 5.17 - Fluorescence intensity against enzyme 
concentration to calculate the limit of detection of trypsin 
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Figure 5.18 - Fluorescence intensity against enzyme 
concentration to calculate the limit of detection of pepsin 
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Limits of detection for each proteolytic enzyme using the substrate BODIPY:a.-
casein are given in table 5.5. 
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PROTEOLYTIC ENZYME LIMIT OF DETECTION (nM) 
ALKALINE PROTEASE 0.880 
PROTEINASE K 4 .630 
a-CHYMOTRYPSIN 0.208 
TRYPSIN 0.148 
PEPSIN 0.771 
Table 5.5 - Limits of detection determined experimentally 
for various proteolytic enzymes using the substrate 
BODIPY:a-casein in a static system 
Limits of detection in the nM region have been achieved for all five proteolytic 
enzymes using this system. These experiments indicate that BODIPY:a-casein 
is promising as a sensitive fluorogen ic substrate for the assay of proteolytic 
enzymes. As these preliminary experiments have proven successful , BODIPY:a-
casein was studied in a flow analysis manifold with four enzymes at different pH 
values. Such a flow set-up would be well suited for use in the high throughput 
screening of candidate drug molecules. 
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5.5 PROTEASE ASSAYS IN A FLOWING SYSTEM 
5.5.1 Procedures 
Fluorescence measurements were made using an F-4S00 fluorescence 
spectrophotometer with excitation and emission bandwidths of 10nm and time 
scans were performed with excitation and emission wavelengths of 605 nm and 
644 nm respectively. Flow system measurements were carried out using the set-
up shown in figure 5.19. 
Figure 5.19 - Manifold for flow injection enzyme and enzyme 
inhibition assays 
G 
H 
A 
(A = buffer, B = peristaltic pump, C = conjugate injection valve, D 
= enzyme or enzyme I inhibitor injection valve, E = switching 
valve, F = incubation loop, G = thermostatted water bath, H = 
fluorescence detector, I = waste) 
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The sequences of events that occur in these flow system experiments are 
depicted in figure 5.20. 
Figure 5.20 - Sequence of events for the determination of proteases and 
their inhibitors in a flow system 
1. 
1. 
145 
Substrate and either enzyme 
or enzyme / inhibitor are 
injected through two 25 IJ.I 
manual injection valves into 
the flowing stream of buffer 
After 14 seconds the assay 
components are all situated 
in the water bath at a defined 
temperature and the 
switching valve is tumed to 
separate the incubation loop 
from the rest of the flow 
system 
The reaction products are 
flowed through to the 
fluorescence detector after a 
set amount of time by 
switching the manual valve 
to rejoin the incubation loop 
into the flow system 
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Photos are shown below depicting the actual set-up of this flow system in our 
laboratory (figures 5.21 (a) and (b)). 
Figures 5.21 (a) and (b) - Actual layout and equipment used 
for flow anaysis protease and protease inhibition assays 
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A flow rate of 1.85 ml / min (calculations in appendix M) was used for all flow 
system experiments . The volume of the incubation loop was calculated to be 
670 III (calculations in appendix N). 
Four protease enzymes, each with varying pH optima , ranging from pH 2.5 - 9.5, 
were investigated in these experiments - alkaline protease, proteinase K, (X-
chymotrypsin, and pepsin. A description of each is given in section 1.6.4. 
5.5.2 Results 
Assay conditions for each enzyme were optimised . The effect of the following 
parameters on the enzyme assay were studied: 
• [enzyme] 
• incubation time 
• temperature 
• pH 
• buffer system 
• [buffer] 
The assay parameters studied and optimum conditions found for each enzyme 
are shown below in table 5.6. 
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KEY: CA = Carbonate, Cl = Citrate, GL = Glycine, PH = Phosphate 
[ENZYME] TIME TEMPERATURE pH BUFFER [BUFFER] 
()lg/ml) (minutes) (Oc) (mM) 
ALKALINE 
PROTEASE 
RANGE STUDIED 0-1.87 1.0 - 3.0 25-50 7 -11 PH / CA 10 -100 
OPTIMUM 0.75 2.0 40 9.5 CA 10 
PROTEINASE K 
RANGE STUDIED 0-1 .87 1.0- 3.0 25-50 7 -11 PH/CA 10 - 100 
OPTIMUM 1.49 1.5 35 9.5 CA 20 
Il-
CHYMOTRYPSIN 
RANGE STUDIED 0-1.49 1.0-3.0 25-50 7-9 PH 10 -100 
OPTIMUM 0.75 1.5 35 7.5 PH 10 
PEPSIN 
RANGE STUDIED 0-44.78 1.0-3.0 25-50 1-3 GLf Cl 10 -100 
OPTIMUM 37.31 1.5 35 2.0 GL 20 
Table 5.6 - Assay parameters studied and optimum conditions for 
various proteolytic enzymes using the fluorogenic substrate 
BODIPY : a -casein in a flow system 
The effect of assay parameters on ly on the proteolytic enzyme pepsin will be 
discussed in detail as it was found that similar trends were observed with all four 
proteolytic enzymes. Optimisation experiments were carried out in duplicate and 
error bars represent plus and minus one standard deviation . All readings were 
corrected for any effects of the assay parameters upon the conjugate. 
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5.5.2.1 Effect of temperature 
Effect of temperature on the activity of pepsin was examined over the range 25 -
50 cC using a thermostatted water bath. As shown in figure 5.22, there was an 
increase in the reaction rate as the temperature was increased from 25 cC to 
35 cC. A maximum level was reached at 35 cC after which the reaction rate 
declined with further increase of temperature. At high temperature, rapid 
denaturation of the quaternary protein structure occurred leading to a disruption 
of the enzymatic activity. 
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Figure 5.22 - Effect of temperature on the activity of pepsin 
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A temperature of 35 cC was selected for subsequent experiments since a 
maximum reaction rate was seen at this temperature. This was expected as 
most biological enzymes operate at 37 cC. 
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5.5.2.2 Effect of pH and buffer system 
Effect of buffer system and pH on the activity of pepsin was also investigated. A 
pH range from 1.0 - 3.0 in 0.5 increments was investigated using citrate and 
glycine buffers. As shown in figure 5.23, pH and buffer system both dramatically 
affected the reaction rate. Higher fluorescence intensities were observed with 
glycine buffer than citrate buffer and a pH optimum of 2.0 was seen with glycine 
buffer. On both sides of this pH value, the fluorescence dropped drastically. 
Figure 5.23 - Effect of pH and buffer system on the activity of pepsin 
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As a maximum reaction rate was achieved with glycine buffer at a pH of 2.0 , this 
buffer system and pH was used for all subsequent experiments. 
150 
Chapter 5 Experimental: single labelled substrate protease and protease inhibition assays 
5.5.2.3 Effect of buffer concentration 
The effect of glycine buffer pH 2.0 concentration was optimised. A concentration 
range of 10 to 100 mM was studied and as shown in figure 5.24. a peak in pepsin 
activity was seen at a concentration of 20 mM. At higher buffer concentrations a 
drop in the reaction rate occurred. 
Figure 5.24 - Effect of buffer concentration on the activity of pepsi n 
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Buffer concentration affected the reaction rate of pepsin on the substrate 
BODIPY:u-casein. A concentration of 20 mM was chosen for further work as this 
concentration gave an optimal reaction rate and was sufficient to maintain 
buffering capacity. 
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5.5.2.4 Effect of incubation time 
The time of incubation of pepsin and BODIPY:a-casein together was investigated 
over the range 1.0 to 3.0 minutes in 0.5 minute increments. Figure 5.25 
demonstrates that incubation time did not greatly affect the reaction rate. 
Figure 5.25 - Effect of incubation time on the activity of pepsin 
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As incubation time had no great effect upon the enzymatic activity of pepsin , an 
incubation time of 1.5 minutes was selected for further experiments. This was 
chosen as it is beneficial to carry out experiments for high throughput screening 
rapidly and difficulties were found using an incubation time of 1.0 minute when 
carrying out injections and switching manually. 
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5.5.2.5 Effect of pepsin concentration on the reaction rate 
Pepsin concentration was varied between 0 and 44. 78 ~g / ml. It can be seen 
from figure 5.26 that between 0 and 15 ~g / ml the formation of product proceeds 
at a rate which is linear with increasing enzyme concentration. In this region 
therefore, the reaction is independent of substrate concentration i.e. substrate is 
present in excess and the reaction is a 'zero order' reaction. However, as 
substrate is used up, the enzyme's active sites are no longer saturated , and 
substrate concentration becomes rate limiting and the reaction becomes first 
order. This is signified by the graph reaching a plateau. Ideally to measure 
enzyme activity, measurements must be made in that portion of the graph where 
the reaction is zero order because the reaction is then independent of substrate 
concentration and dependent only on enzyme concentration . Calculation of the 
limit of detection of pepsin was therefore carried out in the region 0 to 4 ~g / ml , 
as described in section 5.5.2.7. 
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Figure 5.26 - Influence of pepsin concentration on the 
formation of product when incubated with BODIPY:u-casein 
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5.5.2.6 Calibration graphs for BODIPV:u-casein in the flowing system 
Using the optimum assay parameters for each enzyme given in table 5.6, a 
calibration graph for BODIPV:u-casein was obtained by injecting a series of 
standard solutions of BODIPV:u-casein into the flow system with each of the 
enzymes. Measurements were made in triplicate and error bars show plus and 
minus one standard deviation. Each measurement was carried out separately. 
The BODIPV:u-casein conjugate that was used with alkaline protease was a 
different batch from that used with proteinase K, u-chymotrypsin, and pepsin . 
For this reason alkaline protease has been plotted on a separate graph. 
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Figure 5.27 - Influence of substrate concentration on the 
production of BODIPY fluorescence when incubated with alkaline 
protease in a flowing system 
120 
100 
80 
60 
40 
20 
0 
0 200 400 
y = 0.114x - 4.423 
R2 = 0.9949 
600 800 
BODIPV:u -<:asein concentration (pg I ml) 
154 
1000 
Chapter 5 
250 
~ 
~ 
c 
::3 200 1:-
~ 
.c 
... 
~ 150 ~ 
'" c Q) 
.... 
c 100 
Q) 
(.) 
c 
Q) 
(.) 
'" 50 ~
0 
::3 
u. 
0 
Experimental: single labelled substrate protease and protease inhibition assays 
Figure 5.28 - Influence of substrate concentration on the 
production of BODIPY fluorescence when incubated with 
a range of proteolytic enzymes in a flowing system 
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The calibration graphs obtained for BODIPY:a-casein show good linearity in the 
ranges investigated. In this region enzyme is not limiting and so increases in 
substrate concentration are accompanied by an increase in reaction rate, as 
more substrate is available to be converted to product by the enzyme. 
Figure 5.28 shows that different proteases act upon the substrate with different 
efficiencies. Proteinase K cleaves the substrate with a greater activity than either 
a-chymotrypsin or pepsin. These results do show that the activities of a variety 
of enzymes with different pH optima can be compared using the same substrate 
merely by altering the pH and buffer system. 
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5.5.2.7 Determination of limits of detection 
Limits of detection, defined as the analyte concentration giving a signal equal to 
the blank signal plus 3 standard deviations of the blank [291] , were determined 
for each of the four proteolytic enzymes in the flow analysis system. 
Fluorescence intensity against enzyme concentration was plotted for the linear 
portion of the graphs for each of the enzymes, which is the analytical useful 
region for the determination of enzymes due to the fact that the reaction is 
independent of substrate concentration i.e. zero order reaction. These results 
are shown in figures 5.29 to 5.32. Measurements were taken in triplicate and 
error bars are given which represent plus and minus one standard deviation. 
Figure 5.29 - Fluorescence intensity against enzyme concentration 
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Figure 5.30 - Fluorescence intensity against enzyme 
concentration to calculate the limit of detection of proteinase K 
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Figure 5.31 - Fluorescence intensity against enzyme 
concentration to calculate the limit of detection of a-chymotrypsin 
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Figure 5.32 - Fluorescence intensity against enzyme 
concentration to calculate the limit of detection of pepsin 
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Calculated limits of detection for each proteolytic enzyme using the substrate 
BODIPY:a-casein in a flow analysis system are given in table 5.7. 
PROTEOLYTIC ENZYME LIMIT OF DETECTION 
ALKALINE PROTEASE 10 pM 
PROTEINASE K 1.07 nM 
a-CHYMOTRYPSIN 0.21 nM 
PEPSIN 4.49nM 
Table 5.7 - Limits of detection determined experimentally for various 
proteolytic enzymes using the substrate BODIPY:a-casein in a 
flowing system 
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Sensitive detection limits have been determined for these proteolytic enzymes in 
the nM (proteinase K, a-chymotrypsin , and pepsin) and pM (alkaline protease) 
range. If these are compared with those obtained in the static system (table 5.5) 
it can be seen that the detection limits of both alkaline protease and proteinase K 
have been significantly improved. Those of a-chymotrypsin are identical, 
whereas with pepsin it was found that the static system gave a lower limit of 
detection than the flowing system . However, in all cases the time taken to carry 
out the assays was much improved in the flowing system compared with the 
static system as depicted in table 5.B. This has a great advantage when applying 
these protease assays to a high throughput screening format. 
PROTEOLYTIC INCUBATION TIME IN INCUBATION TIME IN 
ENZYME STATIC SYSTEM FLOWING SYSTEM 
Imins) (m ins) 
ALKALINE PROTEASE 10 2.0 
PROTEINASE K 5 1.5 
a-CHYMOTRYPSIN 10 1.5 
PEPSIN 10 1.5 
Table 5.8 - Comparison of assay incubation times for various proteolytic 
enzymes in static and flow system formats 
159 
Chapter 5 Experimental: single labelled substrate protease and protease inhibition assays 
The experiments that have been carried out in the flow analysis system 
demonstrate that the substrate BODIPY:u-casein is a sensitive fluorogenic 
protease substrate and that the flow-based procedure that has been described 
here is well suited for use in high throughput screening . 
5.5.2.8 Comparison with previously published work 
A quenched BODIPY dye-labelled casein substrate for the assay of proteases 
has previously been described by Jones et al. [255] and was described in section 
1.8.3.2.2. In this study a 96-well microtiter plate format was used with the 
BODIPY dyes BODIPY FL and BODIPY TR-X. These had excitation / emission 
wavelengths of 485 nm / 530 nm, and 590 nm /645 nm, respectively. The limits 
of detection (LOO) and the times taken to carry out the assays are given in table 
5.9 and compared with those that have been found in this study. Limits of 
detection have been given in terms of enzyme units as defined by the supplier. 
To convert the limits of detection given in table 5.7 from molar concentrations to 
enzyme units, enzyme activities defined by the supplier of 21 Units / mg protein , 
10.2 Units / mg protein , 51 Units I mg protein, and 4500 Units / mg protein were 
used for alkaline protease, proteinase K, a-chymotrypsin, and pepsin 
respectively. Use of detection limits in enzyme units allows for a fair comparison. 
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M.L.Beaumont Jones et al. 
LOO TIME LOO TIME 
(Units) (m ins) (Units) (m ins) 
ALKALINE PROTEASE 2.1 X 10 -6 2.0 1 X 10 -4 60 
PROTEINASE K 6.3 X 10 .5 1.5 1 X 10 -4 60 
a-CHYMOTRYPSIN 5.5X10·s 1.5 2 X 10-4 60 
PEPSIN 1.4 X 10 .1 1.5 5 X 10 -3 60 
Table 5.9 - Comparison of enzyme limits of detection between 
two different methods using similar protease substrates 
Comparing the limits of detection for the work carried out in our lab with those of 
Jones et al., it can be seen that in each of the cases apart from pepsin the limit of 
detection has been significantly improved. The time taken to carry out the 
assays has also been vastly improved. The limits of detection that have been 
achieved in our lab could also be improved further. A sub-optimal wavelength of 
605 nm was used to excite the BODIPY:a-casein substrate. With the use of 
laser induced fluorescence and cut-off filters an optimal excitation wavelength of 
625 nm could be used, which would improve the sensitivity of the system giving 
improved limits of detection. 
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5.6 PROTEASE INHIBITION ASSA VS 
5.6.1 Procedures 
The effect of a variety of reversible inhibitors on the proteolytic enzymes was 
investigated. Enzyme - inhibitor pairs were chosen from the enzymes already 
studied and a selection of inhibitors consisting of 4-hydroxycoumarin , warfarin , 3-
nitrophenylboronic acid , aprotinin , leupeptin , and pepstatin A A description of 
the inhibitors used during this work is given in section 1.9.2. 
Protease inhibition assays were carried out using the set-up that was shown in 
figures 5.19 and 5.20. Enzyme and inhibitor were pre-mixed before injection and 
then mixed with substrate in the incubation loop. 
5.6.2 Results 
Preliminary experiments were carried out by incubating each proteolytic enzyme 
with increasing amounts of each inhibitor. It was found that neither 4-
hydroxycoumarin nor warfarin had an inhibitory effect upon any of the proteolytic 
enzymes tested . However, it was found that the remaining inhibitors - 3-
nitrophenylboronic acid (3-NPBA), aprotinin , leupeptin , and pepstatin A - each 
inhibited the four proteolytic enzymes to varying degrees. Enzyme - inhibitor 
pairs were selected depending on which inhibitor exerted the best inhibitory 
effect upon which enzyme. 
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The following enzyme - inhibitor pairs were used for all subsequent experiments 
• 3-nitrophenylboronic acid and proteinase K 
• aprotinin and a-chymotrypsin 
• leupeptin and alkaline protease 
• pepstatin A and pepsin 
In addition to the enzyme assay parameters previously optimised (table 5.6) , 
additional inhibition assay conditions were optimised using univariate methods. 
All other conditions such as pH, buffer system, and temperature, were as those 
conditions previously optimised. 
The effect of the following parameters on the inhibition assays were optimised: 
• pre-incubation time 
• incubation time 
• [substrate] 
• [enzyme] 
The assay parameters studied and the optimum values found for each enzyme -
inhibitor pair are given below in table 5.10. 
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PRE-INCUBATION INCUBATION [SUBSTRATE] (ENZYME] 
TIME (mins) TIME (minutes) (ng mr' ) ( ~g mr') 
3-NPBA 
+ 
PROTEINASE K 
RANGE STUDIED 0-5 1 - 5 53.3 - 266.4 0-1 .866 
OPTIMUM 2 2 106.6 0.746 
APROTININ 
+ 
a -CHYMOTRPYSIN 
RANGE STUDIED 0-4 1-5 53.3 - 266.4 0-1 .119 
OPTIMUM 2 1 106.6 0.373 
LEUPEPTlN 
+ 
ALKALINE PROTEASE 
RANGE STUDIED 0 - 5 1-5 53.3 - 266.4 0- 0.233 
OPTIMUM 4 1 213.1 0.093 
PEPSTATIN A 
+ 
PEPSIN 
RANGE STUDIED 0-4 1-5 53.3 - 266.4 0-37.31 
OPTIMUM 2 1 106.6 0.373 
Table 5_10 - Assay parameters studied and optimum conditions for 
various enzyme - inhibitor pairs using the fluorogenic substrate 
BODIPY:a-casein in a flow system 
The optimisation of inhibition parameters will be discussed only for pepsin and 
pepstatin A. Optimisation experiments were carried out in duplicate and error 
bars represent plus and minus one standard deviation . 
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5.6.2.1 Effect of pre-incubation time 
Enzyme and inhibitor were pre-mixed in a glass vial and incubated for a set 
amount of time before injection into the flowing system and incubation with 
substrate. The effect of varying this pre-incubation time was investigated over 0 
to 4 minutes in 1 minute increments. The results of this are shown in figure 5.33. 
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Figure 5.33 -Influence of pre-incubation time on the inhibition 
of pepsin by pepstatin A 
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The effect of pre-incubation time on the inhibition of pepsin by pepstatin A wasn 't 
significant. This was expected as pepstatin A has been reported as an 
uncompetitive inhibitor of pepsin [281) and as described in section 1.9.1.1 , 
uncompetitive inhibitors bind only with the ES complex and not with the free 
enzyme. Increasing the time spent for the enzyme and inhibitor together will 
therefore not increase inhibition. A pre-incubation time of 2 minutes was 
therefore chosen for further studies. 
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5.6.2.2 Effect of incubation time 
Incubation time is defined as the time spent for the substrate , enzyme, and 
inhibitor together in the incubation loop in the thermostaUed water bath after 
injection of each into the flowing system. This assay parameter was investigated 
over the range 1 to 5 minutes in 1 minute increments. Figure 5.34 shows the 
effect of increasing incubation time on the amount of enzyme inhibition seen. 
Figure 5.34 - Influence of incubation time on the inhibition of 
pepsin by pepstatin A 
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From figure 5.34 it is evident that the inhibition of pepsin by pepstatin A was not 
affected by incubation time. As increases in the incubation time of the substrate 
and inhibitor together did not cause an increase in the percentage inhibition, this 
suggests that the binding of inhibitor to the enzyme - substrate complex 
proceeds instantaneously. An incubation time of 1 minute was thus selected for 
further work so as to keep the assay time to a minimum. 
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5.6.2.3 Effect of substrate concentration 
Increasing concentrations of substrate were irijected into the flowing system with 
enzyme and inhibitor to determine the effect of increasing the substrate 
concentration on the inhibition of pepsin by pepstatin A. Figure 5.35 shows the 
results of this experiment. 
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Figure 5.35 - Influence of substrate concentration on 
the inhibition of pepsin by pepstatin A 
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The effect of increasing the substrate concentration was to increase the inhibition 
of pepsin by pepstatin A (figure 5.35) . As pepstatin A is an uncompetitive 
inhibitor of pepsin , the inhibitor binds only with the enzyme - substrate complex, 
not with free enzyme. In this case therefore, as described in section 1.9.1.1 
increased substrate concentration increases the inhibition. A high concentration 
of substrate will not reverse the inhibition , as is the case with reversible 
competitive inhibition. A substrate concentration of 106.6 ng mr1 was used for 
further work. 
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5.6.2.4 Effect of enzyme concentration 
The effect of increasing the concentration of pepsin was determined by injecting 
a series of increasing enzyme concentrations into the flowing system and 
detecting the amount of fluorescence (figure 5.36). 
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Figure 5.36 - Influence of pepsin concentration on the 
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As shown in figure 5.36, as the concentration of pepsin was increased the 
percentage inhibition also increased, although not to a great extent. Since the 
inhibitor only binds with the enzyme - substrate complex and not with free 
enzyme the effect will be minimal as increasing the enzyme concentration would 
only cause an increase in the inhibition through the formation of more enzyme -
substrate, and not through the increased free enzyme. A concentration of 18.66 
f.Lg I ml was used for further work as after this concentration increase in 
percentage inhibition is minimal. 
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5.6.2.5 Problems with inhibitors 
A number of delays were introduced into this work due to problems encountered 
with the inhibitors. 
Leupeptin hemisulfate salt was very problematic with respect to its stabil ity. In 
powder form leupeptin is stable for 2 years if stored frozen and kept very dry. 
However , a 10 mM aqueous solution is stable for a week at 4 QC and at working 
concentrations (10 to 100 J.lM) a solution is stable only for a few hours and the 
stock solution should be stored on ice for intermitted use over several hours. 
Leupeptin was purchased in 5 mg vials , which is equivalent to 2.1 mM. A stock 
solution was made up by adding 1 ml 10 mM carbonate buffer pH 9.5 to the vial 
to give a concentration of 5 mg / ml. This was to prevent loss of leupeptin that 
would occur if weighing out and to prevent inaccuracies due to weighing out of 
very small quantities. These solutions were therefore stable for just one week. 
All experiments involving leupeptin therefore needed to be carried out rapidly and 
this is reflected in the poorer accuracy found with the leupeptin data than with the 
other inhibitors. This accuracy was also affected by the fact that individual 
experiments needed to be carried out in a few hours, as the solutions were stable 
for just several hours when kept on ice. 
Leupeptin has working concentrations of 10 to 100 J.lM . As shown in figure 5.45, 
the leupeptin inhibition curve was carried out using concentrations ranging from 0 
to 3.73 J.lg / ml. This is equivalent to molar concentrations of 0 to 7.8 J.lM . The 
inhibition curve therefore has been carried out at low inhibitor concentrations, 
which is reflected in the low percentage inhibition. However due to the instability 
of leupeptin , which therefore makes it an extremely difficult inhibitor to work with , 
it was felt that spending more money on higher concentrations was not valid as it 
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was only really important to obtain the linear portion of the graph to determine the 
limit of detection. 
A second source of difficulty was found with pepstatin A. This inhibitor has poor 
solubility and does not dissolve in aqueous solutions. Pepstatin A is soluble in 
both dimethyl sulphoxide (DMSO) and methanol. Experiments were carried out 
and it was found that in the presence of inhibitor, the fluorescence intensity 
increased, the opposite of what was expected . The fluorescence of the substrate 
was therefore compared in buffer with that in methanol. As shown in figure 5.37, 
methanol dramatically affected the fluorescence of BODIPY. With increasing 
methanol concentration a concomitant increase in BODIPY fluorescence was 
noted. This response was unexpectedly non-linear. 
Figure 5.37 - Influence of methanol concentration on the 
fluorescence of BODIPV:u-casein 
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The two plots in figure 5.37 represent the fl uorescence intensity at the emission 
wavelength of BODIPY:a-casein and also at the peak emission wavelength 
found. This was because it was also found that the addition of increasing 
amounts of methanol caused a small wavelength shift of the emission maximum 
towards lower wavelengths, as shown in figu re 5.38. 
Figure 5.38 - Influence of percentage concentration of methanol on the 
emission wavelength of BODIPY:a-casein 
3000 
~ 
- 0% ~ 
!: 2500 - 25% ::J 
I::' - 50% 
~ 
- 75% 
.0 2000 ... 
~ - 99 .60% 
.~ 
(/) 1500 !: 
2 
.E 
Q) 
1000 tJ 
!: 
Q) 
tJ 
(/) 
Q) 
500 ... 0 
::J 
u.. 
0 
620 640 660 680 700 
Wavelength (nm) 
It has been noted in the past that methanol dramatically enhances serine 
protease activity under anhydrous conditions [292]. Certain solvents or 
'additives' including dimethylsulfoxide, formamide, and ethylene glycol have also 
been reported in the past to increase enzyme activity when added into the 
organic media along with small amounts of water [293, 294] . 
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In order to determine whether methanol affects the fluorophore only or whether 
the enzyme is also affected by the presence of methanol, methanol concentration 
was increased in the presence of substrate and enzyme (figure 5.39). 
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Figure 5.39 -Influence of percentage methanol on the fluorescence 
of BODIPY: CL-casein and pepsin 
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If the shapes of the two graphs shown in figures 5.37 and 5.39 are compared it 
can be seen that the shapes are extremely similar. This suggests that the effect 
of methanol is purely on the BODIPY:CL-casein substrate and not on pepsin, as if 
pepsin were also affected , the shape of the graph would have altered when 
compared to that of figure 5.37 . 
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The solvent dependent effect that has been observed with BODIPY has been 
documented in the past by a number of researchers for various fluorophores 
[295, 296]. In fact, the Molecular Probes Inc. website records many of the 
BODIPY spectra in methanol as it greatly enhances the fluorescence [297] . 
The effect of incubating BODIPY:a-casein and pepsin over time in the presence 
of a constant concentration of methanol was also investigated. As shown in 
figure 5.40, the presence of methanol has a constant effect over time 
demonstrated by the similar shapes of the curves representing the presence of 
methanol and the absence of methanol (buffer) . 
~ 
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Figure 5.40 - Influence of incubation time on the fluorescence 
of BODIPY:a-casein incubated with pepsin in the presence and 
absence of methanol 
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As DMSO is also a solvent for pepstatin A, the effect of inclusion of DMSO in the 
medium on the fluorescence intensity and emission wavelength of BODIPY:cx-
casein was also studied . 
From figure 5.41 it can be deduced that DMSO also causes an enhancement of 
the 'fluorescence of BODIPY, although at lower percentage concentrations the 
effect is not as dramatic as that seen with methanol. However, the effect of 
DMSO on the optimum emission wavelength was opposite to that caused by 
methanol as shown in figure 5.42. Whilst methanol caused a blue shift of around 
5 nm at 99.6 %, DMSO caused a red shift of about 7 nm at 99.6 %. 
Figure 5.41 - Influence of percentage methanol and DMSO on the 
fluorescence of BODIPY:cx-casein 
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Figure 5.42 - Influence of DMSO percentage concentration on the 
optimum emission wavelength of BODIPY:u-casein 
~ 3000 
~ 
I: 
~ 2500 
~ i 2000 
~ 
:g 1500 
2 
I: 
Cl> 1000 u 
I: 
Cl> 
U 
V) 
e 
o 
::l 
U. 
620 640 660 
Wavelength (nm) 
- 0% 
- 25% 
- 50% 
- 75% 
- 99.60% 
680 700 
As DMSO is more toxic than methanol and as pepstatin A was found to dissolve 
more easily in methanol than DMSO, the decision was taken to use methanol as 
the solvent for DMSO even though the fluorescence enhancement effects were 
greater with methanol than with DMSO. 
A 10 mg I ml stock solution of pepstatin A in methanol was stored in aliquots in 
the freezer where they were stable for months. An aliquot was used for each 
experiment and was made up in 20 mM glycine buffer pH 10.0, which was stable 
for at least one day at room temperature. Accounting for dilution in buffer and for 
additional dilution in the flow system, the actual percentage of methanol present 
during optimisation experiments amounted to only 0.09 %. To take the effect of 
this methanol upon BODIPY:u-casein into account, the same percentage of 
methanol was also included in the blank reading. For the generation of the 
pepstatin A inhibition curve, the amount of methanol in the series of standard 
solutions of pepstatin A injected into the flowing system was kept constant. 
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5.6.2.6 Generation of inhibition curves 
Under the optimum conditions already described , a series of inhibitor standard 
solutions were mixed with enzyme and injected into the flow analysis system to 
be incubated with substrate. The reaction products were detected and the 
fluorescence measured . Measurements were taken in triplicate and error bars 
represent plus and minus one standard deviation. Inhibition curves were 
obtained for each of the four enzyme - inh ibitor pairs. 
Figure 5.43 -Inhibition of proteinase K by 3-nitrophenylboronic acid 
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Figure 5.44 - Inhibition of a-chymotrypsin byaprotinin 
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Figure 5.45 -Inhibition of alkaline protease by leupeptin 
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Figure 5.46 -Inhibition of pepsin by pepstatin A 
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Figures 5.43 to 5.46 show the inhibition of the enzymes proteinase K, 0.-
chymotrypsin, alkaline protease, and pepsin by the inhibitors 3-
nitrophenylboronic acid , aprotinin , leupeptin, and pepstatin A respectively. As 
inhibitor concentration was increased there was an increase in percentage 
inhibition until a plateau point was reached. For the competitive inhibitors (3-
nitrophenylboronic acid, aprotinin , and leupeptin) , as inhibitor concentration is 
increased there is more competition against the substrate for the active site of the 
enzyme and so percentage inhibition increases. At the plateau point of the 
inhibition curves, enzyme becomes limiting and further increases in inhibitor 
produce no increases in inhibition because there are no more enzyme sites to 
compete for. In the case of pepstatin A, which is an uncompetitive inhibitor, 
increases in inhibitor concentration cause more inhibitor to bind with the enzyme 
- substrate complex, preventing the formation of product. This is reflected by an 
increase in the percentage inhibition. However, at the plateau point the formation 
of the enzyme - substrate complex becomes limiting and further increases in 
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inhibitor concentration produce no further increases in inhibition because there is 
no more enzyme - substrate complex to inhibit. 
For the competitive inhibitors at any given inhibitor concentration , if the amount of 
substrate is increased a drop in percentage inhibition would be seen as there 
would be more substrate to compete with the inhibitor for the enzyme active site. 
5.6.2.7 Determination of limits of detection 
Limits of detection, defined as the analyte concentration giving a signal equal to 
the blank signal plus 3 standard deviations of the blank [291], were determined 
for each of the four inhibitors in the flow analysis system. Percentage inhibition 
against inhibitor concentration was plotted for the linear portion of the graphs for 
each of the inhibitors. These results are shown in figures 5.47 to 5.50. 
Measurements were taken in triplicate and error bars are given which represent 
plus and minus one standard deviation. 
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Figure 5.47 - Percentage inhibition against inhibitor concentration 
in linear portion to calculate limit of detection 
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Figure 5.48 - Percentage inhibition against inhibitor concentration 
in linear portion to calculate limit of detection 
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Figure 5.49 - Percentage inhibition against inhibitor concentration 
in linear portion to calculate limit of detection 
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Figure 5.50 - Percentage inhibition against inhibitor concentration 
in linear portion to calculate limit of detection 
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Calculated limits of detection for each inhibitor using the substrate BODIPY:u-
casein are given in table 5.11 . 
I 
INHIBITOR 
I 
LIMIT OF DETECTION 
3-NITROPHENYLBORONIC ACID 2.504 JlM 
APROTININ 0.161 nM 
LEUPEPTIN 0.140 JlM 
PEPSTATIN A 7.20 nM 
Table 5.11 - Limits of detection determined experimentally for 
various protease inhibitors using the substrate BODIPY:u-casein 
in a flowing system 
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limits of detection in the IlM (3-nitrophenylboronic acid and leupeptin) and nM 
(aprotinin and pepstatin A) regions were achieved using the substrate 
BODIPY:a-casein, showing that this f1uorogenic substrate can successfully be 
applied to the sensitive determination of protease inhibitors. 
From graphs 5.47 to 5.50 It is obvious that both aprotinin and pepstatin A are 
both potent senne and aspartate protease inhibitors respectively. This was seen 
by the high percentage inhibition achieved at low inhibitor concentrations. This 
was reflected in the nM limits of detection. Conversely, 3-nitrophenylboronic acid 
and leupeptln were less efficient senne protease inhibitors giving much lower 
percentage inhibitions at higher inhibitor concentrations. ThiS was again 
reflected in the limits of detection, which were obtained in the IlM region. 
The time taken to carry out these inhibition assays was rapid taking at most 5 
minutes for leupeptin and again the flow-based procedure that has been 
described would be easily automatable for use in high throughput screening 
assays. 
The method that has previously been described in section 1.8 3 2 2 by Jones et 
al. [255) was also applied to the determination of aprotinin. This work was able to 
achieve limits of detection in the Ilg I ml range using an assay that took 80 
minutes. The method that has been descnbed in this theSIS has improved on this 
significantly. Aprotlnln has been detected at a concentration of 1.1 ng I ml in just 
3 minutes. 
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5.7 DISCUSSION 
Calculations of dye protein ratios in fluorescent or fluorogenic conjugates usually 
assume that the absorbance characteristics of the conjugated dye are the same 
as those of the free dye. This was clearly not the case at wavelengths at ca. 600 
nm in the present work. Experiments were carried out to establish whether the 
shape change that was observed between the absorbance spectra of the free 
and conjugated dye was due to the formation of covalent H-dimers between 
BOOIPY molecules. The results of these experiments strongly suggested that 
this theory was indeed plausible. O:P calculations were therefore carried out 
using absorbance values at 280 nm and 350 nm to estimate protein and dye 
concentrations respectively. The latter wavelength was chosen because the 
absorbance spectra of the free dye and conjugated dye in this region are very 
similar. Using this method of calculation, it was found that a O:P ratio of 2.35 
BOOIPY molecules to 1 a-casein was optimal for use in these types of assays. 
This was in general agreement With the findings of Jones et al., [255] who 
showed that conjugation of an average of 4.5 to 6 BOOIPY FL or even fewer 
BOOIPY TR-X dye groups to each casein molecule was optimal. Presumably, 
the formation of non-fluorescent dlmers Within the substrate would further help to 
produce a quenching effect due to the fact that the dlmers can absorb the 
exciting light but will not fluoresce. Larger O:P ratios could be achieved by 
Increasing the levels of dye in the reaction mixtures, but this resulted in an 
Increase in background fluorescence, i.e. in the intensity of the unhydrolysed 
substrate, limiting the sensitivity of the assays. 
The relatively low molar ratio of dye to protein used in the present work provides 
an ideal substrate for proteolytic enzymes. Worries that the use of highly 
derivatised molecules might sterically hinder the activity of some proteases are 
minimised. In addition, BOOIPY dyes have no overall charge, so dye conjugation 
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should not greatly affect the protein substrate conformation and enzyme-active 
site interactions. 
The application of BODIPY:a-casein to the determination of different proteolytic 
enzymes with varying pH optima has been demonstrated. Enzyme assays were 
carried out in just 1.5 minutes with the exception of alkaline protease (2 minutes). 
The pH insensitivity of BODIPY means that assays can be carried out in a single 
step without the need to carry out the proteolytic reaction at one pH and the 
measurement at another pH, as would be necessary sometimes in the case of 
fluorescein. The procedure does not require any process such as separation, 
precipitation or centrifugation. 
The suitability of BODIPY:a-casein as a substrate in enzyme inhibition assays 
has also been investigated. Limits of detection of 2.50 /1M, 0.14 /1M, and 7.20 
nM were obtained for 3-nitrophenylboromc acid, leupeptin, and pepstatin A 
respectively. The inhibitor aprotinin has been found to be of benefit during 
paediatric cardiac surgery to reduce blood loss with cardiopulmonary bypass 
[274]. The limit of detection for this inhibitor was 0.161 nM (1.1 ng mrl) using the 
current setup. This is extremely sensitive compared to the assay using a similar 
substrate described by Jones et al [255] who observed inhibition in the /1g mrl 
range. In addition, the assay described by Jones et al. took 1 hour 20 minutes to 
carry out, whereas the assay described here was carried out in just 3 minutes. 
The flUOrogenic assays that have been described here are rapid, taking at most 2 
minutes for the enzyme assays and 5 minutes for the inhibition ~ssays. They 
combine the sensitivity of long-wavelength fluorescence with the ease of 
automation that can be applied to flow injection analysis and could be 
incorporated into a simple portable fluorescence instrument. They have many 
clinical applications, since proteases are involved in Virtually all biological 
functions and dysfunctions and therefore are promising as drug targets. 
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The application of BODIPY:a.-caseln in a flow injection analysis system is a rapid, 
simple and sensitive method for the assay of proteases, essential requirements 
for a routine assay. The whole assay is easily automated and would be well 
suited for use in high throughput screening. 
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CHAPTER 6 
Experimental: 
multi-determination 
protease inhibition 
assays 
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6.1 INTRODUCTION 
The aim of these experiments was to apply those protease inhibition assays that 
had previously been optimised In chapter 5 to a flow injection analysIs system 
such that the system would allow the determination of more than one inhibitor in 
the same assay i.e. multl-determination. 
The need to improve productivity is imperative for drug discovery companies. 
One strategy is: test more discover more. The availability therefore of a simple, 
senSitive, and effiCient method for the multi-determination of proteolytic enzymes 
and their inhibitors would be of much use in the high throughput screening of 
candidate drug molecules. This set-up would allow a much higher throughput 
accompanied by cost advantages. 
An excellent review discusses the determination of two or more species in the 
same sample with a single flow injection analysis system [71] 
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6.2 MULTI-DETERMINATION PROTEASE INHIBITION ASSAYS USING 
CONTROLLED-PORE GLASS AS A SUPPORT 
6.2.1 Procedures 
Fluorescence measurements were made using an F-4500 fluorescence 
spectrophotometer with excitation and emission bandwidths of 10nm. Time 
scans were performed with excitation and emission wavelengt.hs of 605 nm and 
644 nm respectively for BOOIPY and BOOIPY:a.-casein, 280 nm and 350 nm for 
a.-casein, 597 nm and 660 nm for naphthofluorescein, and 640 nm and 664 nm 
forCy5. 
As a starting point for these assays, it was decided that the simplest approach 
would be a dual protease inhibition assay using one buffer system. As it was 
shown that both alkaline protease and proteinase K operated at pH 9.5 (section 
5.5 2, table 5.6), these two enzymes seemed like the obvious chOice. The serine 
protease inhibitor 3-nltrophenylboronic acid was shown to inhibit proteinase K 
(section 5.6.2.6, graph 543) and so this inhibitor was selected for use in this dual 
system. The Ideal set-up for a simple assay was to flow buffer slowly through 
two enzyme reactors, each containing either immobilised alkaline protease or 
immobilised proteinase K, as shown in figure 6.1. A substrate I inhibitor solution 
would be injected and the fluorescence detected through the time-dependent 
separation of the peaks emerging from each of the reactors by having different 
lengths of flow tubing between the enzyme reactors and the detector. 
The other alternative to this set-up was to capture the assay components in each 
column using an incubation loop and 4-port manual switching valve. However, 
this approach seemed more problematic due to having two sWitching valves to 
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operate at exact times , and so the above approach depicted in figure 6.1 was 
chosen as the proposed system. 
Figure 6.1 - Schematic of flow injection analysis system for 
multi-determination protease inhibition assays 
D 
c 
B 
E 
G 
A 
H 
(A = buffer, B = peristaltic pump, C = substrate or substrate I 
inhibitor injection valve, D = enzyme reactor 1, E = enzyme 
reactor 2, F = thermostatted water bath, G = fluorescence 
detector, H = waste) 
Temperature, pH and buffer system conditions for alkaline protease had 
previously been optimised (section 5.5.2, table 5.6) to be 10 mM carbonate buffer 
pH 9.5 and 40 QC. Those for proteinase K were 20 mM carbonate buffer pH 9.5, 
35 QC. By comparing results for buffer concentration and temperature for each 
enzyme, it was decided that the best compromise for multi-determination assay 
conditions was 20 mM carbonate pH 9.5, 35 QC. These conditions were used in 
all experiments. 
The sequence of events using this flow analysis set-up is shown in figure 6.2. 
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Figure 6.2 - Sequence of events for multi-determination 
protease inhibition assays using immobilised enzyme reactors 
Substrate only or substrate and inh ibitor injected 
through a manual injection valve (25 f!1 each) and split 
at aT-junction to flow throuQh two enzyme reactors 
Products from the enzyme reactor with the shorter 
distance to the F-4500 detected first 
Products from the enzyme reactor with the longer 
distance to the F-4500 detected second 
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Controlled-pore glass (CPG) was purchased from Cambio Ltd. and evaluated as 
a support for use in these assays. Immobilisation of alkaline protease and 
proteinase K onto controlled pore glass was carried out as previously described 
by Masoom and Townshend [120] , a description of which is given in section 
2.2.12. 2.5, 5.0, and 7.5 mg alkaline protease and 4.0, 8.0, and 12.0 mg 
proteinase K were used for immobilisation onto 0.5 g CPG. Immobilised enzyme 
was stored in buffer at 4 °C when not in use. The reaction scheme for enzyme 
immobil isation is given in figure 6.3. 
Figure 6.3 - Reaction scheme for the immobilisation of enzyme 
onto controlled pore glass 
Aminopropyl CPG Glutaraldehyde 
OEt o 0 
1 11 11 
CPG- O-Si-(CH2h - NH2 + H-C-(CH2h - C-H 
OEt 
1 
OEt H 0 
1 1 11 
CPG- O- Si- (CH2h-N= C-(CHv3- C-H 
OEt Activated CPG 
+ 
Enzyme ENZ-NH2 
1 
OEt H H 
1 1 1 
CPG- O-Si-(CH2h- N=C- (CH2h - C=N-ENZ 
OEt CPG immobilised enzyme 
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ePG was chosen as a support due to its high surface area , high mechanical 
strength , high flow rate, and rigid glass structure. Initial studies were carried out 
on aminopropyl ePG with a mean pore diameter of 182 A, a particle size of 37-
74 I-lm, and a capacity of 701 .9 I-lmoles amine per g glass. ePG with a mean 
pore diameter of 972 A, a particle size of 37 - 74 I-lm, and a capacity of 67 
I-lmoles amine per g glass was also used. 
A picture of the 182 A aminopropyl ePG was taken using a Scanning Electron 
Microscope (SEM) as shown in figure 6.4. 
Figure 6.4 - SEM pictures showing (a) 182 A aminopropyl glass and 
(b) an individual glass chip 
It can be seen that ePG has the appearance of fine glass chips of irregular 
shape. The best resolution for the SEM is at distances of 100 - 200 I-lm and so 
the pores of the ePG were beyond the capabil ity of the SEM. 
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Immobilised enzyme was packed into Omnifit glass columns with a bore of 3 mm, 
and a length of either 2.5 cm or 5.0 cm corresponding to reactor volumes of 175 
!-II and 350 !-II respectively. Aluminium frits with 2 !-Im pores were used at both 
ends to prevent leakage of the CPG . The appearance of the enzyme reactor 5 
cm in length is shown in figure 6.5. Columns were packed by mounting the 
columns vertically, and connecting the bottom of the column to a peristaltic pump 
that allowed suction of loaded CPG through the top end of the column 
downwards. The glass column was then incorporated into the flowing system 
and clamped vertically in the water bath. Buffer was flowed upwards through the 
column, which was opposite to the direction of packing. This ensured maximum 
contact of the buffer with the CPG and tighter packing . 
Figure 6.5 - Appearance of the enzyme reactors: top -
packed glass column, bottom - empty glass column 
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6.2.2 Results 
Injections of BODIPY:u-casein and naphthofluorescein were made through a 
column packed with 12.0 mg proteinase K - CPG. A high concentration of 
BODIPY:u-casein was used to give sufficient fluorescence intensity, and 
naphthofluorescein was also used as it is extremely fluorescent and therefore 
easy to detect whilst being cheap. When each of these was injected, nothing 
was detected i.e . these dyes appeared to be retained on the column. 
As a control experiment therefore, BODIPY:u-casein was mixed in a standard 3 
ml fluorescence cuvette with a random amount of proteinase K - CPG by 
inverting the cuvette five times. The cuvette was incubated at 35 QC and at time 
intervals the liquid was decanted off and the fluorescence measured. The liquid 
was then again mixed with the beads and returned to the water bath for a further 
time before the liquid was again decanted off and the fluorescence measured. 
This was repeated over time. 
As shown by figure 6.6, it was observed that over time the fluorescence of 
BODIPY:u-casein decreased in the presence of the proteinase K - CPG when 
compared to the fluorescence of BODIPY:u-casein in the absence of CPG. 
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Figure 6.6 - Fluorescence intensity of BODIPY:u-casein over time 
when incubated in the presence and absence of proteinase K - CPG 
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Interestingly it was found that incubation of BODIPY:u-casein for 2 minutes with 
proteinase K - CPG produced an enhancement of fluorescence when compared 
to BODIPY:u-casein incubated with CPG with no proteinase K immobilised 
(figure 6.7) . This suggested that proteinase K was definitely successfully 
immobilised onto the CPG as the fluorescence enhancement indicated that the 
substrate was subjected to proteolytic cleavage. 
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Conversely it was found that when naphthofluorescein was incubated with the 
proteinase K - CPG the fluorescence intensity remained relatively constant over 
time. (It is shown later in section 6.2.2.4 that naphthofluorescein does not 
appear out of the column either. However, this is due to column length, not due 
to sticking to the CPG, which explains the fact that when naphthofluorescein was 
incubated with proteinase K - CPG the fluorescence intensity remained 
constant). 
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The column was re-packed with 7.5 mg alkaline protease - CPG to see whether 
a change in the immobilised enzyme would alter the flow of BODIPY:u-casein 
and naphthofluorescein through the column. However, both were also retained 
in this column. 
Injections of BODIPY:u-casein were then made through a column containing raw 
aminopropyl CPG i.e. without activation or immobilisation of enzyme. From the 
results shown in figure 6.8, it was observed that some BODIPY:u-casein was 
able to flow through this column, although most was retained . 
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Figure 6.8 - Fluorescent peaks of BODIPY:u-casein injected 
into a buffer stream with and without a raw CPG column 
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On the basis of the results that had been found it was decided that a number of 
possibilities could account for the fact that the enzyme reactor retained both 
BODIPY:u-casein and naphthofluorescein. 
It was seen that BODIPY:u-casein was stable with respect to its fluorescence 
intensity over time whereas in the presence of proteinase K - ePG the 
fluorescence dropped. This could be because the stability of the product was 
different to that of the substrate, perhaps due to the fluorophore molecules being 
more exposed in the product. It could also be explained by sticking of the 
substrate or product to the proteinase K - ePG chips, or by the ePG somehow 
quenching the fluorescence of BODIPY:u-casein . 
Another possibility was product inhibition. Product binds to the active site by the 
same bonds that bind the substrate. As a result , enzyme-product complexes are 
formed which prevent the substrate from binding the enzyme. As both substrate 
and product compete for the active site and both cannot bind simultaneously, this 
is a type of competitive inhibition. 
One explanation is that substrate was cleaved into peptides and so enhancement 
of fluorescence was seen. However, with increasing time these peptides may 
have been attracted to each other so that the fluorophore molecules again came 
into close contact and the internal energy transfer effects were again seen. 
One other potential reason was that the pore sizes were too small and therefore 
became blocked. The average pore size was 182 A and if it is assumed that an 
enzyme has a rough size of 60 A, then actual space for the substrate to flow 
through becomes limited . 
A combination of any of these possibilities may also have been true. 
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6.2.2.1 Absorbance experiments to investigate sticking of a-casein to 
glutaraldehyde activated CPG 
An experiment was conducted to determine whether a-casein would stick to 
glutaraldehyde-activated CPG. Absorbance measurements were made at 278 
nm using an Unicam 8700 UV I Visible Spectrometer. A standard 3 ml quartz 
absorbance cuvette was used and baselines were taken with buffer prior to 
measurements. A 0.1 % a-casein solution was made up in 0.1 M phosphate 
buffer pH 6.0 and a random amount of glutaraldehyde-activated beads were then 
added to this solution in a centrifuge tube, the mixture agitated, and then spun 
down using a Clandon MLW T52 .1 centrifuge for 2 minutes. The liquid was then 
decanted off and an absorbance reading was taken . A fresh solution of 0.1 M 
phosphate buffer pH 6.0 was then added to the beads and the method repeated . 
Repetitions were made until protein was no longer detected in the buffer. The 
results are given in figure 6.9. 
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Figure 6.9 - Absorbance of 0.1 % a-casein solution before (1) 
and after (2) mixing with glutaraldehyde-activated CPG and 
subsequent readings of freshly added buffer 
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Comparing samples 1 and 2, it appeared that 11 .28 % of the a-casein was lost. 
However, when fresh buffer was added and then the absorbance measured, 
traces of a-casein were detected, indicating that the a-casein was getting caught 
up in the CPG chips. After fresh buffer was added until a-casein was no longer 
detected, a loss of 2.85 % was found which could be attributed to experimental 
error. This experiment therefore showed that a-casein was not sticking to the 
CPG. 
6.2.2.2 Blocking of free aldehyde groups using ethanolamine 
Free aldehyde groups on the proteinase K - CPG without attached enzyme were 
blocked using ethanolamine as described in section 2.2.11 . This was carried out 
to make sure all aldehyde groups were blocked so that substrate could not bind 
to any free groups. Ethanolamine was used as an alternative to Bovine Serum 
Albumin (BSA) or a-casein that commonly are used for blocking because these 
proteins would be used as a substrate by the immobilised enzyme. Tris 
(hydroxymethyl)amino methane (TRIS) could also have been used, but this is 
more bulky and so 3.0 M ethanolamine pH 9.0 was used. Sodium 
cyanoborohydride (NaCNBH3) at a concentration of 10 mM was used to make 
the linkage permanent. 
It was found , however, that blocking had little effect and BODIPY:a-casein was 
still retained in the enzyme reactor. 
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6.2.2.3 Evaluation of CPG with a larger pore size of 972 A 
CPG with a larger mean pore diameter was evaluated as a support to investigate 
whether pore size was limiting the flow of BODIY:a-casein through the enzyme 
column. Using a larger pore size it was found that whilst 2.95 % 
naphthofluorescein was detected, which was still very poor, both BODIPY and 
BODIPY:a-casein were still retained within the column. This suggested that 
something other than pore size was responsible, although the result with 
naphthofluorescein was a slight improvement. 
6.2.2.4 Evaluation of shorter enzyme reactors 
The 5 cm long glass columns that had been used up to this point were replaced 
with 2.5 cm long columns to see whether this would affect the amount of material 
that was retained . Columns were packed with blocked 8 mg proteinase K - 972 
A CPG and injections of the dyes naphthofluorescein, Cy5, and BODIPY were 
made as well as injections of BODIPY:a-casein and a-casein. 
As shown in figures 6.10 to 6.14, the use of a shorter column made a noticeable 
difference. When naphthofluorescein, Cy 5, and a-casein were injected, all were 
detected. When BODIPY and BODIPY:a-casein were injected, nothing was 
detected. 
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Figure 6.10 -Injection of naphthofluorescein with and without 
2.5 cm column 
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Figure 6.11 -Injection of Cy5 with and without 2.5 cm column 
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Figure 6.12 -Injection of a-casein with and without 2.5 cm column 
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Figure 6.13 - Injection of BODIPY with and without 2.5 cm column 
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These results suggested that for some reason the BODIPY fluorophore was 
sticking to the CPG retaining both the fluorophore and the conjugate, since (l-
casein flowed through freely. BODIPY, as described in section 1.1.4.3, is 
relatively non-polar whereas both naphthofluorescein and Cy 5 are polar 
molecules. It is therefore possible that the polarity of the molecule influences its 
ability to flow through the CPG. One possibility is that polar molecules dissolve in 
the buffer more easily and are pulled through the column in solution. However, 
BODIPY with no ionic charge may stick to the CPG instead of being pulled along 
by the buffer. 
The use of CPG as a support in these assays has proved to be incompatible with 
the BODIPY fluorophore. CPG was therefore not pursued as a support for 
immobilisation. 
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6.3 MULTI-DETERMINATION PROTEASE INHIBITION ASSAYS USING 
PIERCE UL TRALlNK MEDIUM AS A SUPPORT 
6.3.1 Procedures 
UltraLink™ Biosupport Medium, 0.25 g (approximately 2 ml of gel) , was 
purchased from Pierce Chemical Company to investigate whether this medium 
could be used as an alternative to controlled-pore glass for immobilisation of 
proteolytic enzymes and incorporation into a glass column. The immobilisation of 
enzyme onto the UltraLink Medium was carried out according to the 
manufacturer's instructions and is described in section 2.2.13. An 8 mg I ml 
solution of proteinase K (lot 90K8604, 11 .3 Units I mg) was used for 
immobilisation onto 0.1254 g UltraLink Medium. A quench solution of 3.0 M 
ethanolamine pH 9.0 was used to block unreacted azlactone sites. 
Pierce Ultra Link Biosupport Medium is a preactivated , ready-to-use bead with a 
bis-acrylamide I azlactone copolymer composition . The copolymer is slightly 
hydrophobic and highly crosslinked and because the azlactone functionality is 
copolymerised with the matrix material , the binding capacity is an integral part of 
the bead. This results in a high functionality throughout the porous bead matrix. 
The support rapidly reacts with nucleophiles, allowing coupling to a wide range of 
proteins. The beads have an average particle size of 50 - 80 flm in diameter 
with a pore size of 1000 A and a functionality of 250 flmoles per g of beads. The 
matrix is stable over a pH range of 1 - 13 and due to the rigid polymeric nature of 
the support, it has excellent utility in medium to low pressure applications . This 
support was thus chosen for these attractive features and the ease of use. The 
reaction scheme for enzyme immobilisation is given below in figure 6.15. 
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Figure 6.15 - Reaction scheme for the immobilisation of enzyme 
onto UltraLink Biosupport Medium 
UltraLink 
Biosupport 
Medium with 
Azlactone groups 
Amine 
containing 
enzyme 
.. 
Amide bond formation 
with ring opening 
The amount of proteinase K actually immobilised onto the Biosupport Medium 
was determined by measuring the amount of proteinase K left in the filtrate using 
the Bicinchoninic Acid (BCA) protein assay, as described in section 2.2.14. The 
use of Triton® X-1 00 surfactant in the bead production could have interfered with 
an assay using absorbance at 280 nm for the measurement of uncoupled 
enzyme. Hence, the BCA protein assay was used. By subtracting the amount of 
proteinase K left in the filtrate from the total amount of proteinase K added, the 
amount of proteinase K actually immobilised onto the support could be deduced. 
Evaluation of the proteinase K immobilised onto Ultra Link was carried out in a 
flow injection analysis system similar to that depicted in figure 6.1 , but using a 
single stream with one packed column. A flow rate of 1.06 ml / min was used 
with 20 mM carbonate pH 9.5 as the buffer system at room temperature. An 
Omnifit glass column 5 cm in length with a reactor volume of 350 J.!I (figure 6.5) 
was used with 2 J.!m aluminium frits. Columns were packed as described above 
in section 6.2.1 . 
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All fluorescence measurements were made using an F-4500 fluorescence 
spectrophotometer with excitation and emission bandwidths of 10nm. Time 
scans were performed with excitation and emission wavelengths of 605 nm and 
644 nm for BODIPY solution and BODIPY:a-casein conjugate , and 280 nm and 
350 nm for a-casein solution. 
6.3.2 Results 
6.3.2.1 Determination of amount of proteinase K immobilised onto 
UltraLink Biosuppport Medium 
The BeA assay was used to calculate the amount of proteinase K left in the 
filtrate after the immobilisation procedure had been carried out. A set of standard 
proteinase K solutions of concentrations 0.25 mg I ml, 0.50 mg I ml, 1.00 mg I ml , 
and 2.00 mg I ml was used to generate a calibration graph. As shown in figure 
6.16, the calibration graph showed good linearity over this concentration range 
with an R2 of 0.9900. The absorbance of the unknown proteinase K solution was 
1.064 absorbance units. By substituting this absorbance into the equation of the 
calibration graph, the amount of proteinase K left in the filtrate was determined. 
Hence by deduction from the total amount of proteinase K used , the amount of 
proteinase K immobilised onto the UltraLink Biosupport Medium was deduced. 
This was 13.603 mg proteinase K, which corresponds to a coupling efficiency of 
85%. 
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Figure 6.16 - Calibration graph of proteinase K concentration using 
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Evaluation of UltraLink as a support for multi-determination 
protease inhibition assays in a flowing system 
Injections of BODI PY, BODIPY:a-casein, and a-casein were made through the 
column containing proteinase K immobilised onto UltraLink in order to determine 
whether these materials would flow through the column. Injections were also 
made through an empty column as a blank to compare the resu lts. As shown in 
figures 6.17 to 6.19, all three compounds were able to flow through the column 
freely. 
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Figure 6.17 - Injection of BODIPY through both an empty column and 
a column packed with proteinase K - UltraLink 
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Figure 6.18 -Injection of BODIPY:u-casein through both an empty 
column and a column packed with proteinase K - UltraLink 
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Figure 6.19 - Injection of a-casein through both an empty column and 
a column packed with proteinase K - UltraLink 
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As peak broadening occurred . the peak areas were compared in order to 
calculate the percentage of fluorescent material that was flowing through the 
UltraLink Medium compared with that flowing through the empty co lumn. These 
percentages are given in table 6.1. 
MATERIAL 
BODIPY 
BODIPY:a-CASEIN 
a-CASEIN 
AMOUNT FLOWING THROUGH 
UL TRALlNK COLUMN (%) 
118 
369 
107 
Table 6.1 - Amount of different materials flowing through a packed 
proteinase-UltraLink column compared with an empty column 
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It is apparent from table 6.1 that BODIPY, BODIPY:a-casein, and a-casein were 
all capable of flowing through the column containing proteinase K immobilised 
onto UltraLink Biosupport Medium. This was a huge improvement when 
compared to controlled-pore glass and these initial results with Ultra Link were 
extremely promising . It also certainly confirms that a BODIPY-CPG interaction 
was responsible for the problems that were found when using ePG. 
It can be seen that both BODIPY and a-casein flow through the medium freely 
with all the material being detected. The percentage of material flowing through 
the packed column was derived by comparing the peak areas obtained through 
packed and empty columns . However, peak areas were calculated using the 
F-4500 software, which does not give an absolutely accurate value . This may 
account for the fact that the percentages for BODIPY and a-casein are slightly 
above 100 % when in theory a maximum of 100 % should have been recorded. 
The fact that 369 % BODIPY:a-casein appeared to flow through the packed 
column is very encouraging. This suggested that not only was BODIPY:a-casein 
able to flow through this support, unlike controlled-pore glass, but that the 
conjugate was being digested by the immobilised proteinase K into highly 
fluorescent peptides. 
These preliminary results with UltraLink Biosupport Medium indicate that this 
support is more conducive than controlled pore glass for use with BODIPY:a-
casein. No sticking of either dye or protein to UltraLink was observed. 
Unfortunately, as time did not permit, these experiments were not continued and 
would therefore constitute further work. Nevertheless, on the basis of the 
preliminary results presented here, it seems logical to suggest that the 
application of this medium to the set-up shown in figure 6.1 would produce an 
effective multi-determination protease inhibition assay for high throughput 
screening. 
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6.4 MULTI-DETERMINATION PROTEASE INHIBITION ASSAYS USING 
SOLUBLE ENZYME 
As lack of time prevented further investigation into the use of UltraLink Medium in 
flow-based multi-determination protease inhibition assays, the use of a soluble 
enzyme system was very simply demonstrated in order to show the principle 
behind these multi-determination assays. On this kind of macro-system, the 
soluble method would not be preferred due to the high amounts of enzyme 
required and the level of complexity of the flow system when compared to that of 
the flow system incorporating immobilised enzymes. 
6.4.1 Procedures 
All fluorescence measurements were made using an F-4500 fluorescence 
spectrophotometer with excitation and emission bandwidths of 10 nm. Time 
scans were performed with excitation and emission wavelengths of 605 nm and 
644 nm respectively. 
For these assays pepsin and proteinase K were chosen to represent two 
enzymes with pH extremes and from different classes: proteinase K is a serine 
protease working at pH 9.5, whereas pepsin is an aspartate protease working at 
2.0. Pepstatin A was chosen as the model inhibitor as it is active over a wide pH 
range and so would work in either buffer system. 
212 
Chapter 6 Experimental: multi-determination protease inhibition assays 
Enzyme solutions were made up by dissolving enzyme into 500 ml of the 
optimised buffer systems for each enzyme. 0.50 mg / ml pepsin was made up in 
20 mM glycine pH 2.0, and 0.02 mg / ml proteinase K in 20 mM carbonate buffer 
pH 9.5. N2 was then bubbled through each of the enzyme solutions to remove 
O2. Assays were carried out at 35 cC using a thermostatted water bath. 
The flow set-up that was used for these experiments is shown in figure 6.20 and 
the individual steps that were carried out are depicted in figure 6.21 . 
Figure 6.20 - Schematic of flow system used for soluble 
multi-determination assays 
o 
c 
H 
E 
F 
A B 
(A = enzyme solution 1, B = enzyme solution 2, C = peristaltic pump, 
0= substrate or substrate I inhibitor injection valve 1, E = substrate 
or substrate I inhibitor injection valve 2 1, F = thermostatted water 
bath, G = T-junction, H = fluorescence detector, I = waste) 
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Figure 6.21 - Sequence of events for multi-determination protease 
inhibition assays 
1 
1 
Substrate only or substrate and inhibitor were injected through two 
manual injection valves (25 fll each) at identical times 
I 
The products of the first reaction flowing through the shorter length 
tubing were detected first 
I 
The products of the second reaction flowing through the longer 
length tubing were detected second 
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6.4.2 Results 
6.4.2.1 Determination of length of flow tubing required for separation of 
peaks 
As the principle behind this multi-determination assay was to inject two lots of 
substrate with or without inhibitor and detect the two lots of product formed in 
each of the enzyme streams by time-dependent separation, it was important to 
determine the length of tubing required to cause such a separation . The pepsin 
enzyme solution was flowed through the short length of tubing whereas 
proteinase K was flowed through the longer length of tubing . The consequence 
of this was that the first detected peak was due to the pepsin component and the 
second peak was due to the proteinase K component. The tubing that was used 
for these experiments was Omnifit Teflon tubing with an internal diameter of 
0.8 mm. As a minimum length of tubing was required for the shorter length 
pepsin section , a length of 25 cm was used between the injection valve 
connector and the T-junction . This was chosen so that the assay components 
would flow through the thermostatted water bath before detection and to cover 
the physical distance between the injection valve and T-junction. Using this 
length of tubing , the time between injection and detection was 9 seconds. 
A longer length of tubing of 65 cm for the proteinase K part was firstly added. 
However, using this length a time of 16 seconds was observed between injection 
and detection, which was too short for peak separation. In order for a separation 
of the peaks to occur the first peak has to return to the baseline first , so sufficient 
time must be allowed for this to occur. A length of 355 cm was then added which 
equated to a time of 45 seconds between injection and detection. This length 
was enough to separate the two peaks, but the first peak had not quite reached 
the baseline properly. This length was therefore increased to 399 cm, which 
allowed a 50 second separation, and the two peaks were properly resolved as 
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demonstrated by figure 6.22. For further experiments therefore a shorter length 
of 25 cm and a longer length of 399 cm were used. 
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Figure 6.22 - Separation of two enzyme peaks using 25 cm and 
399 cm length tubing 
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The length of tubing that was required for separation of the two peaks was not 
ideal. The length of 399 cm had to be coiled for placement in the water bath . 
This soluble set-up would be much more applicable to a miniaturised system 
where such long lengths would not be needed. 
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6.4.2.2 Multi-determination protease inhibition assay 
As time was very short the idea of this investigation was to demonstrate the 
principle, so the results that are presented here are of a qualitative nature rather 
than quantitative. Triplicate injections of substrate in the absence and presence 
of pepstatin A were made using the system shown in figure 6.20 with tubing 
lengths as described in section 6.4.2.1 . The time scans showing an example of 
these injections are given in figure 6.23. 
300 
~ 
~ 
5 250 
~ 
~ 
-e 200 
~ 
~ 150 
2 
.!: 
Cl) 
CJ 
c: 
Cl) 
CJ 
IJ) 
~ 
o 
::l 
11.. 
100 
50 
Figure 6.23 - Multi-determination using two proteolytic 
enzymes - pepsin and proteinase K - and the selective 
inhibition of these enzymes by pepstatin A 
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From figure 6.23 it can be seen that the effect of an inhibitor on two proteolytic 
enzymes has been determined in the same assay. From the pepsin peaks it is 
evident that inclusion of pepstatin A inhibited pepsin, signified by the reduction in 
fluorescence intensity. However, if the proteinase K peaks are examined, these 
are identical whether pepstatin A was present or not. This indicated that 
pepstatin A did not inhibit proteinase K. This was as expected as pepstatin A is 
an aspartate protease inhibitor. 
Using the substrate BODIPY:u-casein it has been shown that multi-determination 
assays using the described system were possible and these assays have been 
used to show the selective inhibition of two proteolytic enzymes by pepstatin A. 
Not only two proteolytic enzymes, but two enzymes that operate at opposite pH 
values - pH 2.0 for pepsin and pH 9.5 for proteinase K. In addition these 
enzymes represented two different classes of protease - pepsin being an 
aspartate protease and proteinase K being a serine protease. This system would 
be suitable for the high throughput screening of compounds against more than 
one target enzyme. 
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6.5 DISCUSSION 
The suitability of applying the long-wavelength f1uorogenic substrate 
BODIPY:u-caseln to multiplexed protease and protease inhibition assays has 
been Investigated The use of immobilised enzymes in these assays much 
simplifies the flow system needed, and due to the advantages of immobilised 
enzymes as discussed in section 1.7.1, it was decided that immobilisation of 
proteolytic enzymes to a suitable support was required. However, studies on the 
use of controlled-pore glass as a support were unsuccessful due to an 
incompatibility with the BODIPY f1uorophore. It appeared that BODIPY, which 
has no ionic charge, stuck to the support thereby retaining the f1uorophore within 
the enzyme reactor. One hypotheSIS on the cause of this sticking was based on 
polarity. It was found that polar dyes flowed through the CPG column freely, and 
it was thus postulated that the more polar the f1uorophore, the less sticking would 
occur. This possibly may have been due to polar molecules dissolving into 
solution with more ease. 
An alternative support was explored for immobilisation of enzymes and 
subsequent use with BODIPY·u-casein. Pierce UltraLink Biosupport Medium 
was chosen for the reasons discussed and was shown to be extremely promising 
for use in these assays. Enzyme was successfully immobilised onto this medium 
and UltraLink was shown to support the flow of BODIPY:u-casein. Initial results 
also suggested that as BODIPY:u-casein flowed through the enzyme reactor, the 
immobilised enzyme cleaved the substrate into fluorescent peptides. These 
results were extremely encouraging and promising and with more time this 
system could potentially be developed for multi-determination. This would 
constitute future work. 
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Soluble enzyme experiments were carried out as a proof of principle 
determination and it was shown that BODIPV:a-casein could be used as a pH-
Independent substrate for use in flow-based multlplexed screening programmes. 
However, this format was less favourable than that using immobilised proteases, 
'. as the system was more complex. In addition, due to the high concentrations of 
enzyme needed and the long lengths of tubing that were required for peak 
separation, this soluble format would be much more suited to a miniaturised 
system. The application of these assays to a chip-based system would comprise 
future work and will therefore be discussed as such. However, further work on 
the effects of flow rate ought to be carefully studied. At a lower flow rate the 
dispersion of the zones will be less and they Will overlap less, so it may be 
possible to have shorter tubes for the second enzyme. In that case It might be 
pOSSible to get more samples per hour through even though the flow rate has 
been reduced. 
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7.1 CONCLUSIONS 
The objective of this investigation was to develop new fluorescence methods for 
the rapid and sensitive determination of proteolytic enzymes and their inhibitors. 
In addition, the possibilities of applying these enzyme and Inhibition assays to a 
flow injection analysis system and the development of multi-determination assays 
were also to be examined. These assays were aimed at a high throughput 
screening application. 
To a large extent these objectives have been successfully fulfilled. Fluorescence 
polarisation and energy transfer methods have both been explored for use in 
protease and protease inhibition assays. Of these two approaches, energy 
transfer methods have proven superior. As discussed in section 3.4, this is of no 
great surprise as inherent problems in polansation methods Include (a) 
polarisation filters reducing exciting and emitted light intensltles; (b) polarised 
light pre-selectlng only a fraction of the potentially excitable molecules; and (c) 
polarisation changes being small and temperature sensitive. It was found that for 
fluorescence polarisation assays a lig htly labelled substrate was required, and 
these offer an advantage due to less stenc hindrance of the proteolytic enzyme 
over those heavily labelled substrates used in energy transfer methods. These 
substrates using fluorescence polarisation have successfully been used to 
analyse different proteases with broad specificity and fluorescence polarisation 
has the additional benefits of simplicity and relative immunity to the inner filter 
effect. 
However, these pros of fluorescence polarisation are outweighed by the fact that 
the fluorescence polarisation changes are very small which greatly lim its the 
sensitivity of the assay. The pH sensitivity of fluorescein as a label was also 
extremely limiting as easy analysis of acid proteases was prevented. The use of 
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long wavelength fluorophores, which are usually preferred due to the decrease in 
background fluorescence found within the long wavelength region (ca. 600 - 900 
nm), was also unsuccessful. 
The usefulness of this technique was further limited by the requirement of a 
cuvette-based approach, with the associated low throughput and high reagent 
usage 
Energy transfer methods have been Investigated In two different formats (a) a 
single fluorophore used as an excess label attached to a protein substrate, with 
proteolytic action fragmenting It and producing enhanced fluorescence through 
abolition of intemal energy transfer, and (b) use of two fluorophores attached to 
one substrate, with energy transfer from one to another and proteolytic cleavage 
causing a fluorescence enhancement through disruption of the energy transfer. 
Double-labelled energy transfer methods have been investigated using the donor 
I acceptor pairs of FITC I TMRITC and Cy 5 I Cy 5.5 One major advantage that 
this method possesses over the single-labelled energy transfer methods is that 
intensity ratio measurements are made using double-labelled substrates, and so 
instrument fluctuations Will largely cancel out. The use of two fluorophores 
should also produce a larger Stokes shift, helping to solve a real problem in long 
wavelength measurements. 
For reasons discussed in chapter 4, it was found in the double-labelled section of 
work that lightly labelled donor and heavily labelled acceptor conjugates were 
required for use in FRET protease assays. 
FITC I TMRITC, although promising in theory, were found not to be perfect. The 
phenomenon of energy transfer was shown to exist In these conjugates, however 
the results were extremely difficult to interpret and by no means ideal for use in 
protease assays. Initial results with Cy 5 and Cy 5.5 as donor and acceptor 
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respectively were unsuccessful as the two emission peaks were unable to be 
resolved. However, Cy 5 and Cy 5.5 have previously been shown to be a good 
donor I acceptor pair [287,288]. 
It is obvious that the synthesis of double-labelled substrates is more complex 
both to Investigate and to achieve in routine practice than single-labelled 
substrates, although with more work spent this energy transfer method may give 
advantages over other energy transfer methods. 
The use of a single excess-labelled substrate has, by far, been the most 
successful fluorescence method for the determination of proteolytic enzymes and 
inhibitors. A substrate utilising a-casein labelled with a long wavelength BODIPY 
dye has been synthesised. The relatively low molar ratio of dye to protein used 
in this work provides an Ideal substrate for proteolytic enzymes as worries that 
the use of highly derivatised molecules might sterically hinder the activity of some 
proteases are minimised. In addition, BODIPY dyes have no overall charge, so 
dye conjugation should not greatly affect the protein substrate conformation and 
enzyme-active site interactions. 
This substrate has been shown to be a SUitable intramolecularly quenched 
conjugate for the determination of proteolytic enzymes and their inhibitors In flow-
based screening programmes. The application of BODIPY:a-casein to the 
determination of different proteolytiC enzymes with varying pH optima (ranging 
from pH 2.0 to 9.5) has been demonstrated. The SUitability of BODIPY:a-casein 
as a substrate in enzyme inhibition assays has also been investigated. Limits of 
detection of 2.50 IlM, 0.14 IlM, 7.20 nM, and 0.161 nM were obtained for 3-
nrtrophenylboronic acid, leupeptln, pepstatin A, and aprotlnin respectively. The 
assays are rapid, taking at most 2 minutes for the enzyme assay and 5 minutes 
for the inhibition assays. The flow-based procedure that has been described is 
particularly well suited to the high throughput screening of candidate drug 
molecules. 
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The progression of this work was to aim towards the adaptation of the flow-based 
procedure to a set-up that would allow the multi-determination of proteolytic 
enzymes and their inhibitors. This would further improve the throughput of the 
system - an essential requirement of high throughput screening. As time was 
short, only the feasibility of this set-up was explored. The use of immobilised 
enzymes was investigated, as this far simplified the set-up required. Two 
different supports were studied - controlled pore glass (ePG) and Pierce 
UltraLink Biosupport Medium. It was found that ePG was unsuitable for use with 
the BODIPY f1uorophore, thereby preventing its use in these assays. BODIPY 
was found to stick to the ePG resulting In the f1uorophore being retained within 
the enzyme column. This was possibly related to the ionic charge as polar dyes 
were found to flow freely through the column whereas the non-polar BODIPY 
molecule did not. 
Pierce UltraLink Biosupport Medium was therefore investigated as an altemative 
to ePG and was shown to be extremely promising as a support in these assays. 
Enzyme was successfully immobilised onto this medium and UltraLink was 
shown to support the flow of BODIPY:a-casein. Initial results also suggested that 
as BODIPY·a-casein flowed through the enzyme reactor, the immobilised 
enzyme cleaved the substrate into fluorescent peptides. With more time this 
system could potentially be developed for mUlti-determination. 
For proof of principle soluble enzyme experiments were earned out. However, 
thiS format was less favourable than that using immobilised proteases, as the 
system was more complex. In addition, due to the high concentrations of 
enzyme needed and the long lengths of tubing that were required for peak 
separation, this soluble format was much more suited to a miniaturised system. 
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7.2 FUTURE WORK 
7.2.1 Fluorescence polarisation 
Although fluorescence polarisation was found to be less sensitive than energy 
transfer methods, polarisation does possess several attractive features. The 
cuvette-based approach hampered the usefulness of this technique due to the 
associated low throughput and high reagent usage. A flow-based system would 
improve this throughput significantly. It would therefore be extremely useful to 
transfer the assay to a flow injection analysis system similar to that described for 
the quenched substrate, if only to test the sensitivity of polarisation 
measurements in systems where small volumes are Illuminated and observed in 
the instrument. 
Another area that would be worth pursuing is the use of BODIPY and other long 
wavelength fluorophores. Experiments uSing BODIPY:u-casein with 
fluorescence polarisation were unsuccessful. However, these substrates were 
highly quenched, causing significant depolarisation through non-radiative energy 
transfer and thus severely limiting the assay span and sensitivity. A study of 
much more lightly labelled substrates containing little or no quenching and their 
applicability to fluorescence polarisation may prove to be more promising. In 
addition assessment of other long wavelength fluorophores would be useful. For 
use in fluorescence polarisation the dye requires a suitable fluorescence lifetime 
for appreciable Brownian rotation to occur. There are worries about the extent of 
polarisation effects with short-lifetime long-wavelength fluorophore molecules 
(section 1.2.1.3). This may be one of the few areas where long-wavelength 
fluorophores are not very useful. However, If a SUitable long-wavelength 
fluorophore could be found this could prove valuable. 
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7.2.2 Double-labelled substrate 
As double-labelled substrates possess potential advantages over other energy 
transfer methods, more work in this area could be fruitful It IS eVident that much 
more work is required to determine the optimum donor and acceptor ratios 
required for the substrate to be used as a protease substrate. The use of Cy 5 
and Cy 5 5 as donor and acceptor respectively would be worth further study. The 
effect of bandwidth is one experimental parameter that could be investigated. 
The use of narrower bandwidths would result In less direct acceptor excitation, 
although presumably at the expense of sensitivity. Laser excitation may 
therefore be more promising as presumably laser excitation would allow less 
direct excitation of the acceptor along with more sensitivity 
7.2.3 Single-labelled substrate 
This type of assay has been most suited for the determination of proteolytic 
enzymes and their inhibitors for use in flow-based screening programmes. In 
addition to the further work on multi-determination that needs to be carried out, 
which is described in section 7.2.4, the enhancement of the operation of the flow-
based procedure described should be conSidered. Computer-controlled valves 
could replace the manually operated switching and injection valves, thereby 
providing a semi-automated system. 
7.2.4 Multi-determination 
Multl-determination allows a higher throughput and thus is extremely important in 
the future development of the single-labelled substrates for high throughput 
screening. The work that was carried out showed that Pierce UltraLink 
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Biosupport Medium was extremely promising as a support for protease 
immobilisation. To begin, enzyme columns containing this support could be 
integrated Into the proposed dual inhibition assay described in section 6.2.1 and 
depicted in figure 6.1. Using the proteolytic enzymes and inhibitors from the 
assays described in chapter 5, numerous set-ups are possible. Figure 7.1 
illustrates just a couple of examples of possible set-ups out of the many 
combinations that are possible. 
Numerous other set-ups are possible for mUlti-determination and various other 
supports are available for enzyme immobilisation. Much more work can therefore 
be carried out in the area of multi-determination. 
However, although parallel channels allow multi-determination, which in turn 
produces a greater throughput of samples, the current macro-system has a limit. 
It would be impractical to keep paralleling up because of the amount of tubing 
that would be required and the number of injection valves needed. This is 
particularly problematic when carrying out the assays manually. Space 
requirements would also increase, as well as the cost associated with high 
reagent consumption. This macro system therefore becomes limiting. The 
designs of such assays are much more suited to miniaturised assay formats, and 
hence a discussion of the transferral of these protease and protease Inhibition 
assays to a miniaturised system IS given. 
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Figure 7.1 - Possible set-ups for multi-determination assays: (a) one 
inhibitor, three enzymes with three different pH optima, (b) one inhibitor, 
three enzymes with two different pH optima 
(a) 
pH 
7.5 
pH 
9.5 
pH 
2.0 
S + I 
Waste 
Detector 
Substrate (S = BODIPY:o.-casein) and inhibitor (I = aprotinin) are injected 
into three streams of buffer with neutral, alkaline, and acidic pH 
corresponding to streams flowing through o.-chymotrypsin , proteinase K, 
and pepsin enzyme reactors respectively, to the detector which will detect 
selective inhibition of the first peak (o.-chymotrypsin) , and no inhibition of 
(b) 
pH 
9.5 
pH 
7.5 
the second or third peaks (proteinase K and pepsin respectively). 
Waste 
Detector 
Substrate (S = BODIPY:o.-casein) and inhibitor (I = aprotinin) are injected 
into two streams of buffer with alkaline and neutral pH corresponding to 
streams flowing through alkaline protease and proteinase K (alkaline) and 
o.-chymotrypsin (neutral) enzyme reactors , to the detector which will detect 
no inhibition of the first and second peaks (alkaline protease and 
proteinase K), and selective inhibition of the third peak (o.-chymotrypsin). 
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7.2.5 Miniaturised protease and protease inhibition assays 
Section 1.5.1 discussed the pressures that currently face drug discovery 
companies and the role of HTS to harness the discovery potential of large 
numbers of compounds efficiently, by reducing time and cost and increasing 
Information gained. The need to minimise the cost of screening has been 
addressed primarily by reducing the volume of sample to be screened, which, in 
turn, has resulted in the miniaturisation of HTS technology as a whole. 
The benefits of the miniaturisation of HTS were discussed in section 1.5.4, and 
due to the potential improvements that could be achieved by miniaturiSing the 
protease and protease inhibition assays, this seems an obvious step in their 
continuing development. 
Many discussions on the general concepts and techniques, and the background 
of the emergence of this technology can be found [298 - 306). 
Chip-based systems have been described previously for enzyme assays 
including l3-galactosidase [307]. Its inhibition by various inhibitors, performed in a 
microfabricated channel network using electrokinetic flow to precisely mix 
substrate, enzyme and inhibitor, was also illustrated. A schematic of the enzyme 
analysis chip taken from the paper in shown in figure 7.2. 
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Figure 7.2 - Schematic diagram of the chip 
designed for enzyme assays in [307] 
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Microchip-based assays have also been descnbed for protein kinase A [308] and 
ACLARA BioSciences, Inc., have reported the design, fabrication and 
characterisation of plastic microfluidic devices for conducting highly parallel 
enzyme-based assays [309]. Caliper Technologies Corporation have 
commercialised lab-on-a-chip technology [310] and have fabricated high 
throughput systems to perform on the order of tens of thousands of experiments 
per day per chip, using nanoliter volumes of reagents [311]. Chips have been 
designed for assays with fluorogenic substrates, e.g. protease assays, for 
biochemical assays, e g. kinase assays, and for cellular assays, e g. G-proteln 
coupled receptor assays [312]. 
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Using a chip-based system, the ability to manufacture a set-up with many parallel 
channels is much simpler than with a macro system. The soluble enzyme multi-
determination system that was descnbed in section 6.4 would be much better 
'suited to a miniaturised system. Many parallel channels of different lengths 
would be easily manufactured in such a system, allowing the determination of 
two or more activities in nanoliter volumes using time separation. The need for 
such small volumes of reagents means that the soluble enzyme set-up could be 
used without the huge expenses found with such a set-up on a macro scale. The 
small amounts of sample required in miniaturised systems are also much better 
suited to the small amounts of compounds that are synthesised by combinatorial 
chemistry methods, allowing a better connection of combinatorial chemistry to 
HTS. 
Alternatively, the immobilised enzyme format could also be used. The fabrication 
of micro-porous silica structures providing an efficient method of retaining a 
catalyst within a reactor system has been demonstrated by researchers at the 
University of Hull [313). 
One area that needs to be considered in the design of chip-based protease and 
protease inhibition assays IS the method of heating the assay components. From 
an examination of the literature, it appears that several methods are suitable, 
although the following overview is by no means exhaustive. A simple and 
common method to heat fluids in a chip is by the use of heating blocks [314 -
316). This is an example of contact heating. 
Another commonly used method is that of resistive heating [317, 318) Heating 
accomplished using a resistive heater and thermocouple for temperature 
mOnitoring has been used for DNA analysis where the heater and thermocouple 
are mounted to the bottom of the chip [317), and for the polymerase chain 
reaction (peR) mounted on the top [318). An integrated microchip device for the 
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digestion, separation and postcolumn labelling of protein and peptides [319] has 
made use of a small detachable resistive heater. A thin Thermofoll™ Heater 
(Minco Products, Inc.) was used to control the temperature in the reaction 
channel. The heater was attached to the glass chip using a C-clamp and thermal 
contact between the heater and the microchip was provided using a piece of 
thermally conductive Silicone elastomer. The heater temperature and the glass 
temperature on top of the microchip were measured using thermocouples, the 
temperatures of which did not differ more than 2 °C in the temperature range 20 
to 80 °C down the length of the reaction channel. Simplified calculations showed 
that heating less than 2 mm length of the reaction channel (11.4 !lm deep and 
43.6 !lm wide) is necessary to heat the fluid inside to the desired temperature. 
Microfabricated devices constructed from glass and PDMS with integral heaters 
have been descnbed [320], which were used for heterogeneous catalysis 
reactions. The in situ heater was fabricated from Nichrome wire (0.25 mm 
diameter) carefully formed into a serpentine shape and immobilised in the PDMS 
top plate and covering the channels. In the finished chips, the heating element 
was 2 mm from the catalyst surface and was able to heat 15 mm of channel 
length. Heating was achieved by a potentiostat (0 - 270 V) and monitored via a 
digital thermometer with the temperature probe located close to the reaction 
channel. 
The methods already discussed have all been examples of contact heating 
However, non-contact heating allows for fast switching of temperature and 
reactions, as opposed to the conventional contact devices. 
A non-contact heating method has been demonstrated for control of a chemical 
reaction in a microchip by utilising the photothermal effect produced by a 
compact diode laser [321]. A light absorbing target on top of a glass microchip 
above a microchannel through which reactants flowed was utilised to heat the 
reaction media In order to increase the temperature locally in the microchannel, 
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a 10mW diode laser was used to heat an absorbing target (black Ink point, 
produced by felt tiP marker) Heat flux was conducted through the glass cover 
plate and an increase in the temperature of the mixed solution in the main 
microchannel was noted. The reaction media were heated in a stopped flow 
mode. Reaction volume was estimated to be 10 nl and with laser powers of 2,4, 
7,8, and 10 mW, the temperature change induced was estimated to be 1.9, 3.2, 
5.0, 5.6, and 7 oC, respectively for 5 s of irradiation. The small heat capacity of 
the heated reaction space allowed the eqUIlibrium temperature to be reached 
within 2 s 
Non contact heating was also applied to PCR, which was carried out in capillary 
tubes rather than on a microchip (322). Infrared light was produced by a 
tungsten lamp, which was focussed on the optically transparent PCR reaction 
chamber where the sample was heated due to the absorption of radiation. The 
temperature was sensed in a reference capillary with a thermocouple. A mirror 
placed behind the capillaries enhanced the effect of heating. A workable solution 
is provided by the construction of a reference probe that exhibits identical thermal 
properties as the sample. Using this method, a heating rate of 65 °C I s was 
seen. 
Three distinct methods of heating are apparent: heating blocks (contact), 
resistive heating (contact), and uSing a light source (non-contact). Heating 
blocks are simple, but bulky. Resistive heating seems promising, With the 
advantage of different combinations. The Integral heaters immobilised in the 
PDMS top plate used in (320) are easy to produce and the Thermofoil™ heater 
(Minco Products, Inc.) that was used as a detachable heater (319) also appears 
promising. The non-contact methods, although faster, are expensive However, 
the speed obtained With these methods is not crucial for protease and protease 
inhibition assays. 
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A potentially tricky part of the design of a miniaturised system would be the 
excitation of the fluorophore and subsequent detection. Detection of 
fluorescence on a chip is described briefly in many papers [323 - 3301, which 
possess a general scheme of using laser excitation by focusing the laser with a 
lens into the reaction channel and collection of fluorescence with a microscope 
objective and detection using a photo-multiplier tube (PMT). 
Ocvirk, G. et al., [3311 reported a detailed confocal detection scheme for sub-
picomolar detection. Excitation from an air-cooled argon ion laser (488 nm) 
passed through a 485 nm band pass filter, was reflected by a dichroic mirror and 
was focused onto the glass device using a microscope objective. Fluorescence 
emission was collected, passed through a dichroic mirror and measured with a 
PMT. A schematic of this set-up is shown in figure 7.3, taken from the paper. 
Figure 7.3 - Schematic diagram showing the set-up for a 
confocal fluorescence detection on a chip, taken from [331] 
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A completely Integrated microflUldic I micro-optic device has been described 
[332]. in which refractive microlens arrays and aluminium aperture arrays were 
Integrated on both sides of a chemical chip. 
'A disposable sensor chip and optical readout device well sUited for medical pOlnt-
of-care diagnostics used an evanescent field generated by total internal reflection 
of a laser beam [333] This field was then used for excitation of f1uorophore 
markers. The sensor chip was optically connected to a prism of the optical 
readout device by a refractive-index-matching fluid. 
Two different ways to get light into and fluorescence out of a chip seem to be 
~ 
promising. Firstly. the use of lasers (LEDs etc.). focusing lenses I microscope 
objectives. and filters in order to accurately focus the excitation light into the 
channel and then detect using a PMT. Secondly. the fabrication of waveguides 
in the chip coupled to fiber optiCS to get the light both in and out. These methods 
would require much thought and planning in order to develop a realistic 
miniaturised system for the determination of proteolytic enzymes and their 
inhibitors. 
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APPENDIX A 
Supplier names and addresses 
SUPPLIER ADDRESS 
AD Instruments, Ltd. Grove House 
Grove Road 
Hastings 
TN354JS, UK 
Amersham Pharmacia Biotech UK, Ltd. Amersham Place 
Little Chalfont 
Buckinghamshire 
HP79NA, UK 
Anachem, Ltd. 20 Charles Street 
Luton 
Bedfordshire 
LU20EBG, UK 
Cambio, Ltd. 34 Newnham Road 
Cambridge 
CB39EY, UK 
Elkay Laboratory Products (UK), Ltd. Unit 4, Marlborough Mews 
Crockford Lane 
Basingstoke, Hampshire 
RG248NA, UK 
285 
Eppendorf Scientific, Inc 
Fisher Scientific UK 
Grant Instruments (Cambridge), Ltd. 
Hellma (England), Ltd. 
Hitachi Scientific Instruments 
Molecular Probes, Inc. 
286 
1 Cantlague Road 
Westbury 
New York, USA 
Bishop Meadow Road 
Loughborough 
Leicestershire 
LE115RG, UK 
29 Station Road 
Shepreth 
Royston 
Hertforshire 
SG86PZ, UK 
Cumberland House 
24 - 28 Baxter Avenue 
Southend-on-Sea 
Essex 
SS26HZ, UK 
7 Ivanhoe Road 
Appendices 
Hogwood Industrial Estate 
Finchampstead 
Berkshire 
RG404QQ, UK 
Cambridge Bioscience 
24 - 25 Signet Court 
Newmarket Road 
Cambridge 
CB58LA, UK 
Ommfit, Ltd. 
Perkin-Elmer, Ltd. 
Pierce (Perbio SCience UK, Ltd.) 
Precisa Balances Ltd. 
Slgma-Aldrich Company, Ltd. 
USF Elga Ltd. 
287 
2 College Park 
Cold hams Lane 
Cambridge 
CB13HD,UK 
Post Office Lane 
Beaconsfield 
Buckinghamshire 
HP91QA, UK 
Century House 
Tettenhall 
Cheshire 
CH39RG,UK 
4 Vermont Place 
Tongwell 
Appendices 
Milton Keynes, Buckinghamshire 
MK158JA, UK 
Fancy Road 
Poole 
Dorset 
BH124QH, UK 
High Street 
Lane End 
High Wycombe 
Bucks. 
HP1435H, UK 
L-_____________________________________ __ 
Unicam limited 
Whatman International Ltd. 
York Street 
Cambridge 
CB12PX, UK 
St Leonard's Road 
20 I 20 Maidstone 
Kent 
ME160LS, UK 
Table A - Supplier names and addresses 
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APPENDIX B 
Appearance of the model F-4S00 fluorescence spectrophotometer (Hitachi) 
located in our laboratory 
Figure B - Appearance of the F-4500 in our laboratory 
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APPENDIX C 
Block diagram of the layout of the model F-4500 fluorescence 
spectrophotometer (Hitachi) 
Xenon 
Lamp 
Power 
Supply 
Processing 
unit 
Figure C -Internal block diagram of the F-4500 
Xenon Excitation 
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APPENDIX D 
Instrument specifications fo r the Hitach i F-4500 and Perkin-Elmer LS 50B 
fluorescence spectrometers 
PARAMETERS F-4500 LS 50B 
Light source 150 W Xenon lamp Xenon flash lamp, 
pulsed at line frequency 
(50 or 60 Hz) 
Monochromators Excitation: 200 - 600 nm Excitation: 200 - 800 
nm 
Emission: 200 - 900 nm Emission: 200 - 900 nm 
Excitation slit width 1.0, 2.5, 5.0, 10.0 nm 2.5 - 15 nm in 0.1 nm 
increments 
Emission slit width 1.0, 2.5, 5.0, 10.0, 20.0 2.5 - 20 nm in 0.1 nm 
nm increments 
Scanning speed 15, 60, 240, 1200, 2400, 10- 1500 nm I min in 1 
12000,30000 nm I min nm increments 
Wavelength accuracy ± 2.0 nm ± 1.0 nm 
Response 0.004, 0.01 , 0.05, 0.1, 0.02 - 9.98 seconds in 
0.5, 2.0, 8.0 seconds 0.01 s increments 
PMT Voltage 400, 700, 950 V Auto 
Table D -Instrument Darameters of the F-4500 and LS 50B 
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APPENDIX E 
Appearance of the LS SOB fluorescence spectrophotometer (Perkin-Elmer) 
located in our laboratory 
Figure E - Appearance of the LS SOB 
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APPENDIX F 
Block diagram of the layout of the Perkin-Elmer LS SOB fluorescence 
spectrophotometer 
Figure F - Optical layout of the LS SOB fluorescence spectrophotometer 
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APPENDIXG 
Calculation of f1uorescein absorbance at 280 nm as a percentage of that at 
494nm 
Fluorescein A260 nm = 1.023, and ~94 nm = 2.545. Therefore, absorbance at 280 
nm as a percentage of the absorbance at 494 nm = (1.023 I 2.545) X 100 = 
40%. 
APPENDIX H 
Calculation of BODIPY absorbance at 280 nm as a percentage of that at 630 
nm 
BODIPY A280 nm = 0.196, and BODIPY As30 nm = 2.073. Therefore, absorbance at 
280 nm as a percentage of the absorbance at 630 nm = (0.196 I 2.073) X 100 = 
9.5%. 
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APPENDIX I 
Calculation of a-casein molar extinction coefficient (E) at 280 nm 
According to the Beer Lambert Law absorbance is related to the molar extmction 
coefficient E (in cm-1 M-1), concentration c (in M), and path length I (in cm) by: A = 
ECI. A 0.1 % solution of a-casein (0.01 g per 10 ml) was made up and the 
absorbance at 280 nm measured (A280 nm = 0 882). 
Molar concentration = (weight (g) 1 RMM (g» X (1000 (m I) 1 volume (m I» 
= (0.01/24 000) X (1000 110) = 4.17 X 10 -5 M 
Substituting into the Beer Lambert Law: 
E = AI c = 0.882/417 X 10 -5 = 21, 151 cm -1 M -1. 
APPENDIXJ 
Calculation of a-casein absorbance at 350 nm as a percentage of that at 
280nm 
a-casein A280nm = 0.417, and a-casein A350nm = 0046. Therefore, absorbance at 
350 nm as a percentage of the absorbance at 280 nm = (0 046 1 0.417) X 100 = 
11 %. 
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APPENDIX K 
Calculation of BODIPY absorbance at 280 nm as a percentage of that at 350 
nm 
BODIPY A280nm = 0.117, and BODIPY A350nm = 0 338. Therefore, absorbance at 
280 nm as a percentage of that at 350 nm = (0.117/0.338) X 100 = 35 %. 
APPENDIX L 
Calculation of BODIPY molar extinction coefficient (e) at 350 nm 
According to the Beer Lambert Law absorbance is related to the molar extinction 
coeffiCient e (in cm-1 M-1), concentration c (in M), and path length I (in cm) by: A = 
ecl. 
A 1 66 X 10 -5 g / ml solution of BODIPY was made up and the absorbance at 
350 nm measured (A350nm = 1.049). 
Molar concentration = (weight (g) / RMM (g)) X (1000 (m I) / volume (m I)) 
= (1.66 X 10 -5/660.5) X (1000 /1) = 2.52 X 10 -5 M 
Substituting into the Beer Lambert Law: 
e = A / c = 1.049/2.52 X 10 -5 = 41, 627 cm -1 M-I 
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APPENDIX M 
Calculation of flow rate 
Flowing buffer through the flow system and collecting the buffer for 5 minutes in a 
glass vial that had been used to zero the analytical balance was used to 
determine the flow rate for use in protease and protease inhibition assays. The 
weight of the vial was then taken and the weight recorded. This was carried out 
in triplicate. ThiS calculation makes the assumption that 1 g = 1 ml buffer. 
Triplicate weights for 5 minutes: 9.2536, 92417,9.2561. Therefore, the average 
of weights = 9.250467 with a standard deviation (SO) = 0 007694, and 
percentage SO = 0 083. 
9 250467 ml was collected over 5 minutes, therefore for 1 minute 9 250467 I 5 = 
1.85 ml was collected. Therefore, flow rate = 1 85 mll min. 
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APPENDIXN 
Determination of incubation loop volume 
Buffer was flowed through the incubation loop and captured by closing the valve 
so that the incubation loop was segregated from the rest of the flow system. Air 
was then flowed through the rest of the system to remove any traces of buffer. A 
glass vial was used to zero the analytical balance after which the buffer captured 
in the incubation loop was flowed out into the glass vial. The glass vial was then 
re-weighed. This measurement was repeated 6 times. Determination of loop 
volume assumes that 1 g = 1 ml buffer. 
Weight of six readings (mg): 660.6, 667.0, 667.6, 671.0, 675.5, 678.0 ThiS gives 
an average = 669.95, with a standard deviation (SO) = 6 298 and a percentage 
SO = 0 94 %. Therefore, loop volume = 670 f.11. 
298 

